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INTRODUCTION AND OUTLINE OF THESIS

Introduction
INTRODUCTION
The prostate gland is of undoubted importance in reproductive physiology and is one of the 
commonest causes of clinical urological problems in the male patient. Benign prostatic hyperplasia 
(BPH) is an age-related non-malignant disease and classically characterized by a mixed, usually 
nodular proliferation of stromal and epithelial elements. Individual variations however are common, 
with some patients developing predominantly stromal hyperplasia and others mainly glandular 
hyperplasia.1 This condition is common in men over 40 years of age and may lead to awkward lower 
urinary tract symptoms, eventually resulting in referral to a urologist.2
Until recently the only therapeutic option for patients with lower urinary tract symptoms due to BPH 
were surgical. For many years transurethral resection of the prostate (TURP) and retro pubic 
prostatectomy were by far the most common treatment modalities. Because of its high success rate, 
TURP was even nominated the “gold standard”. However, some morbidity is associated with this 
surgical technique as well as the necessity for epidural or general anaesthesia. Complications 
involving blood transfusions and post treatment infections incur risks with a mortality rate of 
approximately 1%.3,4 Furthermore, urinary incontinence and urethral strictures may occur.5,6 In 
addition 10% of patients require re-operation within 8 years.7 Since BPH is principally a disease of 
aging men, the high prevalence of intercurrent medical problems, particularly cardiac, respiratory 
and cerebrovascular disease8,9, further increases the peri-operative risk and post-operative 
morbidity.10,11 With the progressive aging of the population, BPH has become a major public health 
problem with social-economic implications. It is mainly for this reason that there has been such a 
strong revival of interest in BPH by scientists, health care organizations, pharmaceutical and 
biomedical industries.
New invasive and non-invasive therapeutic modalities have been developed and introduced each 
with their own specific implications for patient well being, in terms of efficacy, durability, quality of 
life and morbidity, not to mention economic considerations. The treatment of lower urinary tract 
symptoms due to BPH has more and more become a multi-modality approach; each patient requires 
a tailored solution, with the highest efficacy at the lowest morbidity and cost. Urologists have 
continuously attempted to reduce the traumatic effect of treatment. The introduction of extra 
corporal shockwave lithotripsy (ESWL) as a minimal invasive stone treatment is an example. In 
addition the further refinement in the technique of transurethral resection of the prostate, the 
introduction of optics and endoscopy-techniques constituted an enormous leap forward in the 
management of common urologic problems.
Several non-surgical modalities have emerged during the last decade and of these, microwave 
technology, based on the application of thermal energy deep within a prostatic adenoma, is one of 
the most appealing options.12 Transurethral microwave thermotherapy (TUMT) has been shown to 
be an effective, one hour, anaesthesia free, outpatient treatment modality in patients with lower
11
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urinary tract symptoms (LUTS) and benign prostatic hyperplasia (BPH).13-16 After an initial period 
in which hyperthermia treatments resulted in intra prostatic temperatures of less than 450C, the 
concept of transurethral microwave thermotherapy was developed. Using a specially designed 
antenna together with simultaneous urethral cooling, microwaves were applied deep in the lateral 
prostatic lobes resulting in intra prostatic temperatures exceeding 450C, however not so high as to 
require anaesthesia.
This thesis describes a number of studies in which high energy microwave thermotherapy is applied 
using the Prostatron (EDAP Technomed, France) in combination with software version 2.5. This 
device uses a 1296 MHz microwave generator, delivering the microwave energy through a flexible 
urethral applicator. A frequency of 1296 MH was chosen because the heat distribution pattern more 
or less follows the borders of the transition zone of the prostate. To reach destructive intra prostatic 
temperatures at a depth of 10-15mm from the urethra, the energy delivered is as high as 70Watts. To 
avoid heating of the urethra above 450C, the thermal pain threshold, a urethral cooling system 
continuously protects urethral mucosa and striated sphincter area. Microwave heating is dependant 
on radiation penetrating tissue; the cooling mechanism is based on conductive cooling.
Theoretically, in homogeneous tissue, these two mechanisms, heating by radiation and cooling by 
conduction, result in an intra prostatic heat pattern with a steep ascending slope close to the urethra 
and a progressive descending slope towards the rectal mucosa (Figure).
Conductive cooling
Hot
Radiative heating and conductive cooling
Cold
(Figure courtesy of Vincent Cabane)
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Until recently the object of patient selection in the treatment of BPH was to identify patients 
suffering from lower urinary tract symptoms not related to an obstructing enlarged prostate, as in 
10-25% of these patients surgical intervention for BPH is unsatisfactory.17-19 As is the case of other 
treatment modalities, transurethral microwave thermotherapy, does not have the same high success 
rate as transurethral resection of the prostate.
Although the overall response to high energy thermotherapy is good, analysis of treatment results 
discloses considerable variability in individual patient response.13,19-23 Many patients show an 
excellent response, while some show virtually no response at all. As several treatment protocols are 
available each accompanied by its own morbidity, one should try to select patients who are best 
suited to a specific therapeutic option. Several consecutive treatments should be avoided, when one 
optimal treatment could be selected on the basis of explicit criteria. This will not only be beneficial 
for the patient, but will also be more cost effective. Therefore individualization of therapy by 
identifying predictive baseline parameters would be of great importance. The maximum benefit of 
transurethral microwave thermotherapy can be achieved only after the identification and application 
of the proper selection criteria.
13
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OUTLINE OF THESIS
Since the introduction of transurethral microwave thermotherapy several devices, catheter designs 
and software versions have been described. In chapter 1, a review is presented of transurethral 
microwave thermotherapy in the treatment of patients with lower urinary tract symptoms and benign 
prostatic hyperplasia. Different techniques, clinical results and morbidity of various therapeutic 
modalities, are discussed as well as the current place of transurethral microwave thermotherapy in 
the armamentarium of treatment modalities.
In chapter 2 the clinical results of high energy transurethral microwave thermotherapy are 
presented. When introducing a new treatment modality one should always compare results and 
morbidity with the gold standard method of treatment at that moment. We present results of a 
prospective randomized study performed in a non-affiliated hospital, comparing high energy 
transurethral microwave thermotherapy with transurethral resection of the prostate. The efficacy and 
durability of the treatment are evaluated by analyzing the re-treatment rate. Subsequently the 
durability of the high energy TUMT in 301 consecutive treated patients has been analyzed. In this 
analysis we tried to identify clinical baseline parameters, predictive of treatment durability.
Chapter 3 presents results of 4 clinical studies investigating selection criteria to predict outcome of 
high energy transurethral microwave thermotherapy. Multiple regression analysis was performed in 
a patient cohort of 247 patients to identify any parameter predicting for a good or poor response 
after high energy TUMT, using one particular device; the Prostatron (EDAP Technomed, France). 
For this analysis WHO-criteria were used to define a good and poor outcome following treatment. 
In the following studies with the same patient population cut-off points were calculated to create 
nomograms and graphs which may assist clinicians in selection of patients who are the best 
candidates for high energy TUMT using the Prostatron with software version 2.5. Case selection 
analysis was also performed in patients treated with other devices (Urowave, Prostalund and 
Prostatron) in an effort to identify possible baseline parameters which could be used to 'pre' select 
the best responders to different microwave devices and treatment programs.
In chapter 4 a retrospective analysis is presented in which clinical results of high energy 
transurethral thermotherapy are correlated with patients' physical condition, according to the 
American Society of Anaesthesiologists operative risk classification (ASA).
Because the total amount of energy delivered to the prostate in an operator independent treatment 
procedure is a major predicting factor of a good response in all outcome criteria, a significant 
contribution of 'intrinsic' prostatic factors (tissue composition, vascularisation) is suggested.
For this reason using a combined immunohistochemical and quantitative morphologic technique, 
the microvessel density and stromal epithelial ratio was determined in prostate biopsies from 
different anatomical zones in 43 patients taken prior to high energy microwave thermotherapy. 
These findings were than correlated with treatment outcome.
14
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CHAPTER 1
REVIEW OF TRANSURETHRAL MICROWAVE THERMOTHERAPY IN 
THE TREATMENT OF PATIENTS WITH LOWER URINARY TRACT 
SYMPTOMS AND BENIGN PROSTATIC HYPERPLASIA
Based on:
Current status of thermotherapy of the prostate 
J.J.M.C.H. de la Rosette, F.C.H. d'Ancona, F.M.J. Debruyne 
J.Urol, 157: 430-438,1997

CURRENT STATUS OF THERMOTHERAPY OF THE PROSTATE

Chapter 1
ABSTRACT
We reviewed the available data on Transurethral Microwave Thermotherapy (TUMT) in the 
treatment of patients with benign prostatic hyperplasia (BPH). Furthermore we provide a 
perspective of this minimal invasive treatment modality.
To our knowledge all previously published data from clinical trials of TUMT therapy for BPH are 
reviewed.
TUMT was designed to apply microwave energy deep within lateral prostatic lobes, whilst 
simultaneously cooling the urethral mucosa thus enabling an outpatient based anaesthesia-free 
procedure. Lower energy protocols using the Prostraton device provide a significant symptomatic 
improvement and an improvement in maximum flow of about 35% over baseline. When using other 
TUMT devices, similar changes are being documented. Higher energy protocols, using the 
Prostatron device, result in a similar symptomatic improvement as lower energy protocols, while the 
improvement in flowmetry is much more pronounced. However the latter is achieved at the price of 
increased morbidity. Second generation protocols have not yet been documented by the users of the 
other thermotherapy devices.
Numerous studies unequivocally support the efficacy and safety of transurethral microwave 
thermotherapy for treatment of symptomatic benign prostatic hyperplasia. Significant improvement 
in both objective and subjective parameters has been realized with TUMT across multiple centers in 
the United States and Europe.
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INTRODUCTION
Benign prostatic hyperplasia is a nonmalignant enlargement of the prostate that is due to excessive 
growth of both the glandular and stromal elements of the prostate gland. This is a very common 
condition in men over 40 years of age of all races and cultures and it may lead to troublesome lower 
urinary tract symptoms that usually result in referral to a urological clinic.1
Previously, the therapeutic options for symptomatic benign prostatic hyperplasia mainly consisted 
of surgical resection of the prostate. The transurethral surgical approach (TURP) has dominated 
prostatic surgery because of the high success rate and low morbidity obtained in the hands of 
experienced urologists. Although it is an effective treatment for most men, it is by no means perfect. 
Approximately 20-25 percent of patients that underwent surgery do not have satisfactory long-term 
outcome with a reoperation rate up to about 15% over an 8 year observation period.2,3 Furthermore, 
there is some morbidity of this surgical intervention. The necessity for general or spinal anesthesia, 
possible blood transfusion (5-10%) and infection, involves risks with a mortality rate that still 
amounts to about 1%.4,5 Some degree of urinary incontinence is reported in 2-4% and the incidence 
of urethral strictures even amounts to 2-20% of patients.6,7
Due to the aging population, the costs induced by the treatment of BPH represent a substantial part 
of health expenses in most countries.8 Because of these problems as well as the desire of many men 
to avoid surgery whenever possible, the management of symptomatic BPH is in transition. It now 
also includes medical management that is reversible at the end of the treatment,9-11 and several 
minimally invasive procedures that aim at the removal of tissue.12-16 Efforts to dilate the prostatic 
tract either by balloon or stents have either been abandoned, or reserved for the unfit patient.17,18 
The application of heat in prostatic disease has been advocated over a century.19 Heat is a physical 
agent whose biological effects depend on the intensity, duration and means of application. The 
majority of the several interventional nonsurgical modalities that have emerged the last decade, 
apply the thermal energy to the prostate adenoma by either the rectal or urethral route. Different heat 
applicators have been used, varying from laser-devices to high intensity focused ultrasound and 
radio-frequency. Presently, the major drawback of these options still is the necessity for anesthesia. 
The use of microwave as a heat source, has also been extensively investigated. Pioneer microwave 
research efforts in the early 1980's focused on the use of hyperthermia in the research in prostate 
cancer by applying microwave heat rectally or urethrally. It eventually became apparent that with 
hyperthermia the aimed temperature of 45 °C or less, was not effective 20 and higher temperatures 
were required. This led to development of transurethral microwave thermotherapy that was designed 
to apply microwave energy deep within lateral prostatic lobes, whilst simultaneously cooling the 
urethral mucosa thus enabling an outpatient based anesthesia-free procedure.16
22
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The rational behind microwave thermotherapy
Microwave comprise the 300-3000 MHz range of the appropriate electromagnetic spectrum. The 
entire spectrum of electromagnetic waves (X-rays, visible light, infrared) can interact with living 
matter, but the mechanisms of interaction are not the same in the entire frequency range. The 
interaction with microwaves results in the heating of biological tissue.
As microwaves propagate through the tissue, energy is transferred to heat via electromagnetic field 
oscillation of free charges (electrons and ions) and by polarization of small molecules (mainly H2O). 
The resulting molecular kinetic energy raises the temperature of the tissue and causes heating. The 
penetration of microwaves is greater in low-water content (fat) than in high-water content tissue 
(muscle). 21 Moreover, the higher the frequency, the less the penetration. Consequently, the depth of 
the penetration is dependent on the frequency and the predominant type of the targeted tissue, and at 
any time given frequency, penetration also varies with the temperature.16 Unfortunately, the waves 
are refracted, reflected, and dispersed when met with tissue inhomogeneities. Furthermore, tissue 
temperatures in a microwave field depend, not only on the energy extracted, but also on the thermal 
conduction and convection related to tissue perfusion.
With thermotherapy the transurethral route was chosen to deliver the microwave energy through a 
flexible applicator. Often a frequency of 1296 MHz was chosen, since the isothermic field shows a 
concentric heat distribution more or less following the anatomical borders of the transition zone of 
the prostate and not reaching the maximum temperature in the rectal mucosa. The goal of heating is 
to destroy tissue by achieving temperatures that exceed the cytotoxic threshold and includes cell 
death. The cytotoxic thermal threshold for prostatic adenomatous tissue is 45 °C for 30 minutes.16 
However, the threshold depends on the cell type and thus when heterogenous tissue is treated, not 
all cells within the treated area will die. Furthermore, small capillaries are thrombosed, whereas 
larger vessels are spared because they are cooled by blood flow.
In order to destroy intraprostatic tissue at a depth of 10-15 mm from the urethra, the required power 
would raise the temperature at the urethral level to 75°C to 80°C. Because the thermal pain 
threshold is at 45 °C, the urethral temperature should be no more. Therefore, to avoid heating of the 
urethral mucosa over 45 °C, the urethra is cooled. Whereas microwave heating is depending on 
radiation penetrating tissue, cooling is based on conductivity which has a limited action. These two 
principles, radiative heating and conductive cooling, results in a temperature curve with a steep 
ascending slope and a progressive ‘descending’ slope (figure 1). In this manner, deep within the 
prostate temperatures exceed the cell toxicity threshold with consequent tissue destruction, whereas 
the urethral mucosa remains spared. And in this way, the urethral temperatures maintain below the 
thermal pain threshold which enables the treatment to be performed without the need for anesthesia.
23
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Figure 1. Transurethral Microwave Therapy concept with combination o f radiative heating and 
superficial conductive cooling leads to a temperature pattern with a steep ascending slope and a 
progressive descending slope within the prostate.
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Clinical studies
Many thermotherapy devices have been developed for the treatment of patients with lower urinary 
tract symptoms and benign prostatic hyperplasia: the Urowave (Dornier Medical System, 
Germering, Germany), ECP (Prof.H. Wiksell, Stockholm, Sweden), Prostalund (Lund Instrument, 
Lund, Sweden), T3 (Urologix, Minneapolis, USA), Prostcare (Bruker Spectospin, Wissembourg, 
France), LEO Microthermer (Laser Electro Optics) and the Prostatron device (Technomed Medical 
Systems, Lyon, France). The results of these systems are summarized in table 1 (no data available of 
the ECP device). The Prostatron device has been most widely used and reported, and the authors 
have experience with over 700 patients treated using this device. Therefore, the following section 
reports this experience with the Prostatron device and compares results with those available from 
the other devices and with transurethral resection of the prostate (TURP).
Table 1. Results with different thermotherapy systems.
device authors No.pt baseline 3 Months 12 Months
Qmax SS Qmax SS Qmax SS
T3 Miller62 103 9.4 20.4* 14.3 7.8* na na
Prostalund Roos63 177 8.4 15.1 9.5 9.9 9.9 10.5
Urowave Goldfarb69 62 8.3±0.6 22.6±0.6* 11.3±1.0 10.8±0.8 11.6±0.6 11.2±0.8
Proscare Eliasson70 172 9.8±3.4 12.7±4.6 10.3±3.9 7.0±4.9 10.9±4.2 6.6±4.4
Leo Bdesha66 22 12.3 30* 14.6 11* na na
Prostatron 2.0 Cauwelaert41 128 9.2 11.3 14.9 2.1 na na
Prostatron 2.0 de la Rosette39 130 9.9±3.0 12.7±3.3 na na 11.6±4.3 6.8±4.6
Prostatron 2.0 Ogden25 22 8.5 14.5 13 4.3 na na
Prostatron 2.0 Tubaro47 100 8.6±2.4 14.2±3.8 11.6±4.8¥ 5.5±4.9¥ na na
Prostatron 2.0 Devonec64 818 8.8 13.3 13 5.7 12.6 3.5
Prostatron 2.0 Terrai65 63 6.6±2.4 22.0±7.0* na na 11.4±7.4 13.1±6.6
Prostatron 2.0 Blute22 150 8.5±0.3 13.7±0.3 na na 11.3±0.4 5.4±0.4
Prostatron 2.0 Höfner67 32 11.3 9.9 15.1 3.1 na na
Prostatron 2.0 Kirby68 140 10.1±4.7 23.7±4.4^ 12.3±3.2 10.6±2.7 12.4±3.4 11.6±3.3
Prostatron 2.0 Dahlstrand26 37 8.6±2.5 12.1±3.0 11.6±4.2 2.9±3.0 12.6±3.9 2.2±2.4
Prostatron 2.0 Marteinsson71 115 9.8 15.7 13.3 3.8 13.7 2.6
Prostatron 2.0 Netto60 100 na na na na na na
Prostatron 2.5 Perrin72 72 9.2±0.3 17.5±0.4 15.2 6.5 na na
Prostatron 2.5 de la Rosette36 116 9.6±3.3 13.6±3.6 15.2±6.5 6.0±4.5 14.5±5.9 4.9±4.4
Prostatron 2.5 de Wildt42 85 9.4±3.3 13.9±3.6 15.8±7.0 6.7±4.6 14.9±6.7 5.8±4.7
* IPSS symptom score • Boyarski symptom score
¥  6 months follow-up
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Lower energy protocols
Several versions of the operating software have been used in clinical trials. The standard operating 
software for the Prostatron is version 2.0, and worldwide, remarkably similar clinical results have 
been reported from several centers.22-27
The symptomatic improvement is significant with a decrease in Madsen symptom score from 
around 13 to 4. The changes in objective parameters are less pronounced. Mean maximal flow rate 
increase ranges from 3 to 4 ml/s, representing a mean improvement of about 35% over baseline. 
These improvements are noted from 6 weeks and persist over a period of 3 years.28 
Although these results are very promising, the degree and significance of the placebo effects 
remained controversal29. Several randomized Sham-controlled studies have been conducted using 
Prostasoft 2.0. In a recent paper by de Wildt et al.30 a 12 month study of the placebo effect of TUMT 
and an overview of the published placebo controlled studies of TUMT were presented. It was 
clearly demonstrated that the effect of TUMT is greater than can be accounted for by either the 
associated urethral instrumentation or by any placebo effect. Analyses of the response rate to the 
two treatments showed that 62% had a >50% improvement in symptom score in the treated group as 
opposed to 18% in the Sham group (p=0.001). For flow rate changes the figures were 36% and 11% 
(p=0.002). In figure 2 a review of TUMT data for individual symptom score and uroflow changes 
compared to Sham from baseline are presented compiled from the Sham controlled studies 
conducted.
In order to evaluate the clinical utility of TUMT, a randomized study comparing it with TURP was 
performed by Dahlstrand et al.26 This study showed significant improvements after both TUMT and 
TURP in symptom scores, maximum flowrate, post voiding residual and grade of bladder outlet 
obstruction. Although the decrease in symptom score was more pronounced after TURP (92%) than 
after TUMT(78%) the observed improvement after TUMT corresponds well with that of other 
reports of TURP.31-32 Also the improvements of voiding parameters were significantly more 
pronounced after TURP than after TUMT at 2 years ( see also fig 3). Although TUMT was seen to 
have a lesser effect on uroflow, in favor of this treatment modality is the minimal morbidity. The 
latter will be discussed more extensively in a separate section.
Higher energy protocols
On a conceptual basis, the increase in thermal dose can be seen with the evolution of thermal 
treatment modalities for BPH patients. The elevation of intraprostatic temperatures as measured by 
invasive thermometry during TUMT using version 2.0 operating software has been shown to be 
broadly correlated with clinical outcome.33 The number of patients who had a successful outcome, 
as defined by either a significant increase in maximum flow or decrease of symptoms, was 
significantly greater among those in whom a higher temperature was achieved. Consequently further 
modifications to the operating software have been made in recent years in order to achieve higher 
intraprostatic temperatures to provide greater clinical efficacy. Higher temperatures may be the only
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way to achieve the removal of the obstruction. Program version 2.0 was modified to provide more 
power at a maximum of 70 W and a higher rectal threshold leading to fewer treatment interruptions 
and increase in the energy delivered to the prostate. This new version of the operating software 
known as Prostasoft version 2.5 is currently under evaluation.
The first reports on the application of higher energy levels using Prostsoft 2.5 were by Devonec et 
al. and de la Rosette et al., and demonstrated clinically significant improvement.34,35 More recently, 
the European BPH study group performed a multicenter study in a total of 116 patients using 
Prostasoft 2.5.36 In this study the mean Madsen score improved from 13.6 at baseline to 5.5 at 26 
weeks. In contrast to the lower energy protocol the improvement in flowmetry was more 
pronounced. The maximum flowrate improved from 9.6 ml/s at baseline to 14.1 ml/s at 26 weeks 
follow-up. These objective and subjective improvements sustained to 52 weeks. The improvement 
in uroflowmetry of this high energy protocol over the lower energy protocol can be explained by the 
ablative capability of this treatment protocol: transrectal ultrasonography at 3 months follow up 
identified in almost 40% of patients a cavity. There appeared to be a good correlation between the 
presence of cavities and uroflowmetry improvement. The best candidates for this treatment protocol 
appeared to be patients with moderate-to-severe bladder outlet obstruction, as measured by 
pressure-flow studies, and patients with larger prostates.
Morbidity
Besides a favorable outcome following treatment, morbidity caused following TUMT treatment is 
an important issue. The lower energy TUMT treatment is well tolerated by the patients. Perception 
of discomfort varies from a mild feeling of perineal warmth and a mild urge to urinate to occasional 
significant discomfort. Distraction and reassurance are usually enough, but momentary interruption 
of microwave emission may be useful in those with major discomfort. Most patients experience 
perineal discomfort and urinary urgency for several days after treatment, but not usually longer. 
Occasionally hematuria is noticed. No tissue sloughing occurs, and urinary retention is expected in 
up to 25% of patients.15,16,22,24-26,37-39 In these cases, a catheter may be necessary for an average of 7 
days.
Also the high energy treatment is well tolerated by the patients although pain medication needs to be 
administered in most patients prior to or during therapy. On a trial and error basis, 30 mg MS 
Contin administered 2 hours prior to therapy resulted in the majority of patients in an almost 
complaint free treatment. If requested, patients were given additional drugs during treatment, either 
Diazepam 10 mg and/or Fentanyl 0.10 mg. In contrast to the lower energy protocol, in patients 
treated with Prostasoft version 2.5, a urinary retention is expected in all most all patients treated. 
The need for catheterisation is at average 2 weeks. In table 2, the differences in morbidity, including 
changes in sexual functions, between the two treatment protocols is envisaged in more detail. Only 
two papers mention erectile dysfunction following thermotherapy ranging from 0.8-5%, while the 
majority of papers report no changes at all following high or lower energy TUMT (table 2). In
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patients treated with lower energy protocols, the retrograde ejaculation rate ranges from 0-11% 
while for the higher energy protocols the retrograde ejaculation rate increased up to 44% (table 2).
Table 2. Morbidity after treatment
device authors No. cath. retent haem. infect. Ed. Ep. stric. incon. retre.
T3 Miller62 103 - - - - - - - - -
Prostalund Roos63 177 - 3.3% 2.2% 2.3% - - 0.0% 0.0% 9.0%
Urowave Goldfarb69 62 - 4.8% 12.9% 0.0% 0.0% 3.2% 0.0% 0.0% -
Proscare Eliasson70 172 - 6.0% 62.0% 2.3% - 0.0% - 0.0% 1.1%
Leo Bdesha66 22 - - 31.8% - 0.0% 0.0% - - -
Prostatron 2.0 Cauwelaert41 128 3.1 33.0% 2.6% - 0.0% 0.0% - - 0.6%
Prostatron 2.0 de la 130 - 26.0% 4.5% - - 0.8% 0.0% 0.0% 10.7%
Prostatron 2.0 Ogden25 22 - 22.0% - - - - - - 4.5%
Prostatron 2.0 Tubaro47 100 - - - - - - - - -
Prostatron 2.0 Devonec64 818 - 10- - - 0.0% 0.0% - - 7.0%
Prostatron 2.0 Terrai65 63 3.9 36.0% 1.5%** 1.5% - 1.5% - - -
Prostatron 2.0 Blute22 150 - 36.0% 40.0% - - 0.6% - - -
Prostatron 2.0 Höfner67 32 - - - - - - - - -
Prostatron 2.0 Kirby68 140 - 25.0% 15.0%* 15.0%* 5.0% - - - 3.0%
Prostatron 2.0 Dahlstrand26 37 3580 13.5% 0.0% 13.5% - - - - 10.8%
Prostatron 2.0 Marteinsson71 115 14.8 28.6% - 6.9% 0.8% 1.7% - - -
Prostatron 2.0 Netto60 100 - - - - 0.0% 11.0% - - -
Prostatron 2.5 Perrin72 72 >2wk 80.0% - - - - - - -
Prostatron 2.5 d.l. Rosette36 116 16 100% 76.0% 7.0% 0.0% 44.0% 0.0% 0.0% 5.9%
Prostatron 2.5 de Wildt42 85 14.3 100% - - - 33.0% - - 2.6%
(*haematuria and infections,**clot retention)
cath.: duration of catherisation [days]
retent.: number of patients with retention directly following TUMT treatment Strict.: strictures occuring post treatment
haem.: hematuria following TUMT treatment Incon.: incontinence following TUMT treatment
Infect.: urinary tract infections post treatment Retre.: retreatment after TUMT, containing
Ed: erectile dysfunction posttreatment surgical and/or medical treatments 
Ep: ejaculatory problems (retrograde ejaculation/no ejaculation)
Durability o f response
The retreatment rate after prostatectomy ranges up to 15% and depends on the interval of follow-up. 
It is unknown whether this re-treatment rate is related to the technique used, or to the dimensions of 
the cavity achieved by surgery. Clinical trials have shown a significant benefit from transurethral 
microwave thermotherapy, although it is apparent that not all patients with lower urinary tract 
symptoms and BPH are completely relieved of their symptoms. Several studies using lower energy 
thermotherapy report their surgical re-treatment rate up to 1 year. At Charing Cross Hospital in 
London, 100 patients were followed, and at 1 year 11% had required TURP for persistent symptoms 
or high residual urine.40 De la Rosette et al. presented the results of a group of 130 patients with the 
follow-up of 1 year.39 In this group, 8% of patients were additionally treated with TURP. In a study 
by Dahlstrand et al. of 39 patients treated with TUMT, 10% of the patients were considered non­
28
Chapter 1
responders and, therefore, underwent TURP.26 Blute et al presented the results of 150 patietns with a 
follow up of 1 year, and 12% of patients were regarded as non-responders.22 On the other hand, Van 
Cauwelaert et al.41 and Tubaro et al.24 have reported only low retreatment rates with significant 
subjective and objective improvements.
When applying higher energy levels, outcome seems improved and may eventually result in a more 
durable response. Until now the data on the outcome of the treatment using software version 2.5 are 
limited. In a study by de la Rosette et al.36 it appeared that only in 3 out of 116 patients an additional 
TURP was performed. No bladder neck contraction or urethral strictures were reported. De Wildt et 
al.42 confirmed these findings, documenting 5 surgical interventions at 1 year follow-up in 85 
patients treated.
Durability of response however should be documented with a longer follow-up. Dahlstrand et al.43 
presented data of 3 years follow up and it was shown that the effects persist for at least three years. 
De Wildt et al.44 presented their data in a group of 305 patients treated with Prostasoft 2.0. After 3 
years follow-up 133 patients who had only been treated with TUMT were available. Over this 
period of observation a significant symptomatic improvement over baseline (Madsen from 12.9 to 
5.6, 6.8 and 11.7 at 1,2 and 3 years respectively) and improvement in maximum flow of 2.6 ml/s at 
3 years follow-up was seen. Hundred and twenty-five were retreated with either invasive or medical 
treatment. Lower energy TUMT shows a significant and durable improvement of baseline 
parameters in 51% of patients. A similar trend was observed in a long-term follow-up study by the 
U.S. investigators. However, in contrast with the European study, a larger number of patients had 
additional medical treatment and consequently the number of surgical interventions was lower. Very 
few patients (11.1%) have undergone a surgical intervention despite the group being specifically 
selected to represent patients who would normally be treated by TURP. The results of TUMT at 4 
years show a sustained symptomatic improvement.45
Selection criteria
Analysis of treatment outcome demonstrates considerable variability in individual response. Some 
patients do surprisingly well, while other patients show almost no response to treatment.
Since several treatment protocols are available with different levels of morbidity one should try to 
select patients who are best candidates for this therapy.
In an attempt to provide selection criteria for the lower energy protocol (Prostasoft 2.0), de Wildt et 
al.46 analyzed the patient profile before treatment of a group of responders and nonresponders to this 
TUMT treatment. There was no difference in the two patient groups before treatment with regard to 
age, Madsen symptom score, uroflowmetry performance, postvoid residual volume, or prostate 
volume. It was concluded that there are no clinical parameters either for prediction of clinical 
outcome of for selection of the ideal candidate when using this treatment protocol. On the other 
hand, Arai et al.47 conducted a retrospective analyses and found that patients with apparent 
obstructive symptoms and with a moderate enlargement of the prostate showed a more favorable
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response to TUMT. However this analyses included only 32 patients while the follow-up parameters 
were obtained two months after TUMT.
When more advanced voiding studies were performed, using urodynamic studies with pressure/flow 
analysis, two distinct groups of patients could be identified responding differently to lower energy 
thermotherapy.48-50 It was hypothesized that if thermotherapy is able to modify the elasticity of the 
prostatic urethra, patients suffering from reduced elasticity should be ideal candidates for this 
treatment modality. Indeed an analysis of data of a large European multi center study showed that a 
certain type of obstruction responded favorably to this therapy.48 Although as baseline no significant 
difference was found between the two groups with regard to symptoms or uroflow parameters, the 
changes in objective parameters after treatment differed significantly in the two groups. Patients 
with a predominantly constrictive pattern of obstruction had significantly greater improvement in 
both maximum and average flow rates, as well as decrease in residual urine, than those with 
compressive obstruction.
When treating patients according the higher energy protocol, it appeared that simple clinical 
analysis of the outcome by means of maximum flow rates and Madsen symptoms scores 
demonstrated a substantial advantage of this protocol over the earlier versions. The greater objective 
improvement is explained by the decrease of urodynamic obstruction. Indeed in a recent study, de la 
Rosette et al showed that high energy thermotherapy results in a significant and substantial decrease 
of bladder outlet obstruction and it was concluded that especially patients with higher grades of 
bladder outlet obstruction seem to be best candidates for this treatment.51 Besides the grade of 
bladder outlet obstruction, prostate size seems to be an important parameter. Patients with larger 
prostates also respond best to this treatment protocol.36,42
With the availability of two different treatment protocols, differences in treatment outcome and 
morbidity, one may question the position of these therapies in the armamentarium of treatment 
options. The lower energy protocol, with an excellent subjective response and minimal morbidity, 
should be recommended in patients with smaller prostates and lower grades of bladder outlet 
obstruction. On the other hand, in patients with larger prostates and higher grades of bladder outlet 
obstruction, the higher energy protocol should be recommend resulting in and excellent subjective 
and objective response, however at a higher morbidity.
Since the morbidity is relatively low for both protocols and the treatment can be performed 
anesthesia free, especially patients in poor health seem good candidates for thermotherapy. A group 
of 47 patients, ASA risk groups III-IV, with a retention were treated according to the high energy 
protocol ( Prostasoft 2.5). Good results with regard to catheter release were obtained with a success 
rate of 81% in 6 months (Chaussy personal communication). Finally, with the public awareness of 
minimal invasive anesthesia free therapies for BPH, the demands for these therapies increases. 
Minimal morbidity and a single outpatient treatment are most appealing to many patient and this 
may be the reason why he selects such a therapy in favor to other more invasive therapies, 
disregarding a “better” objective outcome of these therapies. Moreover, at an earlier stage of
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voiding complaints than some decades ago, (younger) patients are in search for (minimal invasive) 
treatments. Treatments such as thermotherapy do not (or only minimally) interfere with the sexual 
functions in these (younger) patients and consequently they prefer to be treated with thermotherapy.
Fig 2. Results o f prospective randomized TUMT (2.0) versus SHAM studies comparing mean values 
o f Madsen Symptom Score and maximum flow rate at baseline, 3 months and 12 months. Data from 
the following studies:
SHAM n=64 
SHAM n=36 
SHAM n=46 
SHAM n=40
Devonec et al. 75 
Biute et al.74 
de Wildt et al.30 
Nawrockl et al.73
TUMT n=191 
TUMT n=75 
TUMT n=47 
TUMT n=40
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Fig 3. Results o f a prospective randomized TUMT (2.0) versus TURP treatment. 
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DISCUSSION
The standard operating software for the Prostatron is version 2.0 and clinically significant objective 
and subjective changes are demonstrated. The mean maximum flow rate improved of about 35% 
over baseline while the symptomatic improvement is comparable to improvements seen following 
surgical resection. The efficacy of thermotherapy has been enhanced by applying higher energy 
levels to increase the intraprostatic temperatures. The results of high energy thermotherapy showed 
significantly better objective improvement over former lower energy protocols with similar 
subjective outcome. However, although the results in a subgroup of patients are comparable to the 
results achieved with surgical resection of the prostate, there still is a significant group of patients 
that does not respond favorably. It became apparent that the size of the prostate and the grade of 
bladder outlet obstruction were indicative for treatment outcome. In patients with small prostates 
and minimal bladder outlet obstruction, lower energy thermotherapy seems most appropriate48,50 
while best candidates for the higher energy protocol are patients with large prostates and moderate- 
to-severe bladder outlet obstruction.36,42 This variability might be explained by the working 
mechanism of the type of heat treatment and the heterogeneity of the prostatic tissue. The difference 
in tissue composition and in particular the vascularisation of the prostate in each individual patient, 
are likely the most important contributing factors. Therefore, to further enhance treatment outcome 
future research efforts should be focused on gaining better insight in prostate vascularisation, tissue 
composition, and temperature mapping of the prostate which may lead to possible adaptions to the 
treatment protocol and/or devices.
Little is known about the difference in vascularisation in each individual prostate and it’s correlation 
in the response to heat treatment. Several authors demonstrated that there was an enormous increase 
in prostatic blood flow by using color Doppler imaging.28,52,53 When quantifying the amount of 
increase in blood flow by using color Doppler imaging, there appeared a 12.5 fold increase in blood 
flow mainly in the adenomatous part of the prostate. This change in blood flow may explain why 
bigger prostates respond better to high energy thermotherapy than smaller prostates. Maybe in larger 
prostates the blood flow response is worse because these prostates are poorly vascularized compared 
to smaller prostates. Thus, the heat sink effect is less effective in these patients, resulting in more 
damage to the treated adenomatous tissue, and eventually resulting in the formation of cavities. 
However, presently color Doppler imaging still lacks high reproducibility and quantification is 
difficult.
Imaging of the vascularisation of the prostate implies a dynamic process, whereas the determination 
of the tissue composition of the prostate relies more on a static condition. The prostate is composed 
from smooth muscle, fibrous tissue, epithelium and glandular lumen. However, the proportion of 
the various components differs for each individual prostate.54 This heterogeneity of tissue, with 
different reactions to microwaves of each component, might partly explain the variety of treatment 
outcome since in theory the TUMT effect is essentially based on the application of heat to
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homogenous tissue. Therefore, to correlate outcome with prostate composition, histology is 
necessary. Hefty et al. showed that there was a difference in the stromal-epithelial ratio of the 
transition zone of the prostate between patients who failed and who were successful to treatment 
with laser.55The specimens for histology were obtained from pretreatment prostatic biopsies. On the 
other hand a morphometric study by Arai et al.56 supports the contention that the histological 
components of the prostatic tissue plays an important role in terms of microwave thermal 
interactions and treatment outcome. The authors suggest that indeed certain ideal prostate 
characteristics may predetermine a response to TUMT. Similar studies to correlate treatment 
outcome after TUMT are currently also conducted at our department. Drawback of these studies is 
the invasive way to obtain histology with consequent risk, and the representability of the biopsies. 
The above mentioned methods that possibly give insight in the properties of the prostate 
composition, do not elucidate the actual effect that heat has on prostatic tissue. Possibly temperature 
mapping contributes to a better understanding. The ideal treatment protocol would be the one that 
continuously measures the intraprostatic temperature at multiple levels in the prostate to form a 
feedback system with the energy delivery system to regulate the determined temperatures. 
Thermometry studies have been performed by applying intraprostatic temperature sensors by the 
perineal route.33,57 Major drawback is the invasive nature of this procedure which limits the amount 
of sensors. Furthermore, they only measure the temperature at predetermined sensor locations, 
which might not correspond to the actual tissue location of interest. Hence, a non-invasive 
temperature feedback method should be investigated that can cover the whole prostatic region. 
Ultrasound is capable to depict tissue temperature changes by measuring shifts in the reflected 
signals that are proportional to the change in tissue temperature.58 Therefore, the theory to combine 
transrectal ultrasound temperature mapping of the prostate with the heat delivery system to establish 
a feedback system, offers unique opportunities to greatly enhance treatment efficacy.
So major research efforts should be aimed at achieving insight in the fundamental dynamic and 
static properties of the prostate to make adaptions to either the treatment protocol and/or devices 
and initiation of clinical trials with proper selection criteria possible. It is clearly shown that from all 
parameters, prostate size and the grade of bladder outlet obstruction are most indicative for 
treatment outcome. However, although transrectal ultrasound of the prostate is a common 
assessment tool in patients with benign prostatic hyperplasia, the use of urodynamic investigations 
with pressure-flow studies is still a matter of debate due to the invasive character of the procedure, 
the costs and the availability of the equipment and personnel.59 Therefore, future clinical trials in 
thermotherapy could greatly benefit from any noninvasive and easy accessible assessment tool, like 
the options which have been discussed in the above paragraphs. These diagnostics are mandatory to 
be able to distinguish possible responders to non responders to TUMT treatment and decide which 
protocol (high or low energy) to be used. Moreover research should be supported aiming at a 
reduction of the morbidity during thermotherapy and at follow up. Can a good treatment outcome be 
maintained following a shorter treatment duration?60 What type of pain medication during therapy
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should be recommended?36 Should we try to replace the transurethral catheter post treatment by a 
temporary transurethral stent?76
The object for further studies must be to determine the thermal dose that will maintain a safe 
treatment with clinically significant improvements, whilst causing minimum morbidity. Only by 
identifying and applying the proper selection criteria, maximum benefit of thermotherapy can be 
achieved.
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HIGH ENERGY TRANSURETHRAL THERMOTHERAPY (TUMT) VERSUS 
TRANSURETHRAL RESECTION OF THE PROSTATE (TURP): 
RESULTS OF A PROSPECTIVE RANDOMIZED STUDY WITH A
1 YEAR FOLLOW-UP
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ABSTRACT
We compared the outcome of transurethral resection of the prostate (TURP) and high energy 
microwave thermotherapy (HE-TUMT) on patients with benign prostatic hyperplasia (BPH). 
Patients with symptomatic BPH were treated by either TURP (21 patients; mean age 69.6 ± 8.5 
years) or TUMT (31 patients; mean age 69.3 ± 5.9 years) and assessed using the Madsen symptom 
score, measurements of voiding parameters, transrectal ultrasound and, cystometry including 
pressure/flow analyzes. Examinations were repeated at fixed intervals for up to 12 months post 
treatment.
After both TURP and TUMT there was a significant improvement in all clinical parameters. At 1 
year follow-up a symptomatic improvement of 78 % in the TURP group was found and of 68 % in 
the TUMT group. The improvements in free flow rate are 100 % and 69 % in the TURP and TUMT 
group respectively. For both groups a significant relieve of bladder outlet measures was found. No 
serious complications occurred in either group while 1 patient in each group required a retreatment. 
Satisfactory results were obtained after both treatments with improvements following HE-TUMT in 
the same range as following TURP treatment.
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INTRODUCTION
In recent years, increasing attention has been paid to when and how patients with Lower Urinary 
Tract Symptoms (LUTS), caused by Benign Prostatic Hyperplasia (BPH), should be treated. The 
dominant instrumental treatment for BPH is still Trans Urethral Resection of the Prostate (TURP), 
which is considered the ‘gold standard’. Questions about the indications, results and complications 
of TURP have focused interest on minimal invasive (anaesthesia free) treatment modalities which 
have become available.1-8 One of these modalities is Trans Urethral Microwave Thermotherapy 
(TUMT).7
TUMT was designed to apply microwave energy deep within the lateral prostatic lobes whilst 
simultaneously cooling the urethral mucosa. 9 Many thermotherapy devices have been developed for 
the treatment of BPH.10-14 Most experience is available with the Prostatron device (Technomed 
Medical Systems, Lyon, France), and has been used with three software programs which have 
different features.15-17 Version 2.0 is the most widely used and the results achieved for symptomatic 
improvement and changes in urinary performance were encouraging: the Madsen symptom score 
decreased from a mean of 13 before treatment to about 4 after treatment, while mean maximum 
flow improvement ranged from 2 to 3 ml. per second. Since clinical outcome could possibly be 
enhanced with higher intra prostatic temperatures, resulting in thermoablation and thus cavity 
formation, modifications to the operating software have been made. Early reports on this high 
energy software version (Prostasoft 2.5)17-18 show a good subjective response and an excellent 
improvement in the objective parameters.
In the evaluation of a new technology for the treatment of BPH, however, the results should be 
compared with those obtained using a generally accepted method. We report on the 1-year follow- 
up of a prospective randomized study comparing high energy TUMT and TURP in patients with 
voiding complaints because of BPH.
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PATIENTS AND METHODS
Fifty two men aged between 54 and 89 years (average 69 years) with benign prostatic hyperplasia 
(BPH) underwent randomization (TUMT:TURP=3:2) in the trial, between January 1994 and August 
1995. All patients signed a written informed consent before participation after both verbal 
explanation and reading an explanatory leaflet. The criteria for entry into the study were: males aged 
45 years or older, candidate for TURP with the presence of a clinically unequivocal benign prostate, 
having a total prostatic length between 25 and 50 mm and a prostate volume between 30 and 100 
cm3, symptoms of bladder outlet obstruction for more than three months, a Madsen symptom score 
of 8 or greater, a peak flow rate of 15 ml/s or less with a minimum voided volume of 100 ml and 
post-voiding residual volume of 350 ml or less, and patient willingness and ability to comply with 
the study follow-up schedule and requirements. Patients with neurogenic disorders which may affect 
bladder function, prostatic carcinoma, surgical treatment of the prostate in the past, patients with 
microwave-possible sensitive implants (pacemakers, hip prosthesis), diabetic neuropathy, urinary 
retention requiring indwelling catheter, evidence of renal impairment, or an obstructed bladder neck 
by an enlarged median lobe of the prostate or patients who were on medication prescribed for the 
treatment of the prostate or bladder, were excluded from the study.
Assessment and follow up studies included general history (including the Madsen symptoms score), 
physical examination with digital rectal examination (DRE), estimation of full blood count, blood 
urea and creatinine, and urine microscopy and culture. Urine cytology and prostate specific antigen 
(PSA: Hybritech, Texas USA) levels were always measured in order to exclude coexisting 
malignancy. Prostate configuration was assessed by performing transrectal ultrasound (TRUSP), 
volume being calculated using the ellipsoid formula with a 7.5 Mhz transrectal probe (Combison 
330 Voluson, Kretz Technik, Austria). In case of an abnormality on either DRE, PSA-level or 
TRUSP, ultrasound guided prostate biopsies were performed.
Table 1. Baseline parameters of TUMT-TURP study.
TURP TUMT 2.5
mean sd mean sd
Age (years) 69.6 8.5 69.3 5.9
prost. volume (cm3) 45 15 43 12
Madsen 13.8 4.2 13.3 4.2
IPSS 16.7 5.6 18.3 6.3
Qmax (ml/s) 9.3 3.4 10 6.1
Vcomp (ml) 178 84.1 193.5 85.7
Res. Urine (ml) 91 105 58 78
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A urethrocystoscopy was carried out to judge the patency of the (prostatic) urethra for the presence 
of strictures or an isolated obstructing prostatic middle lobe and to exclude intra vesical pathology. 
Follow-up visits were scheduled at 1,3,6 and 12 months after treatment. Urodynamic investigation 
with PQ study analysis was performed at baseline and 26 weeks post treatment. Ultrasound of the 
prostate was repeated at 12 and 52 weeks.
The flow rates were recorded using a Dantec Urodyn 1000 flowmeter (Dantec, Skovlunde, 
Denmark), and the figures corrected for artifacts by measuring the peak flow sustained over a period 
of two seconds. Any recorded flow of greater than 15 ml/s excluded the patients from the study. 
Residual urine was measured by suprapubic ultrasound using the 3.5 MHz, abdominal 
probe(Combison 330 Voluson, Kretz Technik, Austria). To quantify the grade of bladder outlet 
obstruction, urodynamic investigation with pressure-flow (PQ) analysis was performed. Intra vesical 
and rectal pressures were recorded using 8 F catheters mounted with microtip-sensors (MTC, 
Dräger, Germany), and detrusor pressure was calculated as the difference between both. The 
digitally stored pressure and flow-data were analyzed by a program developed at our department 
(UIC/BME Research Center, Department of Urology, Nijmegen, The Netherlands). The following 
parameters derived from the pressure-flow analysis were used: detrusor pressure at maximum flow 
(Pdet at Qmax in cmH2O), maximum flow rate PQ-Qmax in ml/s), and the linPURR (obstruction 
grading according to Schäfer). A patient is considered urodynamically obstructed when Pdet at Qmax 
falls into the obstructed area of the Abrams-Griffiths nomogram or when the linPURR is >3.
All TUMT treatments were performed on ambulatory basis using the Prostatron (EDAP 
Technomed, Lyon, France) device and the software 2.5. The method of therapy has been described 
previously. Treatment duration was 60 minutes with increasing thermal dose up to 70 Watts. To 
prevent thermal damage to urethral mucosa and rectal wall thermal sensors, urethrally and rectally 
positioned, give continuously feedback signals about the reached temperature. When the maximum 
allowed temperature is detected by 1 of these thermosensors the program automatically interrupts 
the treatment until the temperature decreases to a preset temperature. Prior to treatment 100 mg 
suppository of diclofenac was administered. Also 2 mg of midazolam was injected intramuscularly. 
During treatment no additional anaesthesia was given but if necessary, intravenous sedation was 
given when patients experienced major discomfort during treatment, which was mostly expressed as 
an intense urge to void, sometimes in combination with an urge to defecate. Since initial experience 
showed urinary retention in nearly all patients, therefore all patients were given a urethral catheter 
with leg-bag directly after treatment.
TURP treatment was performed by two experienced urologists and resection was performed under 
spinal anaesthesia. It was aimed to reach the surgical capsule circumferentially from the bladder 
neck to the verumontanum, using 24 Ch resectoscopes. The specimen weight, operation time, per- 
and post-operative complications were recorded.
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Statistical analysis was done with the Wilcoxon’s test for paired samples and the Mann-Whitney U 
two-sample test for independent samples (non-parametric).
Table 2. Follow-up of 52 patients at 3,6 and 12 months from baseline.
Number of patients 
baseline 3 months
TUMT 31 31
TURP 21 21
1 Bricker
6 months 
27 
1 TURP
1 deceased
2 refuses
20
1 lost in 
follow-up
12 months 
26
1 refuses 
18
1 bladder-neck 
incision
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RESULTS
The entry data for the two groups are given in table 1. No statistically significant difference was 
found between the pre-treatment measures and scores of the two groups. At baseline 52 patients 
entered the study: 31 for TUMT and 21 for TURP. At a year follow-up 44 patients were available 
for analysis. The mean operation time was 51 minutes (range 35-70) with a mean resected weight of 
32 gr. (range 8-100). The follow-up scheme is presented in table 2. At 6 months in the TUMT-group
1 failure of treatment was noted and underwent TURP, one patient died of a non-treatment related 
cause, one patient was lost in follow-up, two patients refused further follow-up visits (one of them 
had a good symptomatic as well as a good objective response, the other experienced even more 
complaints after treatment). At 12 months in this group another patient refused the last visit (also 
with a good subjective and objective response at 6 months). In the TURP-group at 12 months 1 
patient underwent a bladderneck incision because of sclerosis, and another patient underwent a 
cystectomy because of bladder cancer.
Both groups showed significant changes in symptoms scores. At 12 months the mean Madsen 
symptom score improved by 78% for the TURP group and by 68% for the TUMT group. Mean 
symptom scores improved from 13.3±4.2 at baseline to 5.2±4.1 at 3 months, stabilizing occurred at 
4.4±4.4 at 6 months and 4.2±4.6 at one year follow-up for the TUMT group. Similar changes were 
found for the TURP group, improving from 13.8±4.3 at baseline to 3.6±3.2 at 3 months and 2.5±2.3 
and 2.8±4.0 at 6 and 12 months follow-up respectively. Comparable changes were noticed in the 
IPSS scores. Also the mean maximum flow rate showed significant improvement from 10.0±6.0 
ml/s at baseline to 15.1±8.1 ml/s at 3 months follow up and remained stable at 17.0±7.0 ml/s at 6 
months and 16.9±8.1 ml/s at 1 year follow up in the TUMT group. For the TURP group, the mean 
maximum flow rate improved from 9.3±3.4 ml/s at baseline to 19.1±11.0 ml/s, 14.7±6.3 ml/s, and 
18.6 ml/s at 3,6 and 12 months follow up respectively (see also figure 1). Since it is easy for 
individual bad results to get lost in the mean data for the whole group, in table 3 the 50% decrease 
in symptom scores, a 50% increase in maximum flow rate or both for the TURP and TUMT group 
is presented.
Morbidity of the present study is presented in table 4. All patients accepted and tolerated the TUMT 
well. For the TUMT group a prolonged need for catheterisation was noticed when compared with 
TURP (mean: 12.7 days versus 4.1 days, median: 8 days versus 4 days). In this group, also a higher 
incidence of urinary tract infections was found, frequently in combination with irritative voiding 
complaints. The retreatment at 1 year follow-up is for both groups within the same range.
When evaluating the changes in obstruction, in each group improvements are being found (fig 2.). 
In the TURP group the mean URA improved from 45.7±16.5 cm H2O to 21.1±13.6 cm H2O, and the 
mean linPURR improved from 3.2±1.4 to 1.1±1.2. In the TUMT group the mean URA improved 
from 44.1±25.1 cm H2O to 25.1±8.5 cm H2O, and the linPURR improved from 3.3±1.8 to 2.0±0.9 
(Table 5.). According to the Abrams-Griffiths nomogram 76% in the TURP group and 62% in the
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TUMT group were considered obstructed before treatment, while at 6 months follow-up 15% and 
40% were still considered obstructed in the TURP and TUMT group respectively.
Figure 1. Outcome of subjective (A: Madsen Symptom Score, B: IPSS Symptom score) and 
objective (C: maximum flow in ml/s) parameters at baseline (bl) and follow-up (3,6,12 months).
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DISCUSSION
TUMT has recently received FDA approval and is very appealing to many urologist primarily 
because of its ease to use, the minimal morbidity, and the impressive safety profile in comparison 
to TURP. When using the lower energy protocol version (Prostasoft 2.0) an overall significant 
symptomatic improvement has been reported in the majority of patients in conjunction with 
improvement of voiding parameters.19 Since elevation of intra prostatic temperatures resulted in 
improvement of the clinical results, program version 2.0 was modified to provide more power 
leading to an increase in the energy delivered to the prostate. This new version of the operating 
software, known as Prostasoft 2.5, is currently under investigation. The early clinical results when 
using this High Energy Thermotherapy (HE-TUMT) are excellent and superior to earlier treatment 
protocols.18 In patients with larger prostates and moderate to severe bladder outlet obstruction 
(BOO), the results seem even comparable to those of surgical therapy. However, to be able to 
challenge the predominant TURP as an appropriate surgical option for treatment of patients with 
BPH, thermotherapy should in general provide results comparable to TURP. To compare the 
efficacy of HE-TUMT with TURP, this is only possible by performing a randomized controlled 
trial. To our knowledge, this is the first study conducted documenting the 1 year follow-up data of 
such a trial.
The level of improvement in the symptom scores was greater for the TURP-group then for the HE- 
TUMT treated group. However there appeared to be no statistical significant difference in the 
symptomatic improvement between both groups. The objective improvement is expressed in 
uroflowmetry results. The absolute improvement is less for the HE-TUMT treated group than for 
the TURP group; however, the difference between the improvements in maximum urinary flow for 
the two treatment groups was not statistically significant (table 5.). Although uroflowmetry results 
are associated with obstructive voiding, these parameters are not associated with the grade of 
obstruction, and, therefore, they cannot be used to determine
Figure 2. Urodynamic changes in after TURP (A) and HE-Thermotherapy (B), presented in the 
Abrams-Griffiths nomogram. (* represents pre-treatment-value,A represents the post treatment 
value).
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Table 3. 50% improvement in symptom scores (Madsen Symptom Score), maximum flow rate or 
both in respectively the TURP and TUMT group at 52 weeks follow-up.
TUMT TURP
Qmax increase > 50% 10 (32%) 10 (48%)
Symptom score decrease > 50% 17 (55%) 15 (71%)
Qmax and Symptom score improvement > 50% 7 (23%) 9 (43%)
Table 4. Comparison of TUMT or TURP at one year follow-up.
TUMT TURP
Outcome:
Mean symptomatic improvement 68 % 78 %
Mean uroflow improvement 69 % 100 %
Mean obstruction improvement 43 % 46 %
Morbidity:
Hospital admission (range) 0 days 4.1 days (4-5)
Duration catheterisation (range) 12.7 days (6-35) 4.1 days (4-5)
Urinary tract infections 16 % (n = 5) 4 % (n = 1)
Blood transfusion 0 % (n = 0) 0 % (n = 0)
Irritative voiding 29 % (n = 9) 19 % (n = 4)
Retreatment 3.2 % (n = 1) 4.7 % (n = 1)
Complications.
Hematuria requiring additional treatment 0 % (n = 0) 14 % (n = 3, coagulation)
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Table 5. Clinical and urodynamic results in the TURP and HE-thermotherapy group.
TURP TUMT TURP vs TUMT
before 26 wks 52 wks p-value before 26 wks 52 wks p-value p-value
Qmax 9.3 14.7 18.6 0.0024* 10 17 16.9 0.0002* 0.5456°
(ml/s)
Madsen 13.8 2.5 2.8 0.0003* 13.3 4.4 4.2 0.0001* 0.2010°
URA 45.7 21.1 0.003* 44.1 25.1 0.02* 0.01*
(cm H2O)
linPURR 3.2 1.1 0.003* 3.3 2 0.04* 0.14°
*significant and °not significant, according to Wilcoxon’s Rank test for paired samples and the Mann-Whitney U two 
sample test for independent samples.
objectively whether outlet obstruction is relieved.20 To quantify the grade of bladder outlet 
obstruction, urodynamic investigation with pressure/flow analyzes is considered the gold standard.21 
To judge the obstruction-relieving capabilities of HE-TUMT of the prostate, urodynamic studies 
need to be performed before and after treatment. A recent study indicates that HE-TUMT is indeed 
capable to relieve BOO.22 In the present study we found that in both the TURP and HE-TUMT- 
group there was a significant decrease in obstruction parameters (URA and linPURR) however the 
decrease in the TURP group was more pronounced. The difference between the decrease in 
obstructive parameters in both groups appeared to be significant (table 5.).
Despite many surgical and technical improvements, the rate of total morbidity related to TURP has 
remained unchanged over the years.23-25 Therefore, a variety of alternative and minimally invasive 
treatment modalities are under investigation. The major complications such as incontinence, 
transfusion, and TURP-syndrome have not occurred during transurethral microwave thermotherapy 
treatment.26 The morbidity of the microwave therapy following lower energy treatment mainly 
consists of the need for catheterisation in up to 25% of patients during 1 week.16 Following HE- 
TUMT treatment, clinical outcome parameters have improved but also the morbidity caused by this 
treatment protocol is increased compared to lower energy protocols. The high energy treatment is 
well tolerated by the patients but oral pain medication must be administered before or during 
therapy in most cases.18
Moreover the need for transurethral catheterisation post treatment increased as well as the incidence 
of post-treatment irritative voiding complaints. In both groups the incidence of urinary tract 
infections was low, there was no need for a transfusion while the retreatment rate was within the 
same range. The main drawback of TURP is the need for anaesthesia and consequently 
hospitalization. Transurethral microwave thermotherapy can still be performed as an outpatient 
procedure without general anaesthesia.
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Where should we position this high energy thermotherapy treatment? From the prospective 
randomized study of Dahlstrand et al. 27 comparing lower energy TUMT treatment with TURP, we 
have learned that after both treatments there was an improvement in all clinical parameters. The 
improvements in free flow-rate and obstruction were more pronounced after TURP. Serious 
complications occurred only in patients who underwent TURP. Moreover the improvements with 
either treatment lasted in that study for at least 5 years.28 In the present study we found similar 
symptomatic improvements in both groups, comparable to those of the study by Dahlstrand et al.28 
The improvement of the uroflowmetry parameters however, is much more pronounced when using 
the high energy protocol and is (in a subgroup of patients) in the same range as following TURP. 
Moreover, in contrast to lower energy protocols, in a considerable number of patients bladder outlet 
obstruction is relieved.22,29,30 We think that the latter maybe reflects in the durability of the HE- 
TUMT procedure. Although Dahlstrand et al. 27 stated that improvements following Prostasoft 2.0 
treatment lasted for at least 5 years, this could not be confirmed by other authors in a large series of 
patients.31,32 Both Blute et al. and de Wildt et al. found a retreatment rate approximating 50% at 
three to four years follow-up. We strongly feel that the thermoablative HE-TUMT treatment will 
eventually result in a more durable treatment in patients with BOO and a large prostate (>40 gr). In 
patients with no or only minimal BOO, however, we recommend preferably the use of the lower 
energy software version. In these cases a symptomatic improvement can be achieved at minimal 
morbidity.
CONCLUSION
HE-thermotherapy is an operator independent treatment modality in the treatment of BPH.
Overall the objective and subjective improvement attains results that are comparable with the ‘gold­
standard’ transurethral resection of the prostate. The urodynamic results however still show a 
significant difference in relief of obstruction after TURP and High energy TUMT treatment. The 
clinical significance of this difference in desobstructive power however is currently still unknown. 
With acceptable low morbidity high energy thermotherapy appears to be a safe and effective 
treatment with a low retreatment-rate.
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ABSTRACT
We evaluated the outcome and durability of high energy transurethral microwave thermotherapy 
(HE-TUMT) in comparison with transurethral resection of the prostate (TURP).
52 Patients with BPH and lower urinary tract symptoms were randomized and treated either by 
TURP (21 patients; mean prostate volume 45 ± 15 cc) or HE-TUMT (31 patients 43 ± 12 cc). Long­
term results were obtained at a mean follow-up time of 2.4 ± 0.5 years. During follow-up the mean 
symptomatic improvement stabilized at 56% in the TUMT group and 74% in the TURP group. The 
mean maximum flow increased with 62% following TUMT and 105% following TURP. Prior to 
treatment 78% of patients in the TURP group were obstructive according to urodynamic 
investigation; after treatment 14% of patients remained obstructive. In the TUMT group 67% of 
patients were obstructive before treatment and 33% remained so after treatment. Six Patients (19%) 
underwent TURP after TUMT (4 patients after 1 year), 2 patients were treated additionally with 
medication. 1 Patient underwent a bladder neck incision following TURP due to bladder neck 
sclerosis. Three patients were not satisfied with the outcome following additional TURP.
Both treatment modalities show good symptomatic and objective results at 2.4 year follow-up. Most 
re-treatments are performed 1 or more years post-treatment and based on subjective findings.
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INTRODUCTION
Microwave heating using the Prostatron already demonstrated to be an effective, one hour, no 
anaesthesia required, outpatient procedure for symptomatic benign prostatic hyperplasia in several 
sham controlled studies.1-4 Clinical studies using the Prostatron™ 2.5 software demonstrated a 
substantial improvement in symptoms with a symptom score decrease averaging 60% and an 
improvement in maximum flow of almost 50%.5-8 These objective and subjective improvements 
sustained for 52 weeks. Besides excellent short term results, durability of response should also be 
favorable in thermotherapy treatment. When using low energy TUMT, Dahlstrand et al.9,10 presented 
data in comparison to TURP, which showed a persisting effect up to 5 years. De Wildt et al.11 
however showed a retreatment rate either medical or surgical in 125 out of 305 patients at 3 years 
after low energy TUMT. Until now data on the outcome of the treatment using the high energy 
software version are limited. Studies with a 12 months follow-up showed a low rate of additional 
surgical interventions following high energy TUMT.5,8,12 Using the high energy software (Prostatron 
2.5) recently published data demonstrated a low retreatment rate at 2 years follow-up with a 
persistent good symptomatic and objective response.13
In this study we describe the long term results of our prospective randomized study comparing high 
energy transurethral microwave thermotherapy and transurethral resection of the prostate in men 
with lower urinary tract symptoms and benign prostatic hyperplasia.
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PATIENTS AND METHODS 
Clinical param eters
Fifty two men aged between 54 and 89 years (average 69 years) with benign prostatic hyperplasia 
(BPH) were randomized (allocation TUMT:TURP=3:2) in the trial, between January 1994 and 
August 1995. Patient work-up, treatment and follow-up were performed in a non affiliated hospital 
and after obtaining informed consent patients received either high energy transurethral microwave 
thermotherapy or transurethral resection of the prostate. The criteria for entry into the study were: 
males aged 45 years or older, candidate for TURP with the presence of a clinically unequivocal 
benign prostate, having a total prostatic length between 25 and 50 mm and a prostate volume 
between 30 and 100 cm3, symptoms suggestive of bladder outlet obstruction for more than three 
months, a Madsen symptom score of 8 or greater, a peak flow rate of 15 ml/s or less with a 
minimum voided volume of 100 ml and post-voiding residual volume of 350 ml or less, and ability 
to comply with the study follow-up schedule and requirements. Exclusion criteria for participation 
were described earlier.8
Assessment and follow up studies included general history (including the Madsen symptoms score), 
physical examination with digital rectal examination (DRE), estimation of full blood count, blood 
urea and creatinine, and urine microscopy and culture. Urine cytology and prostate specific antigen 
(PSA: Hybritech, Texas USA) levels were always measured in order to exclude coexisting 
malignancy. Prostate configuration was assessed by performing transrectal ultrasound (TRUS) with 
a 7.5 MHz transrectal probe (Combison 330 Voluson, Kretz Technik, Austria), the volume being 
calculated using the ellipsoid formula. In case of an abnormality on either DRE, PSA-level or 
TRUSP, ultrasound guided prostate biopsies were performed. A urethrocystoscopy was carried out 
to judge the patency of the (prostatic) urethra for the presence of strictures or an isolated obstructing 
prostatic middle lobe and to exclude intra vesical pathology.
The flow rates were recorded using a Dantec Urodyn 1000 flowmeter (Dantec, Skovlunde, 
Denmark), and the figures corrected for artifacts by measuring the peak flow sustained over a period 
of two seconds. Any recorded flow of greater than 15 ml/s excluded the patients from the study. 
Residual urine was measured by suprapubic ultrasound using the 3.5 MHz, abdominal 
probe(Combison 330 Voluson, Kretz Technik, Austria). To quantify the grade of bladder outlet 
obstruction, urodynamic investigation with pressure-flow (PQ) analysis was performed. Intra vesical 
and rectal pressures were recorded using 8 F catheters mounted with microtip-sensors (MTC, 
Dräger, Germany), and detrusor pressure was calculated as the difference between both. The 
digitally stored pressure and flow-data were analyzed by a program developed at our department 
(UIC/BME Research Center, Department of Urology, Nijmegen, The Netherlands). The following 
parameters derived from the pressure-flow analysis were used: detrusor pressure at maximum flow 
(Pdet at Qmax, cmH2O), maximum flow rate during urodynamic investigation (PQ-Qmax , ml/s), the 
linPURR (obstruction grading according to Schäfer) and URA (urethral resistance index, cmH2O).
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Follow-up visits were scheduled at 1,3,6 and 12 months after treatment. Urodynamic investigation 
with PQ study analysis was performed at baseline and 26 weeks post treatment. Ultrasound of the 
prostate was performed at baseline and 12 weeks. For long term assessment (mean 2.4 ± 0.5 years) 
all patients were phoned and interviewed. A patient was considered lost to follow-up if no 
knowledge was available of his fate after his last visit to the outpatient clinic, despite several 
attempts to contact him either by mail or telephone. Patients were asked for any additional treatment 
after TUMT or TURP and if no, uroflowmetry or symptom data were taken. Subsequently all 
patients were invited for an outpatient visit to examine uroflowmetry and to fill out a Madsen 
symptom score and an IPSS symptom score.
Treatm ent
All TUMT treatments were performed on ambulatory basis using the Prostatron (EDAP 
Technomed, Lyon, France) device and the software 2.5. The method of therapy has been described 
previously.14 Prior to treatment 100 mg suppository of diclofenac was administered. Also 2 mg of 
midazolam was injected intramuscularly. During treatment no additional anaesthesia was given but 
if  necessary, intravenous sedation was given when patients experienced major discomfort during 
treatment, which was mostly expressed as an intense urge to void. Since initial experience showed 
urinary retention in nearly all patients, patients were given a transurethral catheter with leg-bag 
directly after treatment.
TURP treatment was performed by two experienced urologists and resection was performed under 
spinal anaesthesia. It was aimed to reach the surgical capsule circumferentially from the bladder 
neck to the verumontanum, using 24 Ch resectoscopes. The specimen weight, operation time, per- 
and post-operative complications were recorded.
Statistical method
Statistical analysis was performed using the Wilcoxon Signed Rank test for paired samples and the 
Mann-Whitney 2-sample U test for independent samples.
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RESULTS
Fifty-two patients entered the study with a mean follow-up in the TURP group of 2.5 i  0.5 years in 
the HE-TUMT group of 2.4 i  0.5 years. The two groups were of comparable age (TURP group,
69.6i8.5 years; HE-TUMT group, 69.3i5.9 years), prostate volume (TURP group, 45i15 cc; HE- 
TUMT group, 43i12 cc), Madsen symptom score and maximum flow. (Table 1.)
Table 1. Baseline parameters ±  standard deviation (std).
TURP HE-TUMT
mean std mean std
Age (years) 69.6 S.5 69.3 5.9
prostate volume (cc) 45 15 43 12
Madsen 13.S 4.2 13.3 4.2
IPSS 16.7 5.6 1S.3 6.3
Qmax (ml/s) 9.3 3.4 10 6.1
Voided volume (ml) 178 S4.1 193.5 S5.7
Residual Urine (ml) 91 105 58 78
URA (cmH2O) 44.1 25.1 45.7 16.5
linPURR 3.3 1.S 3.2 1.4
Total Energy (KJ) 151.8 45.5
In the TURP group one patient was lost to follow-up and one patient dropped out at own request 
during the first year; at 2.5 years (mean) follow-up three patients could not be reached by telephone 
or they refused visiting the outpatient department and filling out the questionnaires. Two patients 
appeared to suffer from Alzheimer disease and they could not participate anymore. During the first 
year one patient underwent a bladder neck incision, one patient underwent cystectomy and urine 
derivation according to Bricker because of bladder carcinoma. During the first year 2 patients 
initially treated with HE-TUMT underwent TURP, one patient deceased (non-related disease) and 
one patient refused further participation. At a mean of 2.4 years follow-up in this group, four 
additional patients underwent TURP and two patients received a-blocker medication. Another four 
patients could not be reached or refused further visits. (Table 2.) When questioning the patients by 
phone three of the patients who underwent TURP after HE-TUMT still were not satisfied; In two 
micturition complaints persisted, one mentioned incontinence after surgery.
All patients accepted and tolerated the HE-TUMT treatment well. A prolonged catheterisation 
period however was needed (12.7 days). The morbidity in the first months post treatment was 
described earlier.8 Both groups showed significant changes in symptom scores and uroflowmetry 
parameters: At six months in the HE-TUMT group the Madsen symptom score and IPSS symptom
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score decreased significantly (p<0.05) with 54%. At one year and 2.4 years follow-up the 
symptomatic improvement stabilized. The Madsen symptom score also decreased significantly in 
the TURP group with 82% at 26 weeks stabilizing up to 2.5 years follow-up. The maximum flow 
also showed in both treatment modalities a significant improvement over baseline. At longterm 
follow-up the increase in maximum flow in the TUMT group was 62% (5.8 ml/s) while the increase 
in the TURP group was 105% (9.8 ml/s). (Table 3.) Although analyzes was performed with a small 
number of patients, comparing the improvement of maximum flow and symptom scores between 
the HE-TUMT and TURP group, no significant differences were found (p>0.05) at 12, 26, 52 and
2.5 years follow-up. Urodynamic investigations show a clear decrease in obstruction following both 
treatment modalities. The mean urethral resistance factor (URA) in the TUMT group improved 
from 44.1±25.1 cmH2O to 25.1±8.5 cmH2O, the mean linPURR improved from 3.3±1.8 to 1.9±0.9 
and the mean PdetatQmax improved from 77.7±40.0 cmH2O to 54.0±15.9 cmH2O. The TURP group 
showed improvement in mean URA from 45.7±16.5 cmH2O to 21.1±13.6 cmH2O; the mean 
linPURR improved from 3.2±1.4 to 1.1±1.2 and the mean PdetatQmax improved from 65.4±24.9 
cmH2O to 38.5±24.5 cmH2O. Before HE-TUMT all six patients who underwent additional TURP 
had a URA >29 cm H2O; at 26 weeks follow-up only in 1 patient the URA exceeded 29 cm H2O (30 
cm H2O). Two patients were retreated without having a urodynamic investigation at 26 weeks. 
Recently the International Continence Society provided a provisional recommendation for definition 
of obstruction.15 With this nomogram we identified obstructed, unobstructed and equivocally 
obstructed patients. A total of 78% of the patients in the TURP group and 67% in the TUMT group 
appeared to be obstructed at screening. After TURP 82% of these patients were desobstructed 
compared to 50% in the TUMT group. (Fig 1.)
Table 2. Follow up of 52 patients at 3,6,12 months and at 2.4 years from baseline. When patients 
were not reached they were considered lost to follow up (LTF).
TUMT
TURP
baseline
31
21
3 months
31
21
Number o f patients 
6 months 12 months
28 27
2 TURP 1 refuses
1 deceased
20 17
1 LTF 1 bladder-neck
incision
1 Bladder carcinoma: 
cystectomy
1 at own request
30 months
17 
4 TURP
2 medication 
4 refusal/LTF
12
2 dementia
3 refusal/LTF
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Table 3. The mean ±  standard deviation of subjective and objective parameters by each point of 
measurement after performing High energy transurethral microwave thermotherapy (A) and 
Transurethral resection of the prostate (B).
A:
HE-TUMT baseline 12 weeks 26 weeks 52 weeks 2.5 years
Madsen 13.3±4.2a 5.2±4.1b 4.4±4.4b 4.2±4.6b 5.8i3 .8b
IPSS 18.3±6.3a 6.7 i5 .5b 5.0i2 .7b 5.7i5 .4b 7.9±6.3b
ffvol 193.5±85.7a 244.4i161.0a 258.9i130.0a 274.9i145.2a 249.7i182.0a
ffQmax 9,3±3.9a 15.5i8.0b 17.0i7.5b 17.1i7.8b 15.1i9.6b
ffres 49.5±69.9a 25.5i58.1a 30.6i41.0a 70.4i81.3a 27.4i49.1a
URA 44.1±25.1a n.a. 25.1i8.5b n.a. n.a.
linPURR 3.3i1 .8a n.a. 1.9i0.9b n.a. n.a.
PdetatQmax 77.7i40.0a n.a. 54.0i15.9a n.a. n.a.
Prost.volume 43.4i11.8a 36.6i10.0b n.a. n.a. n.a.
B:
TURP baseline 12 weeks 26 weeks 52 weeks 2.5 years
Madsen 13.8i4.3a 3 .6i3 .2b 2.5 i2 .3b 2.7 i4 .0b 3.6i3 .1b
IPSS 16.7i5.6a 5 .1i3 .1b 4.0±2.1b 3.4i2 .2b 6.3 i4 .8b
ffvol 178.0i84.1a 234.1i95.5a 219.3i107.7a 272.4i151.3a 272.7i133.4a
ffQmax 9.3±3.4a 19.6i11.2b 15.3i5.9b 19.3±10.7b 19.1i8.2b
ffres 91.1i104.7a 10.5i24.5a 52.7i70.7a 23.6i29.8b 9.3i14.6b
URA 45.7i16.5a n.a. 21.1i13.6b n.a. n.a.
linPURR 3.2i1 .4a n.a. 1.1i1.2b n.a. n.a.
P detatQmax 65.4i24.9a n.a. 38.5i24.5b n.a. n.a.
Prost.volume 44.9i15.3a 23.0i8.8b n.a. n.a. n.a.
n.a. not available
Different letters (superscript) indicate statistical significantly differences (p < 0.05) between mean values of subjective 
and objective parameters at different points of measurements (Wilcoxon Signed Rank Test).
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DISCUSSION
When evaluating transurethral microwave thermotherapy in the treatment of patients with benign 
prostatic hyperplasia as an alternative treatment to the ‘gold standard’ transurethral resection of the 
prostate one should not only compare the short time subjective and objective responses, but also 
compare the morbidity, retreatment rate and durability of both treatment modalities. Our study 
showed significant improvement after both high energy TUMT and TURP, in symptom score, 
maximum flow rate, urethral resistance factor (URA) and linPURR obstruction category. The 
absolute improvements in free flow parameters, symptom score and infra vesical obstruction 
parameters were more pronounced after TURP than after TUMT at 1 year and persisted to be so at
2.5 years follow-up. Six patients underwent an additional (TURP) treatment following HE-TUMT,
2 patients received additional medication for their lower urinary tract symptoms. Urodynamic 
investigation prior to retreatment was not performed routinely. As most often occurs in daily 
practice the decision to operate was based upon the complaints of the patient. We belief this may 
explain the fact that 3 out of 6 patients who underwent TURP after TUMT reported no relief of their 
complaints.
Earlier studies already suggested a better outcome of high energy transurethral microwave 
thermotherapy when treating the more obstructed patients with the larger prostates.5,12,16 A recent 
study by d’Ancona et al.17 performing a multi variance analyzes on a large cohort of patients treated 
with high energy TUMT confirmed the predictive value of urodynamic obstruction at baseline, but 
also showed other strong predictive baseline parameters, being the amount of energy applied, 
patients’ age and prostate volume. This indicates that patients should not be selected on one 
baseline parameter alone, but a combination of more baseline parameters should approximate the 
ideal patient profile for therapy as good as possible.
Several studies now showed an improved result following high energy TUMT, emphasizing the 
importance of the total amount of energy for treatment outcome.5-8,13,16,18 The number of patients 
who had a successful outcome, as defined by either a significant increase in maximum flow or 
decrease of symptoms, was significantly greater among those in whom a higher temperature was 
achieved. In our randomized study the total amount of energy delivered to the prostate was 152 KJ. 
Thurhoff et al.19 treated 47 patients, all having urinary retention. A suprapubic catheter was placed 
in all patients and 81% of patients were able to void successfully at 6 months follow-up. In our 
study we used transurethral catheters after treatment and when comparing the duration of 
catheterisation (between 6-35 days) with treatment outcome, no significant difference between 
treatment outcome in the short and in the long catheterisation groups could be found. In this respect 
the theory of infection of necrotic tissue due to the duration of catheterisation and therefore creating 
a cavity as suggested by others20, seems no longer valid. Cavity formation occurs when other 
factors like the total amount of energy delivered, probe design, prostate tissue composition and intra 
prostatic vascularisation eventually result in high intra prostatic temperatures ablating tissue.
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In contrast to our study Ahmed et al.20 reported no improvement in objective variables of 
obstruction after HE-TUMT in a prospective randomized study, comparing transurethral microwave 
thermotherapy and transurethral resection of the prostate. We emphasize that in this study patients 
were preselected urodynamically, having a striking lower prostate volume in the TUMT group 
compared with the TURP group and finally received a mean total amount of energy of only 81 KJ 
during microwave thermotherapy.
Figure 1. Changes in obstruction after TURP (A) and after HE-TUMT (B) presented in the 
provisional ICS nomogram for obstruction.15 Measurements before •  and after treatment 
A;
Qm ax (ml/s)
B:
Q m ax (ml/s)
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An important issue, when evaluating high energy transurethral microwave thermotherapy to TURP, 
is the safety of such a new treatment modality. Two prospective randomized studies 8,20 
demonstrated the safety of high energy microwave thermotherapy, although there is some morbidity 
following this treatment. Major complications and morbidity following TURP appeared to be the 
need for coagulation (3%) and urinary tract infections (4-10%). A blood transfusion after TURP was 
requested in 13%. Following high energy TUMT treatment no bladder neck sclerosis and strictures 
were reported. Urinary tract infections occurred in 3-16% of patients. A blood-stained urethral 
discharge was only noticed for up to 24 hours.
Our study clearly demonstrates a significant objective and subjective improvement after high energy 
TUMT. Although we are aware of the limited numbers of patients available at 2.5 years follow-up, 
the outcome of high energy TUMT appeared to be durable and in the range of TURP. Most 
retreatments were performed after 1 year follow-up, and decision for additional therapy was based 
on subjective findings. Three out of 8 patients who underwent additional treatment did not notice 
any change. One of them became incontinent following TURP.
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ABSTRACT
Since 1993 we have treated patients with lower urinary tract symptoms and benign prostatic 
obstruction using the high energy TUMT-protocol (Prostasoft, software version 2.5). This study was 
conducted to investigate outcome and durability of this treatment modality.
301 Patients with a mean prostate size of 56.4 cc, were treated by high energy TUMT. Patients were 
included having a Madsen symptom score >8, a maximum flowrate less than 15 ml/s, a voided 
volume > 100 ml, a post voided residual less than 350 ml. The prostate volume measured by 
transrectal ultrasound was >25 cc. Follow-up visits were scheduled at 12,52,78 and 104 weeks. 
Patients were stratified according to the response evaluation criteria set at the 3rd International 
Consultation on Benign Prostatic Hyperplasia. These response criteria were measured at 12 weeks. 
At two years there appeared to be a better response in the bigger prostates. Irrespective of relief of 
outflow obstruction a good symptomatic response was seen in both good and poor responders. 22 
Patients were retreated during the 2 year follow-up period; 3 underwent bladder neck incision, 9 
TURP, 2 Laser, 1 open prostatectomy and 7 patients had additional medical therapy.
At two year follow-up high energy thermotherapy results in a durable outcome in 93% of patients 
with an objective improvement of 42% and a subjective improvement of 65%. The best predictor of 
durability of this treatment appeared to be the response evaluation criteria in desobstruction. 
Fourteen patients out of 96 bad responders in this group (linPURR) underwent retreatment, 
compared to 6 patients out of 100 good responders.
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INTRODUCTION
For several years there is a progressive interest of urologist all over the world in alternatives 
concerning the treatment of lower urinary tract symptoms (LUTS) due to benign prostatic 
obstruction (BPO). Until now the therapy of choice has been the transurethral approach (TURP) 
because of the high success-rate and low morbidity when performed by experienced urologists. 
However up to 25 % of patients that underwent a transurethral prostatectomy did not have a 
satisfactory long-term outcome and a 15% retreatment rate (re-operation) is reported.1,2 Because of 
these problems as well as the desire of many men to avoid surgery whenever possible, an increasing 
interest in minimally invasive treatment modalities originated. Transurethral microwave 
thermotherapy (TUMT) offers a great potential as an outpatient anaesthesia-free, single session 
procedure. Therapeutic levels of heating are achieved deep inside the prostate lateral lobes while 
preserving the urethral mucosa by application of microwave radiation from a transurethral antenna 
while simultaneously cooling the urethra. It is aimed to achieve a decrease in adenoma volume and 
destruction of specific cell types that play a role in the outflow obstruction-mechanism. Lower 
energy transurethral thermotherapy (Prostasoft software version 2.0) resulted in a good subjective 
and objective improvement, which is greater than can be accounted for by either urethral 
catheterisation or by any placebo-effect.3 The objective improvement in terms of flow rate was 36% 
while the subjective improvement was more than 50%. When comparing TUMT to TURP 
significant improvements in both TUMT and TURP groups in symptom scores were seen, however, 
the objective improvement was more pronounced in the TURP group. In follow-up studies over a 
period of three years there appeared to be a significant and durable improvement of symptomatic 
parameters in 52 % of patients with a improvement in maximum flow of 2.6 ml/s. 4 
To achieve a higher intra prostatic temperatures and thus enhance the clinical outcome, a higher 
energy software version was developed (Prostasoft version 2.5). Several studies investigating the 
effect of this thermo-ablative treatment showed cavity formation and excellent subjective and 
objective response.5-7
Besides clinical outcome durability of any treatment remains an important clinical issue. Long-term 
follow-up data are now available for the high energy transurethral thermotherapy and we performed 
a retrospective analyses of the clinical and urodynamical parameters to investigate outcome and 
durability of this treatment modality.
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PATIENTS AND METHODS
From October 1993 until December 1996 we treated 301 patients aged between 45 and 89 (mean 67 
years) with the high energy thermotherapy (Prostasoft, software version 2.5) in our department.
All patients included had to comply with the following criteria: males older than 45 years with 
lower urinary tract symptoms, a prostate volume larger than 25 cm3, a Madsen Symptom score of 8 
or greater, a urinary maximum flow of 15 ml/s or less, and a post void residual volume of 350 ml or 
less.
Exclusion criteria were: urinary retention, prostate carcinoma, acute or chronic prostatitis, urethral 
stricture, intravesical pathology (e.g. stones, neoplasm), neurogenic bladder dysfunction, urinary 
tract infection, isolated obstructive middle lobe, use of drugs influencing bladder or prostate 
function, disorders of blood flow or coagulation and diabetes mellitus.
Assessment and follow-up studies included Madsen Symptom score, IPSS-symptom score and 
physical examination. Urine cytology and prostate specific antigen (PSA: Hybritech, Texas USA) 
levels were always measured in order to exclude coexisting malignancy. Prostate configuration was 
assessed by performing transrectal ultrasound (TRUSP), volume being calculated using the ellipsoid 
formula with a 7.5 MHz transrectal probe (Combison 330 Voluson, Kretz Technik, Austria). In case 
of an abnormality on either DRE, PSA-level or TRUSP, ultrasound guided prostate biopsies were 
performed. A urethrocystoscopy was carried out to judge the patency of the (prostatic) urethra for 
the presence of strictures or an isolated obstructing prostatic middle lobe and to exclude intra 
vesical pathology.
Follow-up visits were scheduled at 12,26,52,78 and 104 weeks after treatment. Urodynamic 
investigation with PQ study analysis was performed at baseline and 26 weeks post treatment. 
Ultrasound of the prostate was repeated at 12 and 52 weeks.
The flow rates were recorded using a Dantec Urodyn 1000 flowmeter (Dantec, Skovlunde, 
Denmark), and the figures were corrected manually for artifacts by measuring the peak flow 
sustained over a period of two seconds. Any recorded flow of greater than 15 ml/s excluded the 
patients from the study. Residual urine was measured by suprapubic ultrasound using the 3.5 MHz, 
abdominal probe (Combison 330 Voluson, Kretz Technik, Austria). To quantify the grade of 
bladder outlet obstruction, urodynamic investigation with pressure-flow (PQ) analysis was 
performed. Intra vesical and rectal pressures were recorded using 8 F catheters mounted with 
microtip-sensors (MTC, Drager, Germany), and detrusor pressure was calculated as the difference 
between both. The digitally stored pressure and flow-data were analyzed by a program developed at 
our department (UIC/BME Research Center, Department of Urology, Nijmegen, the Netherlands). 
TUMT treatments were performed in an outpatient setting using the Prostatron device (EDAP 
Technomed, Lyon, France) and software version 2.5. The method of performing therapy has been 
described previously.8 Two hours prior to treatment 40 mg of morphine-sulfate was administered
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orally. Treatment duration was 60 minutes and no additional anaesthesia was required, but if 
necessary, intravenous sedation was given. The energy level during treatment was increased up to 
70 Watts. To prevent thermal damage to the urethral mucosa and rectal wall thermal sensors, 
urethrally and rectally positioned, gave continuously feedback signals about the temperature 
reached.
Posttreatment all patients had a transurethral catheter (Ch 16.) and leg-bag because of urinary 
retention.
In order to evaluate outcome we used the response evaluation criteria stated at the 3rd International 
Consultation on Benign Prostatic Hyperplasia in Monaco.9 Accordingly we stratified patients in 
poor and good responders in symptom scores (using the IPSS symptom scores), maximum flow rate 
and linPURR. Intermediate responders were merged with the good responders in order to create two 
groups comparable in size for analyses. A good responder was defined as a patient with a IPSS 
symptom score at baseline > 19 and a symptom score after treatment less than 8. A good response 
regarding maximum flow rate was defined when the pretreatment value was less than 10 ml/s with 
a post treatment value over 15 ml/s. LinPURR was used to define a response in desobstruction; the 
pretreatment linPURR should be > III, the post treatment value 0 or I. Poor responses were 
determined successively; AUA symptom score improvement < 3, a maximum flow improvement 
less than 3 ml/s and a linPURR improvement < I (table I.).
Statistical analyses was performed with the Wicoxon’s test for paired samples.
Table I. Evaluation Response criteria set at the International Consultation on Benign Prostatic 
Hyperplasia.9
Good responder Intermediate responder Poor responder
IPSS sreening > 19 
posttreatment < 8
change < 3
Uroflow screening < 10 ml/s change < 3 ml/s
posttreatment > 15 ml/s
linPURR screening > III change < I
posttreatment < I
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RESULTS
Of the 301 patients treated with high energy transurethral thermotherapy the average age was 67.0 
years with a prostate volume of 56.4 cc ( range 25-200 cc ). At 2 years follow-up 74 patients were 
available for analyses. 22 Patients were considered a treatment failure so additional treatment, 
(medical or surgical) was necessary. 7 Patients dropped out because of non treatment related death 
and illness. Another 10 patients dropped out at their own request because of other reasons such as 
travel expenses.
19 Patients were lost for follow-up during the 2 year period for unknown reasons. In table II. these 
patient drop-outs, additional treatments and losses in follow-up are presented.
The objective improvement at 2 years is 42 % and the subjective improvement is 65%. Mean 
Madsen symptom scores improved from 14.1 ± 3.8 at baseline to 5.9 ± 4.7 at 12 weeks, 5.2 ± 4.7 at 
52 weeks, 5.6 ± 4.1 at 78 weeks and 5.0 ± 3.9 at 104 weeks. The IPSS scores changed from 18.9 ± 
6.4 at baseline to 8.9 ± 6.0 at 12 weeks, 7.8 ± 6.1 at 52 weeks, 7.9 ± 5.7 at 78 weeks and 7.9 ± 5.7 at 
104 weeks. The maximum flow rate improved from 9.7 ± 3.1 ml/s at baseline to 15.6 ± 6.2 ml/s at 
12 weeks, 15.3 ± 5.9 ml/s at 52 weeks , 13.6 ± 5.0 ml/s at 78 weeks and 13.8 ± 4.8 ml/s at 104 
weeks follow-up. In Figure 1 & 2 these different parameters are shown.
All patients tolerated the TUMT treatment well. The mean catheterisation time was 16.7 days (± 
16.1 day). 3 Patients were unable to void after removing the catheter and eventually were retreated 
(2 TURP, 1 open prostatectomy).
Complete data of pre and posttreatment urodynamics is currently available of 201 patients to 
analyze the changes in obstruction by Pressure-Flow measurements. In figure 3 these changes are 
presented in an Abrams Griffiths nomogram. The mean URA improved from 41.0 cm H2O at 
baseline to 23.8 cm H2O at 26 weeks follow-up (p < 0.0001). Also the linPURR changed from 2.9 at 
baseline to 1.4 at 26 weeks follow-up (p < 0.0001).
Table 2. Number of patients, additional treatments and losses to follow-up. (BI = Bladder neck 
incision, OP = Open prostatectomy, DO = Dropped out at own request, LTF = Lost to follow-up).
number of patients
baseline 12 weeks 52 weeks 78 weeks 104 weeks Total
TUMT 301 251 174 82 74
Medication 0 1 6 7
TURP 3 3 3 9
Laser 2 2
BI 3 3
OP 1 1
Death/Illness 1 6 7
DO 1 7 2 10
LTF 2 13 4 19
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Figure 1. Mean improvement of uroflow indices at baseline, week 12, week 52, week 78 and week 
104 after treatment. (Qmax = maximum flow (ml/s), Volume (ml), Residual urine (ml)).
■  Qmax
□  volume(x10)
□  residual(x10)
Figure 2. Changes in symptom scores (IPSS and Madsen) from baseline at 12, 52, 78 and 104 
weeks after treatment.
□  IPSS 
■  Madsen
Figure 3. Paired data of 201 patients with detrusor pressure at maximum flow (Pdet at Qmax) 
before (0) and 26 weeks after treatment (a ) in an Abrams Griffiths nomogram.
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DISCUSSION
The early clinical results of HE-TUMT are superior to the earlier low energy treatment protocols. A 
recent paper comparing HE-TUMT with the transurethral resection of the prostate showed in both 
groups similar symptomatic and objective improvements which are in both groups in the same range 
and not significantly different.10 Also the urodynamic findings in this study showed in both groups 
a considerable decrease in outflow obstruction. However, no publications are available yet 
describing the long-term efficacy of HE-TUMT. This is the first paper showing data of a large 
patient cohort with a follow-up time up to 2 years. At 1 year follow-up the improvement in 
symptom scores, maximum flow rate and in outflow obstruction is comparable to earlier studies.5- 
7,10-12 When measuring at 78 and 104 weeks follow-up there is a slight decrease in maximum flow 
rate, but the symptomatic improvement remains unchanged.
With the new software protocol a TURP-like relief of obstruction could be observed 6,7 and also in 
the present study a significant improvement of the urodynamic obstruction parameters is presented. 
60% Of patients were obstructed at screening according to the Abrams Griffiths nomogram. In 79% 
of these patients outlet obstruction was relieved. Similar findings were documented when using 
other PQ analyses systems.
In previous studies a substantial increase of morbidity was described when using the higher energy 
protocol. 13 The treatment is generally well tolerated by the patients although pain medication needs 
to be administrated in most of the patients prior to or during the treatment. Also the duration of 
catheterisation is an important issue in evaluating posttreatment morbidity; when creating a 
“survival curve” of the duration of catheterisation (figure 4), 70 % of patients are free of an 
indwelling catheter at two weeks follow-up. The sharp decrease in slope after 1 week is due to the 
fact that in general patients are asked to return to the outpatient department at 1 week to evaluate 
whether the catheter can be removed or not.
Figure 4. “Survival curve” presenting the percentage of patients with a catheter after treatment.
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Table 3. Poor and Good responders stratified according to response evaluation criteria.9 These 
criteria were measured at 12 weeks posttreatment. The linPURR criterium was measured at 26 
weeks after treatment. Changes at 104 weeks are compared to baseline (%).
IPSS
GOOD RESPONSE 
Qmax linPURR IPSS
POOR RESPONSE 
Qmax linPURR
No of patients 192(64%) 167(55%) 100(33%) 48(16%) 84(28%) 96(32%)
Qmax(ml/s) 43% 61% 55% 23% 11% 32%
IPSS 63% 63% 64% 29% 48% 47%
Madsen 67% 69% 71% 54% 58% 54%
URA(cmH2O) 46% 49% 59% 28% 29% 18%
PV(cc) 12% 17% 16% 7% 2% 11%
Energy(KJ) 161.6 160.2 168.7 134.8 150.9 146.9
Retreatment 16 13 6 6 9 16
With the introduction of the higher energy protocol selection of patients becomes an important 
issue. Who are the best responders of this new treatment modality and is there a possibility to pre 
select these patients?
When evaluating our data by using the response evaluation criteria at two years there appeared to be 
a better response in patients with larger prostates. Subsequently we looked at several baseline 
parameters to predict durability of the TUMT treatment. The results are presented in table III.
The patient cohort with a good symptomatic response received more energy, and at two years 
follow up they had a higher increase in maximum flow compared to the poor responders. Patients 
with a good response in uroflowmetry at 12 weeks also received more energy during treatment. In 
these patients the symptomatic improvement was higher than in the poor response group. The 
decrease in the URA was in the good responder group 20% more than the poor responder group. 
Finally in this group the decrease in prostate volume was significant (17% in the good responders 
compared to 2 % in the poor responders). Also the urodynamic improvement, measured at 26 weeks 
is higher than the poor response group. Finally patients with a good urodynamic response had a 
higher symptomatic improvement and a higher maximum flow improvement comparing with the 
poor response group. Irrespective of relief of outflow obstruction (linPURR) there was a good 
symptomatic improvement in both good and poor responders.
Overall a good response at 12 weeks post treatment, whether this is measured in uroflow 
parameters, symptom scores or urodynamic parameters, results in a good response in all parameters 
measured at two years follow-up.
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When evaluating these patients according to the response evaluation criteria the retreatment rate 
(and therefore the durability) is clearly different in both poor and good responders. The best 
predictor of durability of treatment appeared to be the response evaluation criteria in desobstruction 
showing 16 retreatments (17%) in the poor (linPURR) response group while for the good 
responders (100) only 6 patients (6%) received a retreatment.
Overall, when evaluating at 12 weeks follow up, according to the response evaluation criteria the 
good responders continue to preserve this response in all measured parameters at two years. The 
poor responder group received a smaller total amount of energy, and in all measured groups the 
mean prostate volume was less than the good responder-group. This confirms earlier findings 
stating “the best responders are patients with large prostates” .7
CONCLUSION
High energy transurethral microwave thermotherapy in patients with LUTS due to BPO is a safe and 
effective therapy. It results in a durable outcome in 93% of patients with an objective improvement 
of 42 % and a subjective improvement of 65%. Pre treatment selection of good responders is not yet 
clear, however evaluating the response at 26 weeks, the best predictor of durability of this treatment 
modality is the decrease in outflow obstruction. Patients then having a good response according to 
the response evaluation criteria only have 6% change of needing a retreatment medically or 
surgically. Patients with larger prostates are generally the best responders.
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ABSTRACT
We analyzed the individual value of baseline parameters to predict the outcome of high energy 
transurethral microwave thermotherapy in the treatment of patients with lower urinary tract 
symptoms and benign prostatic hyperplasia.
247 Patients with symptomatic benign prostatic hyperplasia were treated with high energy 
microwave thermotherapy using the software 2.5 (Prostatron). Mean age at the time of treatment 
was 66.3 (std. 8.2) years, the mean prostate volume 57.0 (std. 25.2) cc and the mean energy applied 
was 159 (std. 40) KJ. Multi variable analysis on baseline parameters was performed to evaluate 
their predictive value for response using the WHO-response evaluation criteria for IPSS, maximum 
flow and urodynamic obstruction (linPURR). At one year follow-up a 57% increase in maximum 
flow and a 59% decrease in symptom score was noticed following high energy transurethral 
thermotherapy. Fifteen Patients (6%) experienced failure and underwent additional surgical or 
medical treatment. All baseline parameters, except quality of life, residual urine and voided volume 
were predictive for poor response at 26 weeks after treatment of at least one of the three evaluation 
criteria. However, independently predictive baseline parameters for poor response were patients’ 
age, prostate size and grade of bladder outlet obstruction (BOO). The total amount of energy 
delivered during treatment is also correlated with response. For case selection for high energy 
transurethral microwave thermotherapy three baseline parameters can be identified which predict 
response for at least one Response Evaluation Criterium: age, prostate size, grade of bladder outlet 
obstruction (BOO) and total amount of TUMT-energy. Especially the total amount of TUMT energy 
is strongly predictive for all three Response Evaluation Criteria, which suggests an important 
contribution of other mechanisms such as vascularisation and tissue composition to the outcome of 
high energy TUMT treatment.
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INTRODUCTION
The urological community is in an era of transition, embracing minimal invasive treatment 
modalities. The treatment of renal calculi, for example, has undergone dramatic changes. 
Improvements in imaging-technology combined with the advent of extra corporeal shockwave 
lithotripsy (ESWL) virtually have eliminated the need for open stone surgery.1 Indeed, since the 
introduction of ESWL into clinical practice, this technique rapidly has become the treatment of 
choice for most renal calculi. In some circumstances, however, percutaneous procedures, 
ureteroscopy, or even open surgery are the preferred treatment options.2 In other words one should 
keep in mind, when applying new technologies to the management of patients, multiple factors 
should be considered: each patient requires an unique solution.
At the moment a similar trend is observed in the management of male voiding dysfunction caused 
by benign prostatic hyperplasia (BPH). The number of surgically treated patients with lower urinary 
tract symptoms (LUTS) has decreased significantly and alternative treatment options are 
numerous.3,4 Several interventional non-surgical modalities have emerged during the last decade and 
microwave technology is one of the most appealing options, applying thermal energy deep within 
the prostatic adenoma.5 Overall the balance between treatment outcome when using the first 
generation transurethral microwave thermotherapy (TUMT software low energy) on the one hand 
and the morbidity caused on the other hand are in favor of this treatment. More recently the second 
generation TUMT (software high energy) has been introduced resulting in improvements of 
thermotherapy treatment outcome in general but at the cost of increased morbidity.6 With the 
availability of different treatment protocols, one may ask what the position of this so-called high 
energy thermotherapy (HE-TUMT) treatment is. Since the advantage of the microwave technology 
lies in its power to tailor the treatment to the individual need we should indeed try to identify the 
ideal patient profile for this high energy treatment modality. During the International Consultation 
meeting on BPH in Monaco 1995 7, a serious effort was made to describe outcome criteria in order 
to make treatment evaluation possible. Although we are aware of the fact that other outcome criteria 
are described (for example 30 or 50 % improvement) we feel that at that meeting a consensus was 
reached for evaluation criteria. The following article describes the results of a multi variable 
analysis in a large cohort of patients treated with HE-TUMT, aiming at baseline parameters to 
independently predict treatment outcome.
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PATIENTS AND METHODS 
Study-population
Between October 1993 and July 1996, 247 men with lower urinary tract symptoms and BPH were 
treated using the high energy thermotherapy protocol (Prostasoft 2.5). All patients provided written 
informed consent before participation after verbal explanation and reading an explanatory leaflet. 
Inclusion criteria were: males aged 45 or older, with a total prostatic length of 25 mm or more and a 
prostate volume of 30 cc or more, voiding symptoms for longer than three months, a Madsen 
symptom score of 8 or greater, a peak flow rate of 15 ml/s or less with a minimum voided volume 
of 100 ml and post-voiding residual volume of 350 ml or less, and willingness and ability to comply 
with the study follow-up schedule and requirements. Patients with neurogenic disorders which may 
affect bladder function, prostatic carcinoma, surgical treatment of the prostate in the past, patients 
with possible microwave sensitive implants (pacemakers, hip prostheses), diabetic neuropathy, 
urinary retention requiring indwelling catheter, evidence of renal impairment, or an obstructed 
bladder neck by an enlarged median lobe of the prostate or patients who were on medication 
prescribed for the treatment of the prostate or bladder, were excluded from the study.
Clinical param eters
A urethrocystoscopy was carried out to judge the patency of the (prostatic) urethra for the presence 
of strictures or an isolated obstructing prostatic middle lobe and to exclude intra vesical pathology. 
Follow-up visits were scheduled at 12,26 and 52 weeks after treatment and at every visit patients 
were asked to fill out a Madsen-Iversen symptom score and a IPSS symptom score. Urodynamic 
investigation with pressure-flow (PQ) study analysis was performed at baseline and 26 weeks post 
treatment. To quantify the grade of bladder outlet obstruction, urodynamic investigation with PQ 
analysis was performed. Intra vesical and rectal pressures were recorded using 8 F catheters 
mounted with microtip-sensors (MTC, Dräger, Germany), and detrusor pressure was calculated as 
the difference between these. The digitally stored pressure and flow-data were analyzed by a 
program developed at our department (UIC/BME Research Center, Department of Urology, 
Nijmegen, The Netherlands). The following parameters derived from the pressure-flow analysis 
were used: detrusor pressure at maximum flow (PdetatQmax in cmH2O), maximum flow rate (PQ- 
Qmax in ml/s), the linPURR (obstruction grading according to Schäfer) and the urethral resistance 
index (URA in cmH2O).
Prostate configuration and prostate volume were assessed at screening, 12 weeks and 52 weeks 
follow-up, by performing transrectal ultrasound (TRUSP) with a 7.5 MHZ transrectal probe 
(Combison 330 Voluson, Kretz Technik, Austria), volume being calculated using the ellipsoid 
formula. In case of an abnormality on either DRE, PSA-level or TRUSP, ultrasound guided prostate 
biopsies were performed.
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Treatm ent
All TUMT treatments were performed on ambulatory basis using the Prostatron (EDAP 
Technomed, Lyon, France) device and the software 2.5. The method of therapy has been described 
previously.8 Treatment duration was 60 minutes with increasing thermal dose up to 70 Watts. To 
prevent thermal damage to urethral mucosa and rectal wall thermal sensors, urethrally and rectally 
positioned, give continuous feedback signals about the temperature reached. When the maximum 
allowed temperature is detected by 1 of these thermo sensors the program automatically interrupts 
the treatment until the temperature decreases to a preset value. Two hours prior to treatment 40 mg 
of morphine sulfate was administered orally. During treatment additional intravenous sedation was 
given in 60 (24%) of patients, when they experienced major discomfort during treatment, mostly 
expressed as an intense urge to void. Since from initial experience we learned that urinary retention 
occurred in nearly all patients, patients were instructed in the need for a transurethral catheterisation 
for at average two to three weeks. Therefore in most cases the first visit was at two weeks post 
treatment.
Statistical methods
Differences in the subjective and objective parameters between the points of measurement were 
tested for statistical significance using the test of Friedman with corresponding contrast-tests.
In order to evaluate outcome we used the Response Evaluation Criteria as stated at the 3rd 
International Consultation on Benign Prostatic Hyperplasia in Monaco.7 In the Response Evaluation 
Criteria patients are stratified as poor, intermediate and good responders using either the IPSS 
symptom scores or the maximum flow rate or linPURR. The Kruskall-Wallis test was used to test 
for statistical significant differences in the baseline parameters between the response groups of each 
criterium at each point of measurement.
Since we aimed at identifying responders from non-responders, so-called intermediate responders 
were merged with the good responders. Differences in the baseline parameters between non­
responders and responders at 26 weeks after treatment were expressed as crude odds ratios with 
95% CI, using univariate logistic regression.
Multi variable logistic regression with forward selection procedures were used to select the baseline 
variables that contribute independently to the risk of non-response at week 26. Because forward 
selection procedures do not identify the other important variables, the p-values for entry into the 
model were considered in order to find close alternatives to the variables selected. Data were 
presented as adjusted odds ratios with 95% CI. of the final model.
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RESULTS
At screening 247 patients with a mean age of 66.3 years (std; 8.2 years) were treated with a mean 
total energy level of 159 KJ (std; 40 KJ). All patients tolerated the TUMT treatment well. The mean 
catheterisation time was 16.8 days (std; 16.1 day). The evaluation period was set at 12 weeks as 
follow-up data on all patients (n=247) studied was then available. 205 Patients however could be 
followed for 1 year as not all patients fulfilled 52 weeks follow-up. During the follow-up 15 patients 
(6%) needed additional medically or surgically therapy. One patient underwent a bladder neck 
incision, 1 urethrotomy because of a stricture, 9 transurethral resection of the prostate, 2 laser 
prostatectomy, 1 open prostatectomy and 1 additional medical (a- adrenoceptor antagonist) 
treatment (Table 1.). Eventually 16 patients dropped out for reasons other than failure such as travel 
expenses, death not related to therapy and illness.
Table 1. Number of patients, additional treatments and losses to follow-up ( BI: Bladder neck 
incision, OP: Open prostatectomy DO: Drop out at own request).
Number of patients
baseline 12  weeks 2 6  weeks 52  weeks total
number of visits 247 242 221 187
Medication - - - 1 1
TURP - 3 1 5 9
Laser - - - 2 2
BI - - - 1 1
OP - - - 1 1
Stricture - - 1 - 1
Death/ Illness - 2 1 4 7
DO - - 4 5 9
247 247 228 205 31
Because baseline parameters were investigated in a predictive manner in this study, possible 
correlations between these variables were analyzed using the Spearman Rank correlation test. The 
symptom score-parameters did not significantly correlate with uroflowmetry (voided volume, 
maximum flow rate and residual urine) and urodynamic (URA, linPURR, PdetatQmax) parameters. 
Age had a reversed correlation with the Madsen and IPSS symptom score and a positive correlation 
with PSA-level and prostate volume. Uroflowmetry baseline parameters showed a weak but 
significant correlation with the urodynamic parameters.
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Table 2. The mean ±  standard deviation of subjective and objective parameters at each point of 
measurement. Uroflow parameters: voided volume (Ffvol), maximum flowrate (FfQmax) and 
residual urine (Ffres). Urodynamic parameters: urethral resistance index (URA), the linear-PURR 
nomogram according to Schäfer (linPURR) and the detrusor pressure at maximum flow (Pdetat 
Qmax).
baseline l2  weeks 26 weeks 52 weeks
Madsen 14.1 i  3.8a 5.8 i  4.7b 5.3 i  4.6b 5.4 i  4.7b
IPSS 18.8 i  6.4a 8.6 i  5.9b 8.2 i  6.1b 7.8 i  6.2b
Ffvol (ml) 234.6 i  119.7a 259.8 i  140.6a 295.6 i  134.3b 274.1 i  137.6b
FfQmax (ml/s) 9.8 i  3.1a 15.9 i  6.3b 14.2 i  5.9c 15.4 i  5.9bc
Ffres (ml) 70.5 i  83.0a 32.1 i  61.3b 32.3 i  83.1b 30.2 i  49.2b
URA (cmH2O) 41.2 i  16.6a n.a. 23.6 i  12.1b n.a
linPURR 2.9 i  1.3a n.a. 1.4 i  1.2b n.a.
PdetatQmax (cmH2O) 64.4 i  26.7a n.a. 40.2 i  17.8b n.a.
PSA (^g/l) 5.5 i  4.6a 4.7 i  4.3b 4.9 i  4.6b 5.3 i  5.2b
Prostate volume (cc) 57.0 i2 5 .2 a 47.3 i  21.7b n.a. 49.5 i  25.7b
a, b, c: Different letters (superscript) indicate statistical significantly differences (p < 0.05) between mean values 
of subjective and objective parameters at different points of measurements (Friedman test and contrast- 
test).
n. a.: not available
Table 2 shows the mean of the subjective and objective parameters at each point of measurement. 
Statistical significant improvement (59%) was observed in the Madsen symptom score at 12 weeks 
stabilizing up to 52 weeks follow-up. The same trend was observed for the IPSS score. The 
significant decrease in prostate volume persisted after 12 weeks follow-up. At 26 weeks the 
urodynamic parameters significantly improved from baseline. The uroflow parameters showed a 
significant improvement in voided volume at 26 weeks stabilizing up to 52 weeks, whereas the 
residual urine decreased significantly at 12 weeks. The maximum flow rate improved significantly 
(62%) at 12 weeks. At 26 weeks, probably due to urodynamic investigation performed at that time, 
a little dip in improvement can be noticed. The patient distribution of the outcome (poor, 
intermediate and good response) at each point of measurement for the IPSS symptom score, for the 
maximum flow rate and for the urodynamic response, is presented in Table 3. This shows that the 
number of poor responders on Qmax and in linPURR is considerable at 26 weeks after treatment. 
Table 4. presents the mean values of five baseline parameters (age, TUMT-energy, URA, linPURR 
and prostate volume) when stratifying the patients according to the response evaluation criteria. Not 
all parameters differ in the Response Evaluation Criteria at the different points of measurements, as 
is even more evident after the forward selection procedure. The poor responders in IPSS symptom 
score at 12 weeks for example received a significantly (p < 0.05) smaller amount of energy during
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treatment (138.4 KJ, labeled b) as compared with the intermediate and good responders (164.9 KJ 
and 159.2 KJ). The intermediate and good responders did not differ significantly in this respect (and 
are therefore both labeled a). Evaluating the response in IPSS at 52 weeks the good responders are 
significantly younger (63.0 years, labeled a) compared with the poor responders 
(68.5 years, labeled b).
Table 3. Patient distribution (numbers of patients; percentage between brackets) when stratifying 
them according to the Response Evaluation criteria set at the 3rd International Consultation on 
Benign Prostatic Hyperplasia.7
Criteria Response 12 weeks 26 weeks 52 weeks
good screening 2 19 
posttreatment < 8
37(17%) 40(20%) 32(20%)
IPSS intermediate else 143(65%) 123(60%) 107(66%)
poor change < 3 39(18%) 40(20%) 22(14%)
good screening < 1 0  ml/s 
posttreatment > 1 5  ml/s
40(19%) 23(12%) 24(15%)
Qmax intermediate else 107(49%) 83(42%) 71(45%)
poor change < 3 69(32%) 90(46%) 63(40%)
good screening i  III 
posttreatment < I
_ 62(34%) _
linPURR intermediate else - 32(17%) -
poor change < I - 89(49%) -
not available (LinPURR response is only measured at 26 weeks follow-up)
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Table 4. Mean values ( ±  standard deviation) of baseline parameters: Age, TUMT energy, URA, 
linPURR and Prostate volume for the Response Evaluation Criteria; IPSS, maximum flow and 
linPURR stratified for good, intermediate and poor responders.
Response Age (years) Energy (KJ) URA linPURR PV (cm3)
(cm H20)
IPSS
good 64.0 ± 8.4“ 159.2 ± 41.3* 42.7 ± 11.7* 3.1 ± 1.1* 55.0 ± 18.8*
week 12 intermediate 65.7 ± 8.2“ 164.9 ± 38.3* 40.3 ± 15.8* 2.8 ± 1.4* 56.5 ± 24.1a
poor 69.2 ± 7.1b 138.4 ± 4 2 .5b 39.7 ± 15.5* 2.8 ± 1.3* 51.0 ± 19.8*
good 62.2 ± 6.4“ 169.1 ± 32.6* 43.8 ± 15.0* 3.1 ± 1.4* 54.9 ± 18.2“
week 26 intermediate 66.7 ± 8.3b 166.5 ± 37.8* 40.5 ± 16.3* 2.9 ± 1.3* 59.8 ± 25.6*
poor 67.8 ± 8.1b 138.0 ± 43 ,0b 39.0 ± 14.8* 2.7 ± 1.3* 49.3 ± 17.3*
good 63.0 ± 7.2“ 177.0 ± 31.3* 44.0 ± 14.0* 3.2 ± 1.2* 57.7 ± 19.5*
week 52 intermediate 66.1 ± 8.1,b 165.4 ± 36.1* 41.3 ± 16.9* 2.9 ± 1.4* 59.4 ± 25.6*
poor 68.5 ± 8.4b 138.1 ± 45 .3b 31.0 ± 12,1b 2.9 ± 1,3b 48.0 ± 19.5*
Qmax
good 66.8 ± 8.5“ 164.7 ± 40.3* 43.4 ± 16.9* 3.0 ± 1.4* 58.2 ± 27.4"
week 12 intermediate 64.5 ± 7.8“ 162.0 ± 37.1a 39.5 ± 13.3* 2.9 ± 1.2* 54.6 ± 20.6*
poor 66.5 ± 7.5“ 147.9 ± 46.2“ 38.7 ± 14.9“ 2.7 ± 1.3* 55.1 ± 24.1a
good 68.3 ± 7.1a 175.4 ± 35.2“ 43.5 ± 18.3* 3.0 ± 1.6* 65.8 ± 28.9*
week 26 intermediate 64.4 ± 8.9b 164.6 ± 36.2 ,b 42.6 ± 15.6* 3.1 ± 1,2ab 56.0 ± 22.0*
poor 67.0 ± 7.5“ 153.6 ± 43 .0b 38.4 ± 15.2“ 2.7 ± 1,3b 55.6 ± 21.9“
good 66.5 ± 9.7“ 179.5 ± 33.1* 48.6 ± 18.4“ 3.3 ± 1.5* 72.2 ± 29.3*
week 52 intermediate 65.0 ± 8.3“ 166.7 ± 32.1a 39.0 ± 14.5* 2.8 ± 1.3* 54.7 ± 22.1a
poor 66.0 ± 7.1a 156.1 ± 44.8* 41.0 ± 16.9* 2.9 ± 1.3* 58.0 ± 22.9“
linPURR
good 66.9 ± 8.7“ 169.9 ± 32.3* 49.7 ± 12.6* 3.8 ± 0.7" 63.6 ± 25.1*
week 26 intermediate 67.1 ± 7.4" 172.3 ± 40.2“ 46.7 ± 18.0* 3.6 ± 1.2* 59.1 ± 25.7,b
poor 65.7 ± 8.6“ 149.6 ± 44 .3b 33.4 ± 13,2b 2.1 ± 1,2b 53.2 ± 20,5b
a, b: Different letters (superscript) at each point o f measurement indicate statistical significantly differences (p < 0.05) between the 
response groups (Kruskall Wallis test and contrast-test). For example: At week 12, the good and intermediate responders for IPSS 
are significantly younger compared to the poor responders. Good and intermediate responders however, do not significantly differ 
in age.
The intermediate responders show no significant difference in age (66.1 years, labeled a,b) as 
compared with the good or the poor responders. Overall a higher age at baseline showed a poor 
response in the IPSS evaluation independent of the response measurement date (12,26 or 52 weeks 
post treatment), while the maximum flow response showed only a significantly higher age at
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baseline when measured at 26 weeks. In the urodynamic outcome analysis, age did not differ 
significantly in the responder groups.
Regarding the total energy delivered the poor responders received significantly less energy 
compared to the good responders for IPSS at 12, 26 and 52 weeks. The energy delivered in poor 
responders for maximum flow was significantly lower than in good responders at 26 weeks which is 
also noticed for the poor responders for linPURR.
The urodynamic parameters only showed a lower obstruction level at baseline in the poor response 
group for IPSS at 52 weeks and not at 12 and 26 weeks. Evaluating the uroflowmetry outcome, only 
at 26 weeks was significantly lower linPURR at baseline noticed in the poor responder group. 
Finally the prostate volume at baseline appeared to be significantly lower in the poor responder 
group for linPURR while there was no significant difference found in the IPSS and uroflow- 
responder groups.
In order to identify the poor responders in each of the three evaluation criteria using baseline 
parameters, we focused on the 26 weeks follow-up. Fig. 1. presents the odds ratio’s and 95% 
confidence intervals (CI) for poor response of each evaluation criteria of all baseline parameters 
sorted by magnitude for each response evaluation criterion. The horizontal reference line indicates 
an odds ratio equals one. For instance, in figure 1A. the odds ratio for age at baseline is 1.034 this 
indicates that the relative chance for a poor response in IPSS at 26 weeks increases with 3.4% every 
year the patient is older at baseline which is, according to the 95% CI (0.99-1.08), not significant. 
Delivering 1 KJ less energy to a patient however significantly increases the chance for poor 
response in IPSS with 2% (odds ratio 0.98, 95% CI 0.97-0.99)
In figure 1A the total amount of energy delivered, the prostate volume, the PSA-level, the total 
Madsen score and the IPSS score are presented as being predicting baseline variables for a poor 
response in IPSS at 26 weeks follow-up. Figure 1B shows baseline parameters predictive for poor 
response in maximum flow at 26 weeks follow-up; linPURR, TUMT energy, PdetatQmax and 
maximum flow. Finally figure 1C presents the PdetatQmax, the maximum flow during urodynamic 
studies, the total amount of energy delivered, the prostate volume, the voided volume, the URA, the 
PSA-level and linPURR as predicting baseline variables for a poor response in linPURR at 26 
weeks.
A forward selection procedure was performed with these baseline parameters to identify those 
baseline parameters that independently predict poor response. Table 5 shows the adjusted odds- 
ratio’s for poor response. Increasing age of patients, small prostates at baseline and a low total 
amount of energy delivered to the prostate were independently predictive factors for poor response 
in IPSS at 26 weeks. Following these variables, the IPSS and Madsen did not improve this model 
significantly.
When regarding the maximum flow rate as response at 26 weeks, the total energy applied and a low 
linPURR at baseline is predictive for a poor response. Using these variables, uroflowmetry variables 
did not improve this model. The next best alternative for linPURR when performing the selection
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procedure appeared to be PdetatQmax. When considering the linPURR at 26 weeks as outcome 
criteria a small prostate and a low total energy applied, are independently predictive baseline 
parameters for a poor response. Alternatives for prostate size in the selection appeared to be URA, 
PdetatQmax, linPURR and maximum flow during urodynamic investigation.
Figure 1. The unadjusted odds ratio and 95% confidence interval for poor response using the 
Response Evaluation Criteria (A: IPSS, B: maximum flowrate and C: linPURR) at 26 weeks. 
Baseline parameters are presented in order of magnitude: Uroflow parameters: maximum flow rate 
(Qmax in ml/s), voided volume (void.volume in ml.), residual urine (residu in ml.); Urodynamic 
parameters: linPURR, URA, PdetatQmax in cmH2O, maximum flow at pressure flow measurement 
(Qmax(PQ) in cm H2O); Symptom scores: IPSS and Madsen symptom scores and Quality o f life 
question (QL); Prostate volume (prost.vol.in cc); PSA; Total TUMT energy (energy in KJ) and age 
in years.
A: IPSS-Response Evaluation
B: Maximum flow - Response Evaluation
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C: linPURR - Response Evaluation
Table 5. Adjusted odds ratio for poor response for the Response Evaluation Criteria at week 26, 
using multiple logistic regression. The selected baseline variables were found using forward 
selection procedures on all parameters.
Baseline parameters IPSS Maximum flowrate linPURR
odds ratio (95%CI) odds ratio (95%CI) odds ratio (95%CI)
Age (years) 1.058 (1.006-1.116) 
p = 0.030
- -
TUMT-energy (KJ) 0.985 (0.975-0.994) 0.992 (0.984-0.999) 0.988 (0.980-0.996)
p = 0.001 p = 0.032 p = 0 .004
Prostate volume (cc) 0.974 (0.952-0.993) 
p = 0.011
- 0.983 (0.969-0.997) 
p = 0.019
linPURR - 0.795 (0.630-0.996) 
p = 0.048
“
-: not selected in the stepwise procedure
C I: Confidence Interval
Example: The probability of poor response o f IPSS at 26 weeks increases by 5.8% by every year of
increasing age. (Which implies an increase of 76% by every 10years)
97
Criteria to predict outcome
DISCUSSION
The treatment of lower urinary tract symptoms due to benign prostatic obstruction has more and 
more become a multi-modality therapy. At the moment the major medical treatment options are 
either alpha-blocker therapy or 5-alpha reductase inhibitor therapy. Treatment outcome for these 
therapies differ not only because of different mechanisms of action but also because the clinical 
trials use different inclusion criteria. Recently this resulted in an attempt to individualize the 
medical treatment in BPH, stratifying patients by their baseline prostate volume assessed by either 
transrectal ultrasound or MRI. The PROSPECT Study9 with finasteride (5a-reductase inhibitor) 
treatment showed a significant reduction in symptoms and improvement in maximum flow over 
baseline. With a maximum flow increase of 1.4 ml/s and a decrease of symptom scores with 2.1 
points further studies were advocated to determine if preselecting patients would improve the 
response rate and whether finasteride therapy would reduce the need for other (invasive) therapies. 
The meta-analysis by Boyle et al. 10 suggested a better outcome when using finasteride in patients 
with larger prostates ( > 40 cc). With the arsenal of treatment modalities and in view of the different 
etiologies causing “symptomatic BPH”, this kind of case selection will become more and more 
important.
Transurethral microwave thermotherapy has been shown to be an effective, one hour, without 
anaesthesia, outpatient treatment modality in patients with lower urinary tract symptoms (LUTS) 
and benign prostatic hyperplasia (BPH). Clinical studies of TUMT using the Prostatron with the 
high energy software 2.5, not only revealed a significant subjective improvement, but also showed a 
significant objective improvement in the same range as transurethral resection of the prostate.6,10-13 
Despite these good results, in a homogeneous population of patients there appeared to be a subgroup 
who responded better to treatment. Adaptation of vascularisation during the application of heat and 
inter individual variations in tissue composition of the prostate were considered to play an important 
role.14,15 To provide selection criteria for the lower energy protocol using the Prostasoft 2.0 de Wildt 
et al.16 analyzed the patient profile at baseline in a group responders and non-responders to this 
treatment. No clinical parameters could be identified to predict clinical outcome or to preselect the 
ideal candidates for this treatment modality. When evaluating the results of the higher energy 
protocol version, it seemed that the best responders were patients with moderate to severe outflow 
obstruction and patients with larger prostates.6,11,12 These results were obtained by stratifying 
patients in pre-selected cohorts without knowledge of the contribution of each individual baseline- 
parameter to therapy-outcome.
Although the current analysis is performed for the prediction of a poor response, it confirms the 
predictive values of both prostate volume and bladder outlet obstruction. However, depending on 
which evaluation criterion one selects, both parameters have different predictive values. Therefore a 
proper selection should be based on the use of a combination of baseline parameters (Table 5).
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In our analysis, the total amount of energy delivered by the Prostraton 2.5 software device, persisted 
in being of predictive value for outcome either in IPSS symptom score improvement, maximum 
flow improvement or urodynamically measured desobstruction. Urodynamic baseline parameters 
predicted outcome for maximum flow and IPSS at 26 weeks and 52 weeks, suggesting that these are 
more important in the prediction of durability of the symptomatic response to treatment. In an 
earlier study of d’Ancona et al.17 the same suggestion for durability was made.
Furthermore we found older patients to have less chance of a favorable outcome in symptom scores 
than the younger patients. The total amount of energy applied is of course not a baseline parameter, 
but directly post treatment it can be useful to be informed about the chances of a good or poor 
response. Being an operator independent procedure, the total amount of energy during high energy 
transurethral microwave thermotherapy varies markedly between patients due to the automatic 
urethral and rectal feedback mechanisms. The higher the amount of energy, the better the outcome, 
suggesting that other ‘baseline’-factors such as vascularisation and tissue composition of the 
prostate may be very important. Moreover it confirms the thermo ablative mechanism of the high 
energy transurethral thermotherapy.
Earlier studies18,19 already suggested the predictive value of urodynamic studies with pressure flow 
analysis and this study also confirms the importance of this investigation when predicting outcome. 
Especially in predicting a poor response in the maximum flow parameter the pressure flow findings 
are very useful.
Finally after thorough investigation four baseline parameters remained highly predicting for poor 
responses in the different evaluation categories. These variables have different predictive values 
depending on the response evaluation criteria used. To refine this case selection, further 
stratification of these parameters must be performed to identify the “ideal” response profile for high 
energy transurethral thermotherapy in the treatment of BPH.
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CONCLUSION
High energy transurethral microwave thermotherapy in patients with lower urinary tract symptoms 
due to BPH, results in a significant subjective and objective improvement. A high age, small 
prostates and a mild to moderate obstruction classification according to the pressure flow analysis at 
baseline, were identified as predicting baseline parameters for a poor response.
The total amount of energy applied during treatment is not a baseline parameter but also has a 
highly predictive value for outcome. A perfect patient profile to predict treatment outcome is yet to 
be assessed. Other factors are most likely to be very important, such as vascularisation and tissue 
composition of the prostate.
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ABSTRACT
Patients’ age, prostate size, grade of outlet obstruction and total amount of energy are independent 
predictive parameters for treatment outcome in patients having lower urinary tract symptoms and 
benign prostatic hyperplasia treated with high energy transurethral microwave thermotherapy (HE- 
TUMT). We combined these parameters as predictors of response for three different response 
evaluation criteria to provide nomograms predicting treatment outcome following HE-TUMT.
247 Patients with lower urinary tract symptoms and benign prostatic hyperplasia were treated with 
high energy microwave thermotherapy using the Prostatron™ device, software version 2.5. To 
evaluate outcome the WHO-Response Evaluation Criteria were used. Age, prostate volume, total 
amount of energy and grade of outflow obstruction were categorized using the Akaike-Information- 
Criterium. The probabilities of good and intermediate response at 26 weeks according to these 
criteria were calculated.
Three nomograms are presented providing the estimated probability (95% confidence interval) for 
good and intermediate response of the evaluation of IPSS at 26 weeks by categories of prostate 
volume, total amount of TUMT energy and age, of Qmax by categories of bladder outlet obstruction 
(linPURR) and total amount of energy and of linPURR by categories of prostate volume and total 
amount of energy. The total amount of energy appeared to have the most impact for the prediction 
of good and poor response in all three response evaluation criteria.
Nomograms have been constructed to assist urologists in making clinical recommendations for the 
treatment of men with lower urinary tract symptoms and benign prostatic hyperplasia, using high 
energy microwave thermotherapy.
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INTRODUCTION
Surgical prostatectomy is the most commonly used treatment for benign prostatic enlargement 
causing infra vesical obstruction. Overall this therapy is considered as gold standard, against which 
other therapies need to be judged. The significant morbidity and mortality associated with surgery 
via the transurethral route1,2, recognition of the slow clinical progression of benign prostatic 
hyperplasia and increased public awareness of non-surgical or minimally invasive treatment options, 
have raised a number of questions as to the ideal therapy in contemporary practice. Transurethral 
microwave thermotherapy has now evolved into a mature minimal invasive treatment modality for 
patients with lower urinary tract symptoms due to benign prostatic hyperplasia. Recent publications 
demonstrated a substantial improvement in symptoms averaging 60% and an improvement in 
maximum flow of almost 50%.3,4 These objective and subjective improvements sustained for 52 
weeks. Besides excellent short term results, durability of response and safety should also be 
favorable. Studies with a 12 months follow-up showed a low rate of additional surgical 
interventions following high energy TUMT.3,5-9 Using the high energy software (Prostatron™ 2.5) 
recently published data demonstrated a low retreatment rate at 2 years follow-up with a persistent 
good symptomatic and objective response.4 Although results are very encouraging, in a studied 
population of patients there appeared to be a subgroup with a considerable number of non 
responders to this new treatment modality. Therefore individualization of therapy by identifying 
predicting baseline parameters would be of great interest.
Earlier studies with high energy transurethral thermotherapy already indicated that the size of the 
prostate and the grade of bladder outlet obstruction were major predictive parameters for treatment 
outcome.5,6,10 In a previous study11 stepwise logistic regression was performed to find a model of 
variables of uroflow parameters, urodynamic parameters, symptomscore, total TUMT energy, PSA 
and age with a high predictive power of non response of the clinical evaluation criteria (stated at the 
3rd International Consultation on Benign Prostatic Hyperplasia in Monaco12) at 26 weeks after 
treatment. Finally, age, prostate volume, obstruction grade according to linPURR and total amount 
of energy delivered were found to be independently predicting for non-response for the evaluation 
criteria IPSS, maximum flow and linPURR.
The current analysis resulted in nomograms to predict outcome of high energy TUMT in analogy to 
the presentation of Partin et al.13,14, who showed in a similar way baseline parameters predicting 
final pathological stage in men with clinically localized prostate cancer. Our nomograms however 
predict clinical good and intermediate outcome at 26 weeks after high energy TUMT and may assist 
clinicians in selecting and advising patients as best candidates for high energy TUMT using the 
Prostatron™ with software version 2.5.
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M ATERIAL AND METHODS
Between October 1993 and July 1996, 247 men with lower urinary tract symptoms and BPH were 
treated using the high energy thermotherapy protocol (Prostasoft™ 2.5). All patients provided 
written informed consent before participation after verbal explanation and reading an explanatory 
leaflet. Inclusion and exclusion criteria were extensively described before.11
Clinical param eters
Uroflowmetry was performed at baseline and at every visit patients were asked to fill out a Madsen- 
Iversen symptom score and an IPSS symptom score. A urethrocystoscopy was carried out at 
baseline to judge the patency of the (prostatic) urethra for the presence of strictures or an isolated 
obstructing prostatic middle lobe and to exclude intra vesical pathology. Urodynamic investigation 
with pressure-flow (PQ) study analysis was performed at baseline and 26 weeks post treatment. To 
quantify the grade of bladder outlet obstruction, urodynamic investigation with PQ analysis was 
performed. The following parameters derived from the pressure-flow analysis were used: detrusor 
pressure at maximum flow (PdetatQmax in cmH2O), maximum flow rate (PQ-Qmax in ml/s), the 
linPURR (obstruction grading according to Schäfer) and the urethral resistance index (URA in 
cmH2O).
Prostate configuration and prostate volume were assessed at screening and follow-up, by performing 
transrectal ultrasound (TRUS). In case of an abnormality on either digital rectal examination, 
prostate specific antigen level or TRUS, ultrasound guided prostate biopsies were performed.
Treatm ent
The TUMT treatments were performed on ambulatory basis using the Prostatron™ (EDAP 
Technomed, Lyon, France) device and the software 2.5. The method of therapy has been described 
previously.15 Treatment duration was 60 minutes using the Prostanec™ catheter, with an increasing 
thermal dose up to 70 Watts. To prevent thermal damage to urethral mucosa and rectal wall thermal 
sensors, urethrally and rectally positioned, give continuous feedback signals of the temperature 
reached. When the maximum allowed temperature is detected by 1 of these thermosensors the 
program automatically interrupts the treatment until the temperature decreases to a preset value. 
Two hours prior to treatment 40 mg of morphine sulfate was administered orally. During treatment 
no additional anaesthesia other than topical applied Instillagel™ was given, but if  necessary 
intravenous sedation was given when patients experienced major discomfort during treatment. Since 
initial experience showed urinary retention in nearly all patients, patients were given a transurethral 
catheter with leg-bag directly after treatment.
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Statistical methods
In order to evaluate outcome we used the Response Evaluation Criteria as stated at the 3rd 
International Consultation on Benign Prostatic Hyperplasia in Monaco.12 (Table 1.) In the Response 
Evaluation Criteria patients are stratified as poor, intermediate and good responders using either the 
IPSS symptom scores or the maximum flow rate or linPURR. Since we aimed at identifying 
responders from non-responders, so-called intermediate responders were merged with the good 
responders and defined as good responders.
The Akaike-Information-Criterium (AIC) was used to optimize the dividing of the explanatory 
variables in each logistic model in equal distances. The probabilities of poor response at 26 weeks 
according to these categories are presented in so called nomograms.
The performance of a logistic model can be judged on its goodness of fit and on its discriminatory 
power. Two measures for goodness of fit are calculated. The first is the statistic H of Hosmer and 
Lemeshow16: this is a $2-statistic with the number of degrees of freedom equal to the number classes 
minus two. The deciles of predicted probability were used. If necessary, consecutive classes were 
combined to attain a minimum of five patients in each class. The second is the statistic Q of Liu and 
Dyer.17 This is a linear transformation of the Mann-Whitney statistic (and thus of the Wilcoxon two 
sample statistic) comparing the predicted probabilities of two groups.
Table 1. Evaluation Response criteria set at the International Consultation on Benign Prostatic 
Hyperplasia.12
Good responder Intermediate responder Poor responder
IPSS screening 19 screening < 19, changes > 3 change 3
and or
posttreatment 8 posttreatment >8, change > 3
UROFLOW screening < 10 ml/s screening > 10 ml/s, change > 3 change 3 ml/s
and or
posttreatment > 15 ml/s posttreatment < 15 ml/s, change > 3
linPURR screening III screening < III, change > 1 change I
and or
posttreatment I posttreatment > I, change > 1
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RESULTS
At screening 247 patients with a mean age of 66.3 years (std; 8.2 years) were treated with a mean 
total energy level of 159 KJ (std; 40 KJ). All patients tolerated the TUMT treatment well. The mean 
catheterisation time was 16.8 days (std; 16.1 day). The evaluation period was set at 26 weeks as 
follow-up data on all patients studied was then available.
A multi variate logistic regression analysis performed earlier revealed that four parameters at 
baseline (age, prostate volume, obstruction grade and TUMT-energy) were independently predicting 
for a response to high energy TUMT treatment of the clinical research criteria at 26 weeks follow- 
up.11
The combination of age, TUMT-energy and prostate volume gave a good fit in predicting a good 
response of IPSS. Age was negatively correlated and TUMT-energy and prostate volume were 
positively correlated with good response of maximum flowrate. The combination of TUMT-energy 
and prostate volume gave a good fit in predicting response of linPURR. Both were positively 
correlated with good response of linPURR. The correlation between these two parameters at 
baseline was relatively small (Spearman Rho<0.3) and small enough to contribute independently to 
the prediction of good response.(Table 2.) Significant but weak correlations were found between 
patients’ age and the prostate volume (Spearman Rho=0.27, p =<0.001), between TUMT energy and 
prostate volume (Spearman Rho=0.22, p < 0.001) and prostate volume and grade of obstruction 
(Spearman Rho=0.39, p < 0.001).
In order to create nomograms, each predictive parameter was divided in a necessary and sufficient 
number of equidistant classes, using the Akaike-Information Criterium (AIC) in each multi variate 
model separately. As a result of this, we found 3 age classes, 5 TUMT energy classes, 7 prostate 
volume classes and 3 linPURR classes as presented in Table 3.
Table 2. Spearman rank correlation coefficient between the predicting baseline parameters that are 
predictive for good response at 26 weeks after high energy TUMT.
Age
(n; p)
Total energy
(n; p)
Prostate volume
(n; p)
Outflow-Obstruction
(n; p)
Age na -0.026 0.265 0.084
(n; p) (246; 0.682) (247; 0.0001) (245; 0.192)
Total energy -0.026 na 0.224 0.094
(n; p) (246; 0.682) (246; 0.0004) (244; 0.145)
Prostate volume 0.265 0.224 na 0.386
(n; p) (247; 0.0001) (246; 0.0004) (245; 0.0001)
Obstruction 0.084 0.094 0.386 na
(n; p) (245; 0.192) (244; 0.145) (245; 0.0001)
na: not applicable 
n: number of pairs
p: p  value for test of statistical significant difference from zero
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Table 3. The number of cases in each subclass of respectively age, total amount o f TUMT energy 
delivered, prostate volume and grade ofobstruction at baseline.
FREQUENCY PERCENT
AGE (YEARS)
< 65 112 45.3 %
65 -75 98 39.7 %
> 75 37 15 %
TUMT ENERGY (KJ)
< 100 26 10.6 %
101 - 130 30 12.2 %
131 - 160 51 20.7 %
161 - 190 73 29.7 %
> 190 66 26.8 %
PROSTATE VOLUME
< 40 70 28.3 %
40 - 50 55 22.3 %
51 - 60 41 16.6 %
61 - 70 24 9.7 %
71 - 80 13 5.3 %
81 - 90 16 6.5 %
> 90 28 11.3 %
LinPURR
0,1&2 91 37.1 %
3 63 25.7 %
4,5&6 91 37.1 %
Tables 4,5 and 6 demonstrate nomograms combining prostate volume, age, grade of obstruction 
and total amount of energy delivered by the device to predict a good response for each of the 
Response Evaluation Criteria. The nomograms represent the percentage probability of having a 
good response, based on the multiple logistic regression model. Also the 95% confidence interval 
was calculated and presented in subscription. For example a 70 years old patient with a prostate 
volume of 75 cc has a chance of responding well in IPSS minimally 66% (CI: 45-82%). In the 
assessment of a patient, a urodynamic study with pressure flow analysis may be included. Assuming 
this patient having a severe obstructive outflow obstruction (linPURR > III), than his chance on a 
good response in maximum flow is minimally 49% (CI: 31-67%). The chance of being 
desobstructed (i.e. 1 point or less change in linPURR) after treatment in this patient is minimally 
38% (CI: 22-57%). In general: the higher the total amount of energy absorbed, the better the 
outcome for all three criteria. The assessed H-statistics show that the observed and predicted values 
agree with each other: this means a good fit of the three models presented. The Q-statistics indicate 
that the models presented must be considered appropriate to distinguish between the two groups 
(poor response and intermediate or good response) on behalf of the predictive values. The IPSS 
response model is the better of the three models, both in terms of discriminating power and 
goodness of fit. For the interpretation of the predicting values presented in our tables we calculated 
a cut of point for equal costs for misclassification for cases and non-cases. Note that this cut of point 
is much higher in the IPSS-model (cut off point=0.79) compared to the other two models (cut off 
point= 0.53, 0.56 for the Flow model and linPURR model respectively). (Table 4-6).
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Table 4. The estimated probability (95% confidence interval) for good response of the evaluation of IPSS at 
26 weeks by categories o f prostate volume, total amount o f TUMT energy and age.
SYMPTOM SCORE (IPSS)
<65 years
Age (years)
65-75 years >75 years
Prostate
Volume
(rr) < 100 100-130
Energy (KJ) 
130-160 160 - 190 > 190 100 100-130
Energy (KJ) 
130-160 160 - 190 > 190 100
Energy (KJ)
< 40 0.57 0.68 0.77 0.85 0.90 0.42 0.54 0.65 0.75 0.83 0.29
0.36-0.75 0.52-0.80 0.65-0.86 0.75-0.91 0.80-0.95 0.25-0.61 0.39-0.68 0.52-0.77 0.62-0.85 0.69-0.92 0.13-0.53
40 - 50 0.63 0.73 0.81 0.88 0.92 0.48 0.60 0.71 0.80 0.86 0.34
0.42-0.79 0.59-0.84 0.72-0.88 0.80-0.93 0.85-0.96 0.31-0.65 0.47-0.71 0.61-0.79 0.70-0.87 0.76-0.93 0.17-0.57
50 - 60 0.68 0.77 0.85 0.90 0.94 0.54 0.66 0.76 0.83 0.89 0.40
0.47-0.84 0.63-0.87 0.76-0.91 0.83-0.94 0.87-0.97 0.37-0.71 0.54-0.76 0.68-0.82 0.76-0.89 0.81-0.94 0.21-0.62
60 - 70 0.73 0.81 0.88 0.92 0.95 0.60 0.71 0.80 0.86 0.91 0.46
0.51-0.88 0.67-0.91 0.78-0.94 0.85-0.96 0.89-0.98 0.41-0.76 0.58-0.81 0.71-0.86 0.79-0.91 0.84-0.95 0.26-0.67
70 - 80 0.78 0.85 0.90 0.94 0.96 0.66 0.76 0.83 0.89 0.93 0.52
0.54-0.91 0.69-0.94 0.79-0.96 0.86-0.97 0.90-0.98 0.45-0.82 0.61-0.86 0.73-0.90 0.81-0.94 0.86-0.97 0.29-0.74
80 - 90 0.82 0.88 0.92 0.95 0.97 0.71 0.80 0.87 0.91 0.94 0.58
0.56-0.94 0.70-0.96 0.80-0.97 0.87-0.98 0.91-0.99 0.47-0.87 0.62-0.91 0.74-0.94 0.82-0.96 0.87-0.98 0.33-0.80
> 90 0.85 0.90 0.94 0.96 0.98 0.76 0.84 0.89 0.93 0.96 0.64
0.58-0.96 0.71-0.97 0.81-0.98 0.88-1.0 0.91-0.99 0.49-0.91 0.64-0.94 0.75-0.96 0.83-0.97 0.88-0.99 0.35-0.85______
The cut o ff point for prediction o f good response under the condition o f equal costs o f misclassification in cases and non-cases is 0.79 (sensitivity 
76%, specificity 67%)
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Table 5. The estimated probability(95% confidence interval) for eood response ofthe evaluation of 
the Qmax at 26 weeks by categories o f Bladder outlet obstruction (linPURR) and total amount of 
TUMT energy.
UROFLOWMETRY (QMAX)
linPURR (Schafer) TOTAL AMOUNT OF TUMT ENERGY (KJ)
< 100 KJ 100 - 130 KJ 130 - 160 KJ 160 - 190 KJ > 190 KJ
0 & I & II 0.30 0.35 0.41 0.47 0.53
(not-obstructive) 0.17-0.47 0.24-0.49 0.30-0.52 0.36-0.58 0.39-0.67
III 0.39 0.45 0.51 0.57 0.63
(moderate obstructive) 0.25-0.55 0.34-0.56 0.43-0.59 0.50-0.65 0.52-0.73
IV & V & VI 0.49 0.55 0.61 0.67 0.72
(severe obstructive) 0.31-0.67 0.41-0.69 0.50-0.71 0.56-0.76 0.60-0.82
The cut o ff point for prediction o f good response under the condition o f equal costs o f misclassification in cases and non-cases is 
0.53 (sensitivity 68%, specificity 55%).
Table 6. The estimated probability(95% confidence interval) for good response ofthe evaluation of 
Obstruction erade (linPURR) at 26 weeks by categories o f prostate volume and total amount of 
TUMT energy.
'OBSTRUCTION GRADE ACCORDING TO SCHÄFER (LINPURR)'
---------PROSTATE--------
VOLUME (prv)
< 100 KJ
----------- TOTAL AMOUNT OF TUMT ENERGY (KJ)------
100 - 130 KJ 130 - 160 KJ 160 - 190 KJ > 190 KJ
< 40 (cc) 0.22 0.29 0.36 0.45 0.53
0.12-0.38 0.18-0.42 0.26-0.48 0.34-0.56 0.39-0.67
40 < prv< 50 (cc) 0.25 0.33 0.41 0.49 0.58
0.14-0.41 0.23-0.45 0.32-0.50 0.40-0.59 0.46-0.69
50 < prv < 60 (cc) 0.29 0.37 0.46 0.54 0.63
0.17-0.45 0.27-0.49 0.37-0.54 0.46-0.62 0.52-0.73
60 < prv < 70 (cc) 0.33 0.42 0.50 0.59 0.67
0.20-0.51 0.30-0.54 0.41-0.59 0.50-0.67 0.56-0.77
70 < prv < 80 (cc) 0.38 0.46 0.55 0.64 0.71
0.22-0.57 0.33-0.61 0.44-0.66 0.53-0.73 0.56-0.81
80 < prv < 90 (cc) 0.42 0.51 0.60 0.68 0.75
0.24-0.63 0.35-0.67 0.46-0.73 0.55-0.79 0.61-0.85
> 90 (cc) 0.47 0.56 0.64 0.72 0.78
0.26-0.70 0.36-0.74 0.47-0.79 0.56-0.84 0.63-0.89
The cut o ff point for prediction o f good response under the condition o f equal costs o f misclassification in cases and non-cases is 
0.56 (sensitivity 58%, specificity 74%).
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DISCUSSION
In this study we succeeded to create nomograms of the baseline predictive parameters for good and 
poor response of the evaluation response criteria.
In the treatment of benign prostatic hyperplasia currently several non invasive, minimal invasive 
and invasive therapies are available. One could well use all these possibilities to treat a patient 
sequentially; first step could be phytotherapy, alpha blockage therapy or 5 alpha reductase inhibitor 
therapy. If this fails minimal invasive treatments such as TUMT, TUNA (Transurethral Needle 
Ablation), or laser prostatectomy may be considered. Finally if these treatments fail, one can always 
rely on the “gold-standard” TURP or the open prostatectomy. Instead of this policy, another (and 
better) approach is to select a therapy with a high success rate, using non or minimally invasive 
investigations to identify “predictive baseline parameters” for the several treatment modalities. At 
the moment the total symptom score improvement and uroflowmetry improvement as well as an 
overall decrease in obstruction parameters is regarded crucial in selecting a therapy. Other important 
considerations should be the safety and morbidity of the available treatment modalities. Therefore, a 
minimal invasive, non anaesthesia, outpatient procedure like transurethral microwave 
thermotherapy is an appealing treatment modality for patients with BPH and lower urinary tract 
symptoms.
The present analysis showed that we can identify baseline parameters which can a priori predict, 
within a certain range, response for outcome in three different evaluation criteria; IPSS, maximum 
flow and linPURR. We will now first discuss the response criteria separately:
Response in IPSS: Older patients have a less favorable symptomatic outcome following TUMT. 
The fact that older patients received less energy could explain why they have a higher chance on a 
poor response in IPSS, but not why they actually received less energy. Less energy can only be 
explained by either interrupting the treatment manually or by rectal and urethral triggering. In this 
cohort we did not interrupt the treatment sessions but feedback triggers occurred often. Urethral 
triggering and rectal triggering have different outcome on total amount of energy, and the rectal 
triggers contributed most in eventually receiving less energy in these patients.
When considering the response in IPSS one can see that the older patients respond worse, despite 
the fact that one should assume a compromised vascularisation in their prostates resulting in a better 
thermic effect (damage) and subsequently a better response. Older patients receive less energy and 
one could imagine that this neutralizes the fact that older prostates should respond better on heat 
treatment. Still we do not know why they receive less energy with increasing age: Probably there is 
an equilibrium between prostate size, aging of the prostate tissue and vascularisation and total 
amount of energy which supports a treatment optimum with a minimum of rectal and urethral 
triggers to provide the best outcome in symptom score. However we already know the poor 
correlations between symptomatic and objective parameters in the analysis of LUTS.18,19 and it 
could well be that older patients have a higher chance for poor response in IPSS because of
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additional pathology which can reflect on their perception of well being. Further analysis in looking 
at patients performances (ASA score; American Society of Anaesthesiologists operative risk 
classification) and their outcome in symptoms post TUMT could verify this assumption. More 
research in the role of prostate vascularisation and histology as well as to the possibility of 
decreasing bladder function in aging men will also clarify some of this matter.
Response in Qmax: This study shows that patients with higher grades of obstruction at baseline 
respond better in maximum flow improvement. Although one should think that the higher grades of 
obstruction are caused by the large prostates and leading to poor flows at baseline we found that the 
obstruction grade has a significant but weak correlation with prostate volume (in our cohort 
Spearman Rho = 0.39, p = 0.0001) and also with maximum flow (in our cohort Spearman Rho = 
0.25, p = 0.0001). The latter has been confirmed in an earlier study [20]. The contribution of the 
total amount of energy to the response in maximum flow is therefore clear and understandable since 
we expect a more thermoablative effect with higher energy levels.
Response in linPURR: Two parameters (prostate volume and energy) are predicting for a good 
response in obstruction grade, since the larger prostates should be able to absorb more energy. This 
ia in accordance to findings in the literature.5,6,10
What we also learned from this analysis is that the tables clearly show that higher energy levels do 
result in a higher chance of having a good response in either one of the criteria.
What is the value of predictive baseline parameters when a “non baseline parameter” as total 
energy, appears to be the most important predictor in all three evaluation criteria for good 
response? One can imagine that it could be of interest to be informed directly post treatment about 
the probability of good and poor response in a particular patient to inform this patient about the 
expectations. On the other hand it can also satisfy the curiosity of the physician performing the 
treatment. But more important one could consider to modify the software and focus on a minimal 
energy input to certify a certain outcome. (Simply by adjusting treatment time)
Higher energy during the transurethral microwave thermotherapy results in higher chance for good 
response. The treatment session is standardized and therefore one can not (yet) predict the total 
amount of energy a patient will eventually get. Therefore one should consider to guarantee a 
minimal amount of energy (and eventually maybe prolong the treatment guided by the total amount 
of energy delivered). Larger prostates are supposed to absorb a greater deal of energy and in our 
cohort indeed TUMT energy is significantly correlated with prostate size but this is a weak 
correlation.
What did we learn from this analysis besides the fact that we made a device specific “manual” to 
identify responders? First of all we have learned that parameters can be identified to predict 
responses using the WHO-criteria which means that although the prostate is composed of very 
heterogeneous tissue with variable intrinsic parameters (vascularisation, tissue, size, obstruction) the 
response is predictable within a certain range. A better prediction for a good response than 78% for 
obstruction grade, 72% for maximum flowrate and 97% for IPSS with these data is not yet
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possible. Furthermore we learned more about the prostate model with all inter individual variations 
and although certain parameters (size, obstruction) will hardly be controlled, others (histology and 
vascularisation) might be changed or compromised to approve the thermal effect and to improve 
treatment outcome. With knowledge from these really intrinsic parameters it should also be 
possible to improve the prediction for response and therefore to individualize the high energy 
transurethral thermotherapy, not only for the Prostatron device but also for the other devices.
In contradiction to the work of Partin13,14 we did not only identify baseline parameters being 
predicting for responders to high energy thermotherapy. We also found total amount of energy 
delivered predicting for response, being a “post priori” parameter and future research in prostate 
architecture and vascularisation can possibly identify other a priori parameters to replace or to 
complement this predictive parameter.
The current nomograms can guide urologists in their decision to treat a patient with lower urinary 
tract symptoms and BPH, using the high energy transurethral microwave thermotherapy with the 
Prostatron (software version 2.5) device. This way the physician will be able to verify whether high 
energy transurethral microwave thermotherapy treatment is justified using objective criteria.
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ABSTRACT
To assist urologists selecting patients for high energy transurethral microwave thermotherapy, based 
on baseline characteristics.
247 Patients with lower urinary tract symptoms and benign prostatic hyperplasia were treated with 
high energy microwave thermotherapy using the Prostatron™ device, software version 2.5. To 
evaluate outcome at 26 weeks, the WHO-Response Evaluation Criteria were used. Multiple logistic 
regression models were created to identify the predictive value of baseline parameters and total 
amount of energy used. Furthermore receiver-operating-characteristic curve (ROC) and the best 
cut-off point for the prediction of good response of each criterium under the condition of equal 
'costs' of misclassification to cases and non-cases were calculated.
For each of the three Response Evaluation Criteria, graphics are presented to determine whether 
high energy microwave thermotherapy using the Prostatron can be justified. Only the total amount 
of energy delivered by the device has major impact in all three Response Evaluation Criteria used. 
From our analysis graphs have been constructed to assist urologists in making clinical 
recommendations for treatment based on the expected outcome when using high energy microwave 
thermotherapy.
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INTRODUCTION
To select a patient for treatment with high energy TUMT, we should be able to make this decision 
with an accurate estimation for outcome and therefore maximize the chance of selecting patients 
where treatment is justified (sensitivity). On the other hand we want to reduce the number of 
patients that are not selected for treatment but who could benefit from it (1-specificity).
Earlier studies with high energy transurethral thermotherapy already indicated that the size of the 
prostate and the grade of bladder outlet obstruction are major predictive parameters for treatment 
outcome.1-3 In a recent study4 stepwise logistic regression was performed to construct a model of 
variables with a high predictive power of good response of the clinical evaluation criteria (stated at 
the 3rd International Consultation on Benign Prostatic Hyperplasia in Monaco5) at 26 weeks after 
treatment. From this analysis age, prostate volume, obstruction grade according to linPURR 
(obstruction grade according to Schäfer)6 and total amount of energy delivered as strong were found 
to be independently predicting for good response of at least one of the evaluation criteria IPSS, 
maximum flow and linPURR. Although the total amount of energy is not a ‘a-priori’ parameter as 
such, the fit of the model to the data decreased considerably when this parameter is omitted from the 
model.4 These predicting ‘baseline’ variables may contribute in individualization of this treatment 
modality. This is not only important in determining the place of high energy transurethral 
thermotherapy in the armamentarium of new minimal invasive treatment modalities for BPH, but it 
also helps to understand the several mechanisms of heat response in the prostate gland.
In the present study, guidelines for eligibility for high energy TUMT treatment are presented. Cut­
off points for the prediction of good response for each response evaluation criteria5 are calculated. 
Also graphs are created to guide urologists in decision making whether they should recommend 
high energy thermotherapy in a specific patient or not.
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M ATERIAL AND METHODS
From October 1993 until July 1996, 247 men with lower urinary tract symptoms (LUTS) and benign 
prostatic hyperplasia (BPH) were treated applying high energy transurethral microwave 
thermotherapy (EDAP Technomed, Lyon, Prostasoft™ 2.5). Patients included had to comply with 
the following criteria: males older than 45 years with lower urinary tract symptoms, a prostate 
volume larger than 25 cm3, a Madsen Symptom score of 8 or greater, a urinary maximum flow of 15 
ml/s or less, and a post void residual volume of 350 ml or less.
Exclusion criteria were: urinary retention, prostate carcinoma, acute or chronic prostatitis, urethral 
stricture, intra vesical pathology (e.g. stones, neoplasm), neurogenic bladder dysfunction, urinary 
tract infection, isolated obstructive middle lobe, use of drugs influencing bladder or prostate 
function, disorders of blood flow or coagulation and diabetes mellitus. Assessment and follow-up 
studies included Madsen Symptom score, IPSS-symptom score and physical examination. Prostate 
configuration was assessed by performing transrectal ultrasound (TRUSP). In case of an abnormal 
digital rectal examination, PSA-level or TRUSP, ultrasound guided prostate biopsies were 
performed. A urethrocystoscopy was carried out to judge the patency of the (prostatic) urethra for 
the presence of strictures or an isolated enlargement of a prostatic middle lobe and to exclude intra 
vesical pathology. Follow-up visits were scheduled at 12,26 and 52 weeks following treatment. 
Ultrasound of the prostate was repeated at 12 and 52 weeks. Urodynamic investigation with PQ 
study analysis was performed at baseline and 26 weeks post treatment to quantify the grade of 
bladder outlet obstruction. The digitally stored pressure and flow-data were analyzed by a program 
developed at our department (UIC/BME Research Center, Department of Urology, Nijmegen, the 
Netherlands).
TUMT treatments were performed in an outpatient setting using the Prostatron device (EDAP 
Technomed, Lyon, France) and software version 2.5 with the Prostanec™ catheter. The method of 
performing therapy has been described previously.7 Two hours prior to treatment 40 mg of 
morphine-sulfate was administered orally. Treatment duration was 60 minutes and additional 
intravenous sedation was required in 24% of cases. The energy level during treatment was gradually 
increased up to 70 Watts. Posttreatment all patients had a transurethral catheter (Ch 16.) with leg- 
bag because of urinary retention.
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Statistical methods
In the evaluation of outcome of treatment we used Response Evaluation Criteria as stated at the 3rd 
International Consultation on Benign Prostatic Hyperplasia in Monaco5 (Table 1.), in which patients 
are stratified as poor, intermediate and good responders using the IPSS symptom scores, the 
maximum flow rate or linPURR. Since we aimed at identifying responders from non-responders, 
so-called intermediate responders were merged with the good responders. The probability of good 
response at 26 weeks after high energy TUMT treatment (p) of a patient (i) in a logistic model can 
be calculated as follows:
Pi
e ^
1 + e PX
Using the logistic models of the three Response Evaluation Criteria from our previous study4, PX 
is:
IPSS: PX. = 1.375 -  0.057*agej. + 0.015*TUMT-energy. + 0.027*P-volume.
FFQM: pX. = -1.836 + 0.008* TUMT- energy. + 0.230 *linPURRi 
UPSC: pX = -2.779 + 0.012* TUMT- energy. + 0.017 *P-volume.
with aget the age (years), P-volumet the volume of the prostate (cc), TUMT-energy the energy used 
for treatment (kJ) and linPURRj the grade of obstruction according to Schäfer, of the patienti.
The explanatory variables statistically significantly contribute to the probability of good response at 
each of the evaluation criteria at 26 weeks after high energy TUMT treatment (likelihood ratio: p < 
0.01).
A cut-off point for p was determined where the sum of the sensitivity and the specificity (J) is 
maximal. This is the best cut-off point for the prediction of good response under the condition of 
equal 'costs' of misclassification of cases and non-cases.
The performance of a logistic model can be judged on its goodness of fit and on its discriminatory 
power. Two measures for goodness of fit are presented. The first is the statistic H of Hosmer and 
Lemeshow8: this is a $2-statistic with the number of degrees of freedom equal to the number classes 
minus two. The classes are based on the deciles of predicted probabilities. The second is the statistic 
Q of Liu and Dyer. 9 This is a linear transformation of the Mann-Whitney statistic (and thus of the 
Wilcoxon two sample statistic) comparing the predicted probabilities of two groups.
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A measure of the discriminatory power is the largest value of the Youden statistic (J*). Both this 
Youden statistic and the Kolmogorov-Smirnov two-sample statistic are linear combinations of the 
maximal distance between the cumulative distribution functions on the predicted values of the 
samples. Also, J* is the maximal distance between the receiver-operating-characteristic curves 
(ROC) and the line y=x.
Table 1. Evaluation Response criteria set at the International Consultation on Benign Prostatic 
Hyperplasia. 5
Good responder Intermediate responder Poor responder
IPSS screening > 19 
and
posttreatment < 8
screening < 19 
or
posttreatment >8 
and
change > 3
change 3
UROFLOW screening < 10 ml/s 
and
posttreatment > 15 ml/s
screening > 10 ml/s 
or
posttreatment < 15 ml/s 
and
change > 3 ml/s
change 3 ml/s
linPURR screening > III 
and
posttreatment < I
screening < III 
or
posttreatment > I 
and
change > 1
change I
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RESULTS
Earlier studies4,10 revealed the predictive value of patients’ age, obstruction grade and prostate 
volume for a good response. The total amount of energy delivered by the device appeared to be a 
very important post priori parameter in the prediction of a good response of all three Clinical 
Research Evaluation Criteria. Table 2 shows the percentages of patients with good response 
stratified for the predictive variables and the evaluation response criteria. For example, the 
percentage of good response of IPSS after 26 weeks is negatively correlated with age and positively 
with both prostate volume and total amount of energy.
The assessed H-statistics show that the observed and predicted values agree with each other which 
shows a good fit of the three models presented. The Q-statistics indicate that the models presented 
must be considered appropriate to distinguish between the two groups (poor response and 
intermediate or good response) on behalf of the predictive values. The same holds true for J*, as 
illustrated by the receiver operating characteristic (ROC) curves (Figure 1), which are fairly distinct 
from the y=x line. Each point of the ROC-curve represents the sensitivity and the specificity at a 
certain cut-off point for the predictive values. The boundary p* at which the distance between the 
ROC-curve and the y=x line is maximal (J*), is suggested as the best cut-off point for the prediction 
of good response at 26 weeks after treatment. This holds under the condition that 'costs' (in a broad 
sense) of misclassification to cases and non-cases are equal. Subsequently this value can be used to 
dissociate the good and intermediate and poor responders. The boundary value of p, the specificity 
and the sensitivity reached at this point are presented in table 3. We found that on these three 
aspects; goodness of fit (H,Q), explained variation and discriminating power, the three models are 
acceptable, although the explained variation is low. All three models are good considering 
goodness-of-fit, but only the model predicting good response of IPSS scores overall better and 
shows an acceptable discriminatory power.
124
Chapter 3
Table 2. The percentage of patients with good response of each evaluation criterium by grouped 
age, energy, prostate volume and grade ofobstruction.
IPSS___________________________ Qmax___________________ LinPURR
Good/
Intermediate
Poor Good/
Intermediate
Poor Good/
Intermediate
Poor
n % n total n % n total n % n total
Age (years) 
<65
i
82 87.2 12 94 50 56.2 39 89 41 49.4 42 83
65-75 55 74.3 19 74 37 52.9 33 70 36 53.7 31 67
>75 19 70.4 8 27 13 52 12 25 14 56 11 25
TUMT-energy (kJ) 
<100 12 63.2 7 19 5 27.8 13 18 5 26.3 14 19
101­
130
10 43.5 13 23 11 50 11 22 7 33.3 14 21
131­
160
29 85.3 5 34 18 60 12 30 16 59.3 11 27
161­
190
56 86.2 9 65 35 53.9 30 65 32 55.2 26 58
>191 49 90.7 5 54 31 63.3 18 49 31 62 19 50
Prostate volume (cc)
<40 33 67.4 16 49 21 45.7 25 46 18 42.9 24 42
41-50 41 86.1 5 46 27 62.8 16 43 19 45.2 23 42
51-60 24 70.6 10 34 19 57.6 14 33 11 35.5 20 31
61-70 15 79 4 19 11 57.9 8 19 16 84.2 3 19
71-80 13 100 13 6 50 6 12 7 70 3 10
81-90 10 76.9 3 13 6 46.2 7 13 6 50 6 12
91 20 95.2 1 21 10 55.6 8 18 14 73.7 5 19
linPURR
0+1+2 57 78.1 73 31 44.3 39 70 10 14.9 57 67
3 38 79.2 48 22 52.4 20 42 25 62.5 15 40
4 47 82.5 57 37 64.9 20 57 41 80.4 10 51
5+6 14 82.4 17 10 66.7 5 15 15 88.2 2 17
156 80 39 195 100 54.4 84 184 91 52 84 175
Note that the explained variation is low maybe due to general dispersion; however this should never be confused with lack o f fit.
Figures 2a-c show the area of each model where the estimated probability for good response is 
above that boundary: this means that treatment is preferable under the condition of equal 'costs' of 
misclassification and patients with predicted probability below this area could be argued for benefit 
of the treatment of that patient according to these Criteria.
125
Patient selection
Table 3. Measures for goodness-of-fit and discriminatory power of the logistic regression model 
for predicting good response of IPSS, Qmax and linPURR, respectively at 26 weeks after treatment.
Hosmer & Lemeshow AUC Equal cost classification
1 2 3 4 5 6 7 8
Evaluation critérium H d.f. P J* p* spec. sens.
IPSS 5.41 8 0.71 0.75 0.43 0.79 0.67 0.76
Qmax 2.11 8 0.98 0.62 0.23 0.53 0.55 0.68
linPURR
d f :
4.37 8
Degrees of freedom
0.82 0.68 0.32 0.56 0.74 0.58
P
J*
Sens.
Spec.
The cut-off point for the probability o f good response at 26 weeks after treatment, under the 
condition of equal costs of misclassification of cases and non-cases.
Maximum Youden index
Sensitivity o f the test when the cut-off-point of p  equals p *
Specificity of the test when the cut-off-point o f p  equals p*
*Column 1-3 show that this model (statistic H) adequately fit to the data (large p), which was in agreement with the Q 
statistic (not presented)
*Column 4: The area under the curve (AUC)
*Column 5: The discriminatory power of the model (0-1)
Figure 1. ROC-curves presenting the discriminatory power of the prognostic models for good 
response at 26 weeks after high energy TUMT ( distance between ROC-curve and the x  = y  line) of 
the IPSS - model (fat solid line), the linPURR - model (broken line) and the Qmax - model (thin 
solid line). A star indicates the proposed cut-off point for the probability o f good response under the 
condition of equal cost classification.
1 - SPECIFICITY
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DISCUSSION
In this study we calculated a cut-off point for the prediction of good response of each evaluation 
response criterium to evaluate whether high energy TUMT treatment is preferable in a particular 
patient.
Due to the considerable variability in individual response to TUMT treatment many investigators 
have searched for selection criteria to predict clinical outcome.11-19 Although surgical treatment for 
bladder outflow obstruction and BPH has been well established for many years, no consensus has 
yet been reached on how success and failure should be defined. The published studies use different 
endpoints for responders and non-responders and are therefore difficult to compare.
To standardize the analysis of clinical outcome we used the WHO-response evaluation criteria as set 
during the consensus meeting in 1995.5 The recently FDA-approved second generation high energy 
TUMT (software 2.5) has been introduced resulting in improvements of thermotherapy treatment 
outcome, but at the cost of increased morbidity.20 With the availability of different treatment 
protocols, one should try to identify the ideal profile of a patient for this high energy treatment 
modality.
The present analysis reveals three baseline parameters (prostate volume, age, obstruction grade 
(linPURR)) and one post priori parameter (TUMT energy) with predictive values for the several 
response evaluation criteria (IPSS, maximum flow, grade of obstruction). The use of the predictive 
values in finally selecting a patient for the high energy thermotherapy still remains difficult and is 
depending on the level of sensitivity and specificity urologists aim at. We defined cut-off points 
were the sum of sensitivity and specificity is maximal for the different models representing the 
condition that 'costs' (in a broad sense) of misclassification to cases and non-cases are equal. 
Although the presented graphs can be used in the selection of patients at baseline under the 
assumption of reaching certain total energy levels, an increase in discriminatory power of the three 
models is preferable.
The variables used were found to be the best set of variables in our patient group to predict 
outcome, but also other variables from the same population could possibly produce a similar 
predictive power.4 If for example different categories (histology, vascularisation) of parameters are 
added to the model, the specificity and sensitivity may increase and eventually the predictive power 
may raise.
Predicting the outcome of a heat generated process in vital tissue by only analysing clinical 
parameters seems quite unlikely to succeed completely. Therefore further investigations are needed 
to analyse the contribution of intrinsic prostate variables like prostate histology and vascularisation 
in the outcome of transurethral microwave thermotherapy. On the other hand many clinical features 
derive directly from intrinsic factors of the prostate and may be therefore useful in the current 
evaluation. Moreover in the assessment and selection of patients it is the most elegant way to obtain 
clinical baseline information instead of performing invasive diagnostic procedures to predict
127
Patient selection
outcome of treatment more accurate. Because of these techniques and their minimal morbidity 
inflicting, we could perhaps accept more false positive responders, and therefore accept more 
unjustified treatments (according to the models). When for example “costs” for non-treatment 
increase compared to treatment (than we accept more patients to be treated without an objective 
justification), the area where treatment still is preferable will increase. As our analysis clearly 
shows, the total amount of energy is a ‘a posteriori’ variable in the prediction of response for all 
three evaluation criteria at 26 weeks and therefore it seems to be crucial in the evaluation of this 
treatment. Without this variable the accuracy of the prognostic value of the model would be 
considerably lower. Because of this it maybe optional to change the software program of the device 
and make it energy-guided, so that a larger number of patients will be treated justified.
In figure 2 this will result in a parallel shift of surface, and line towards the white space. Because the 
outcome criteria are measured at 26 weeks, no information is yet known concerning durability. In an 
earlier publication it was suggested that a good response in terms of desobstruction was the most 
predictive parameter for durability and retreatment.21,22 The white area ( LinPURR < 0.57), would 
create a higher chance of having a poor response and therefore raises the chance of receiving a 
retreatment.
In view of using selection criteria to predict outcome of high energy transurethral thermotherapy we 
could consider two questions; what will be the loss when not treating a potentially good responder? 
And what will be the benefit when we do not treat a patient who is likely to respond poorly on 
TUMT? Although the complication rate in high energy TUMT is low, patients suffer a certain 
amount of discomfort during treatment and they all need an indwelling catheter for at average two 
weeks. Furthermore a delay will occur towards the most efficient therapy ("costs" will be raised) 
and therefore individualizing the therapy seems rational.
The response of high energy TUMT is measured by three separate "evaluation response criteria". 
These three items collectively create a situation of good or poor response, depending on the 
individual concern of symptoms, uroflowmetry or desobstruction. Using these Response Evaluation 
Criteria however does have limitations, especially when defining intermediate responders. On the 
other hand these definitions are a product of a consensus meeting (WHO, Monaco, 1995) in which 
authors are recommended to use these criteria to calculate and compare outcome in a standardized 
way.
According to this consensus, the total amount of energy delivered by the device is the crucial 
predictive factor for outcome. The prostate volume is a predicting parameter in the symptomatic 
response at 26 weeks as well as the response in des-obstruction. Finally age is solitarily predicting 
for symptom score improvement and obstruction grade at baseline predicts the outcome in 
maximum flow rate improvement.
The current graphs can guide urologists in their decision to treat a patient with lower urinary tract 
symptoms and BPH, using the high energy transurethral microwave thermotherapy with the 
Prostatron (software version 2.5) device. This way the physician will be able to verify whether the 
treatment is justified using objective evaluation response criteria.
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Figure 2r The area where the estimated probability o f good response under the condition o f equal lust classification is ow r 0.79 (A. IPSS-tnodel), 
0.33 (B: Qmax model), over 0.56 (ÌmPURR-rnodel)
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ABSTRACT
Transurethral microwave thermotherapy (TUMT) is a minimal invasive outpatient procedure for the 
treatment of BPH. Different devices and operating software have been used in various clinical trials. 
The objective of this study is to identify the possible baseline parameters which could be used to 
identify the best responders to different microwave devices and treatment programs. Data from 
three different high energy thermotherapy devices (Urowave, Prostalund and Prostatron) were 
collected and analyzed.
At one year follow-up 166 patients were available for the Prostatron system. Fifty-two had 50% or 
larger change in both symptom score and peak flow rate while one hundred-fourteen patients were 
considered as non-responders. Responders were characterized, at baseline, by a lower peak flow rate 
(8.80 vs. 10.48 ml/s, p <_0.0001), a larger degree of outlet obstruction as measured by the URA 
parameter (45.33 vs. 36.70 cmH2O, p < 0.0300), a larger energy dose was delivered during 
treatment in this group (173.36 vs. 156.40 KJ, p < 0.0258).
A total of 19 patients were available from the Prostalund cohort. No significant difference was 
found in the value of baseline parameters between responders (5 patients) and non-responders (14 
patients).
Stratification of 143 patients treated with the Urowave resulted in 29 responders (50% improvement 
in both Qmax and AUA score) with a significant difference in the baseline value of peak flow rate 
(7.0 vs. 8.0 ml/s, p <_0.026) at 6 months follow-up. At 12 months however this significance 
difference could not be found any longer.
In conclusion, baseline parameters with significant predictive value for clinical response could be 
identified for the Prostatron device only. The results of this study further confirm the importance of 
an extensive laboratory and clinical research program to fully understand the clinical response 
obtained with a certain microwave and a particular treatment software and to get most advantage 
from these new alternative treatments. Further exploratory work is required to understand the role of 
other parameters such as prostate tissue architecture and vascularity, microwave frequency, 
applicator design, intra prostatic temperature and treatment duration in the clinical response to 
microwave thermotherapy.
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INTRODUCTION
Minimal invasive treatments are designed to reduce the morbidity while maintaining the efficacy of 
more invasive therapies. Unfortunately, this is not always the case. Transurethral microwave 
thermotherapy (TUMT), as other alternative treatments of BPH, does not have the high success rate 
of transurethral resection of the prostate (TURP) although a recent report suggests the outcome of 
the two techniques is closer than expected.1
For many years patient selection in the treatment of BPH was mainly aimed at identifying patients 
with lower urinary tract symptoms caused by neurological or detrusor problems rather than by an 
enlarged prostate who would not benefit from desobstructive surgery. The issue is not insignificant 
since 10 to 25 per cent of patients are known to be dissatisfied with BPH surgery.2-4 
Case selection recently involved medical treatment of BPH, trying to identify those patients in 
which the physiopathological problem was related to the mechanisms of action of the different 
drugs. Alpha-adrenergic blocking agents were found to improve lower urinary tract symptoms 
(LUTS) independently from the patients’ obstructive conditions, while clinical response to 5-alpha 
reductase inhibitors appeared to be dependent upon prostate volume.5,6
Case selection for microwave thermotherapy can not be investigated without taking into 
consideration the distinctive characteristics of this treatment modality and the diversities existing 
between the different equipment’s. The treatment effect is in fact determined by many different 
factors such as the design of the transurethral applicator, the chosen microwave frequency, the 
energy dose and different treatment parameters.
In this paper we describe the different selection criteria by which best clinical responders to the 
different high energy thermotherapy devices available on the market can be be identified. 
Notwithstanding all our efforts, data were not provided by all the investigators we approached and 
the analysis is therefore limited to the three data sets.
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M ATERIAL AND METHODS
Between May and June 1997 we approached chief investigators for Urowave® (Dornier Medical 
System, Germering, Germany - Dr.Trachtenberg), Prostalund® (Lund Instrument, Lund, Sweden - 
Dr. Nordling) Proscare® (Bruker Spectospin, Wissembourg, France - Dr. Eliasson), T3® 
(Urologix, Minneapolis, USA - Dr. Larson) and the Prostatron® (Technomed Medical Systems, 
Lyon, France - Dr. d’Ancona). Participating centers were asked to review their database on high 
energy TUMT and to provide what they considered to be the best parameters to identify best 
responders to the individual treatment devices. Responders and non-responders to microwave 
thermotherapy were defined according to the criteria proposed by Aso at the 2nd International 
Consultation on BPH 7. Patients with less than 50% change in either symptom score or peak flow 
rate were considered non-responders, patients with a 50% or greater improvement in both symptom 
score and peak flow rate were categorized as good responders. Most data about the change in lower 
urinary tract symptoms are given as percentages in order to compensate for the use of different 
symptom scores (IPSS symptom score, Madsen-Iversen symptom score, Boyarski symptom score 
and the Danish symptom score) in the various prostate centers. Follow-up data obtained at 26 weeks 
post-treatment were used to define clinical response to high energy TUMT, pressure-flow study and 
trans-rectal prostate sonography is in fact usually repeated at this point in most centers. All 
subjective and objective parameters of BPH severity which were investigated at baseline were re­
evaluated during the follow-up visits. Clinical response was judged based on the total symptom 
score (Madsen and IPSS) and peak flow rate (PFR), further parameters such as prostate volume (cc) 
and the total energy applied to the prostate (KJ) during treatment were considered as well. The 
following parameters were obtained from the pressure-flow tracings: maximum flow rate (Qmax), 
detrusor pressure at maximum flow rate, whenever possible the minimal urethral opening pressure 
(Pmuo) were provided 8. Bladder outlet obstruction was graded according to the Schäfer classes of 
obstruction (LinPURR) and the group specific urethral resistance algorithm (URA). 8
Prostatron
301 Patients, treated at one institution and complying with the following inclusion criteria were 
analyzed (age: 45 years or older, Madsen symptom score >8 for longer than 3 months, prostate 
volume larger than 25 cc, PFR of 15 ml/s or lower, post void residual urine lower than 350 ml. The 
following exclusion criteria were used: acute urinary retention, evidence of prostate carcinoma, 
acute or chronic prostatitis, urethral stricture, history of bladder cancer, bladder stones, neurogenic 
bladder dysfunction, active urinary tract infection, isolated obstructive middle lobe, use of drugs 
interfering with bladder or prostate function, coagulation disorders, diabetes mellitus. Baseline 
investigations and follow-up visits included: history, physical examination with digital rectal 
examination, Madsen Symptom score, IPSS-symptom score, uroflowmetry, pressure flow study.
Prostalund
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The main investigators of the Prostalund device analyzed 19 consecutive patients treated with the 
high energy thermotherapy. Male patients of 50 years of age or older with lower urinary tract 
symptoms (IPSS >9) for longer than 3 months were included. The following exclusion criteria were 
used: evidence of prostate carcinoma, prostatitis, urethral stricture, bladder stones, bladder 
neoplasm’s, neurogenic bladder dysfunction, active urinary tract infection, isolated obstructive 
middle lobe. Further details about the Prostalund thermotherapy device and software are provided 
elsewhere in this issue.
Urowave
The investigators of the Urowave device performed a similar analyses of 143 patients evaluated at 6 
months. Patients were included with an age between 55 and 85 years old, an AUA symptom score $ 
13, two peak flow rates less than 12 ml/s with a voiding volume #125 ml., and a prostate weight > 
25 and < 100 cc, a prostate length > 3 cm. Patients were excluded who underwent previous 
treatment, i.e. TURP, TUIP, balloon dilatation or thermotherapy, patients having used medication 
with antiandrogens, androgen blockers or 5 " -reductase inhibitors within 6 months, medication with 
alpha-adrenergic blockers within 4 weeks, a post-void residual > 250 ml, interest in future fertility, 
urinary retention or an indwelling catheter, prostate cancer, PSA > 10 ng/ml, bacterial prostatitis, 
previous rectal/anal surgery that would make placements of the rectal probe difficult or 
inappropriate, previous pelvic surgery or radiotherapy, a large median lobe of the prostate, evidence 
of renal impairment or chronic retention or upper urinary tract obstruction, any type of urethral 
stricture, bladder cancer, hematuria or cystolithiasis within 3 weeks, neurological disorders that 
might effect the bladder function, evidence of disorders of hemostasis, uncontrolled cardiac 
arrhythmia, cardiac pacemaker, presence of total hip replacement or other pelvic or femoral metallic 
implants, evidence of diabetic neuropathy, presence of penile prosthesis, latex sensitivity.
All TUMT treatments were performed in an outpatient setting. Further details about the Urowave 
thermotherapy device and software are provided elsewhere in this issue.
Analysis of variance was carried out by the Student’s t-test or the Wilcoxon Rank Sum W test for 
paired data as appropriate. An a  value of <0.05 was considered to be significant.
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RESULTS
Investigators of the Proscare device were uncomfortable about delivering data of their patients 
treated with the high energy software because of their short experience; their large database of 
patients treated with the low energy software was not considered suitable for participation in our 
study. We were not able to obtain any valid information from investigators of the T3 device. 
Consequently data from three different devices: Prostalund, Urowave and Prostatron were 
evaluated.
A total of 166 patients with one year follow-up were available for the Prostatron device. Significant 
improvement of lower urinary symptoms and urinary flow rate was found at 12 months (IPSS from 
18.6 ± 6.2 to 7.7 ± 6,1; maximum flowrate from 9.9 ± 3.1 to 15.3 ± 5.9 ml/s; post void residual 
from 71.4 ± 83.8 to 32.4 ± 56.4 ml). On average, peak flow rate at 12 months was higher than the 
threshold for inclusion criteria into the clinical study the patients participated. A decrease of all 
parameters of the pressure-flow study was found following microwave treatment; patient 
distribution in the obstructed, equivocal and unobstructed categories according to the Schäfer 
nomogram at baseline (65, 23 and 12 per cent, respectively) was found to be reversed at the six 
months follow up (12, 23 and 60 per cent, respectively). Interestingly, a decrease of prostate volume 
by 20% could be demonstrated at 52 weeks (from 59.3 ± 24.4 to 49.5 ± 25.6 cc). Cumulative 
percentages of improvement in symptoms and maximum flow rate are presented in figures 1 and 2. 
One hundred-fourteen patients were considered as non-responders while 52 had 50% or larger 
change in both symptom score and peak flow rate (Table I). Urinary flow rate at baseline, URA and 
total amount of energy delivered during treatment were significantly different in the two groups. 
Responders were characterized by a lower peak flow rate (8.8 vs. 10.5 ml/s), a larger degree of 
outlet obstruction as measured by the URA parameter (45.3 vs. 36.7 cmH2O), a larger energy dose 
was delivered during treatment in this group (173.4 vs. 156.4 KJ). Responders where found to be 
more obstructed at baseline also according to the linPURR classification (3.2 vs. 2.8) although the 
difference was not statistically significant (Tab. I).
Figure 1. Cumulative frequency ofsymptomatic improvement at 12 months in174 patients receiving 
high energy microwave thermotherapy with the Prostatron device.
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Figure 2. Improvement in IPSS (%) C u m u l a t i v e
frequency of peak flow rate
improvement at 12 months in 174 patients receiving high energy microwave thermotherapy with the 
Prostatron device.
T a b l e  I. Improvement in Qmax (%) B a s e l i n e
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parameters in the Prostatron cohort, patients are stratified according to the clinical response 
observed at 52 weeks follow-up (Mean ± SD).
IPSS or PFR IPSS and PFR *p IPSS change IPSS change *p PFR change PFR change *p
change < 50% change 50% <50% 50% < 50% 50%
N. of. Pts. 114 52 71 111 93 81
IPSS 18.3 ± 6.1 18.8 ± 6.2 0.6495 17.5 ± 6.8 19.3 ± 5.9 0.0092 17.9 ± 6.0 18.3 ± 6.4 0.7046
PFR (ml/s) 10.5 ± 3.1 8.8 ± 2.7 0.0010 9.8 ± 2.9 10.0 ± 3.2 0.7009 8.6 ± 2.8 10.9 ± 3.0 0.0000
PVR (ml) 62.2 ± 23.4 69.2 ± 26.1 0.1058 79.3 ± 81 68.6 ± 89.1 0.2715 66.6 ± 74.2 75.5 ± 93.1 0.8799
PdetQmax (cmH2O )t 73.6 ± 81.6 64.2 ± 88.8 0.1809 57.1 ± 22.0 67.0 ± 24.0 0.0427 64.3 ± 23.3 65.2 ± 25.3 0.8982
Pmuo (cmH2O t 30.0 ± 15.6 35.3 ± 20.3 0.1854 28.4 ± 15.7 32.8 ± 17.7 0.2926 30.6 ± 15.3 33.5 ± 19.2 0.5675
LinPURRJ 2.8 ± 1.3 3.2 ± 1.4 0.0799 2.6 ± 1.3 3.1 ± 1.4 0.0823 2.9 ± 1.3 3.0 ± 1.4 0.7062
URA (cmH2O) 36.7 ± 16.2 45.3 ± 16.9 0.0303 36.4 ± 14.2 43.3 ± 17.1 0.0476 40.6 ± 16.2 43.0 ± 16.7 0.3975
Prostate volume (ml) 57.5 ± 22.6 60.1 ± 26.2 0.6408 55.4 ± 23.6 58.6 ± 23.8 0.7515 58.3 ± 22.1 59.6 ± 25.9 0.8994
Total energy (KJ) 156.4 ± 40.9 173.4 ± 33.0 0.0258 148.9 ± 40.8 170.4 ± 35.3 0.0023 155.8 ± 42.8 171.5 ± 32.2 0.0468
*Wilcoxon Rank Sum W Test, fUrodynamic parameters at 26 weeks
Analysis of symptomatic improvement following microwave heating suggested that both the degree 
of bladder outlet obstruction and the amount of energy released during treatment were of 
importance to achieve an optimal clinical outcome. Patient experiencing a 50 per cent or larger 
improvement of lower urinary tract symptoms had a higher values of PdetQmax and URA at 
baseline and received a larger energy dose (Tab. I).
Stratification of patients according to the percentage increase of urinary flow rates suggested that 
clinical response was dependent upon the baseline value of peak flow rate and the amount of energy 
released during treatment (Tab. I) High energy thermotherapy using the Urowave system resulted 
into a significant decrease of lower urinary tract symptoms as evaluated by the AUA symptom score 
(-52%) and a nice improvement of urinary flow rates (+40%). No decrease was found in the total 
volume of the prostate gland. No urodynamic data was available for the Dornier system. 
Stratification of patients according to the percentage increase of symptom score and peak flow rate 
(29 responders and 51 non-responders) resulted into a significant difference in the baseline value of 
peak flow rate (7.0 ± 1.9 vs. 8.0 ± 1.9 ml/s, p<0.026) at 6 months follow-up (Table II). At 12 
months however the difference was not significant any longer disappeared although the trend 
remained evident (6.9 ± 1.0 vs. 8.0 ± 2.0 ml/s, p<0.055). No difference whatsoever was found in the 
remaining parameters.
No baseline or treatment parameter was found to be associated to the change of lower urinary tract 
symptoms observed at six months (Tab. II).
Baseline value of peak flow rate and the energy dose delivered during treatment appeared to be of 
importance to achieve a larger improvement of urinary flow rates (Tab. II).
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A total of 19 patients were available from the Prostalund cohort. No significant difference was 
found in the value of baseline parameters between responders (5 patients) and non-responders (14 
patients) (Table III). Patient with a 50% or larger change in both the DAN-PSS and PFR had a 
lower peak flow rate (10.0 vs. 12.6 ml/s), larger prostates (48.3 vs. 40.2 ml) and received an higher 
amount of energy (172.0 vs. 147.2 KJ) although the difference did not reach statistical relevance. 
The modest numerosity of the group may be responsible for the observed lack of significance.
Table II. Baseline parameters in the Dornier cohort, patients are stratified according to the 
clinical response observed at 26 weeks follow-up (Mean ± SD).
IPSS and PFR IPSS and PFR 
change <50% change > 50%
IPSS change IPSS change PFR change PFR change
N. of. Pts. 
IPSS
PFR (ml/s) 
PVR (ml) 
PdetQmax 
(cmH2O)
Pmuo 
(cmH2O) 
LinPURR 
URA (cmH2O) 
Prostate
volume (ml)
Total energy 
(Watts)
51
24.0 ± 5.7
8.0 ± 1.9 
64.3 ± 8.9
n.a.
n.a.
n.a.
29
24.0 ± 5.3
7.0 ± 1.9 
66.3 ± 80.0
n.a.
n.a.
n.a.
0.916
0.026
0.402
<50%
74
23.6 ± 5.6 
7.7 ± 2.0
75.7 ± 67.8 
n.a.
n.a.
n.a.
50%
69
23.7 ± 5.3
7.7 ± 2.0 
63.2 ± 72.8
n.a.
n.a.
n.a.
0.8750
0.9840
0.5820
<50%
91
23.8 ± 5.5 
8.1 ± 1.9 
71.6 ± 63.2 
n.a.
n.a.
n.a.
50%
52
23.5 ± 5.6 
7.0 ± 1.9 
92.8 ± 79.3 
n.a.
n.a.
n.a.
0.8500
0.0020
0.2380
45.6 ± 1.5 45.0 ± 23.3 0.444 43.1 ± 20.5 45.4 ± 21.3 0.4980 45.6 ± 21.0 41.9 ± 21.0 0.3080
79.7 ± 16.7 85.0 ± 9.4 0.233 81.5 ± 15.1 83.0 ± 11.5 0.811 80.5 ± 15.0 85.2 ± 9.6 0.0480
*Wilcoxon Rank Sum W Test
Table III. Baseline parameters in the Prostalund cohort, patients are stratified according to the 
clinical response observed at 26 weeks (Mean ± SD).
IPSS and PFR change <50% IPSS and PFR change 50% *p
N. of pts. 14 5
DAN-PSS 22 ± 14,9 22,6 ± 9,3 >0.05
PFR (ml/s) 12,6 ± 6,0 10,0 ± 3,5 >0.05
PVR (ml) n.a. n.a.
PdetQmax (cmH2O) 72,9 ± 37,5 61,0 ± 19,0 >0.05
Pmuo (cmH2O) 33,0 ± 26,2 31,5 ± 14,1 >0.05
LinPURR n.a. n.a.
URA (cmH2O) 33,6 ± 17,3 26,5 ± 8,6 >0.05
Prostate volume (ml) 40,2 ± 15,1 48,3 ± 32,0 >0.05
Total energy dose (KJ) 147,2 ± 45,7 172,0 ± 15,3 >0.05
*Wilcoxon Rank Sum W Test
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DISCUSSION
The most appropriate endpoint of a clinical trial on the treatment of BPH is either patient’s quality 
of life or re-operation rate, both criteria are seldom used in the evaluation of new forms of 
treatment. Relief of lower urinary tract symptoms and improvement of patient’s voiding 
performances may have in fact a negligible effect on the overall quality of life in elderly men which 
is sometimes compromised severely by chronic and degenerative disorders other than BPH.9 The 
need for re-treatment or additional therapy is of major concerns in evaluating the economics of a 
certain disease and the clinical benefit of a new treatment modality. Proper investigation into the 
duration of clinical response induced by a certain therapy requires less than five years and 
inevitably comes last among the different information which are available of a novel for of 
treatment. Currently used endpoint are based on short (six months) and mid-term (12 or 24 months) 
clinical response. Lower urinary tract symptoms, which is the actual reason patients are seeking 
medical care for, and bladder outlet obstruction, which is the issue urologists are often most 
concerned with, are the most frequently used parameters upon which the clinical judgment is based. 
We have little information as to the normal values of urodynamic parameters in elderly men so that 
the values obtained following open or transurethral surgery have been considered as the 
reference.10,11 Furthermore, lower urinary tract symptoms may be independent, to some extent, from 
outlet resistance but rather be related to degenerative processes of central and peripheral nervous 
systems, decrease of oxygen supply to the aging detrusor and impairment of muscle fibers 
contractility. Removal of prostatic adenoma and relief of outlet resistance by either surgical of 
physical means does not necessarily result in the complete elimination of lower urinary tract 
symptoms. Nevertheless, the percent change in lower urinary tract symptoms and urinary flow rates 
are frequently used endpoint of clinical trials on the treatment of BPH. A consensus has not been 
reached yet as to the optimal threshold to define success and failure notwithstanding different 
parameters were proposed over the years. A fifty per cent change in both categories (symptoms and 
flow rate) has been frequently used to define a satisfactory clinical outcome while a lower than 50 
per cent change in any of the two parameters suggests an unsatisfactory clinical response.7,12 
Unfortunately limited information is available in the literature concerning responders and non­
responders to microwave thermotherapy and other different alternative treatments of BPH. 13-15 
The analysis proposed in the present paper suggests that different baseline parameters have a 
significant prognostic value for high energy microwave thermotherapy. Peak urinary flow rate, 
group specific urethral resistance algorithm and total amount of energy delivered appeared to be 
best associated to clinical outcome.
Peak flow rate values can easily be obtained by free uroflowmetry and their relation to the observed 
clinical response was consistent in different databases, caution is nevertheless required when using 
the baseline value of an outcome parameter to identify best responders to a certain form of treatment 
since an inevitable link exists between pre and post treatment values of peak flow rate. More
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interesting, in our opinion, is the association between the degree of outlet resistance, as judged by 
either PdetQmax or URA, and clinical response; no correlation exists in fact between these 
urodynamic parameters and the two outcome ones at baseline.
Bladder outlet obstruction is known to be unrelated to the amount of lower urinary symptoms when 
correlation tests are used 16, nevertheless the degree of outlet resistance was found to be 
significantly associated to the symptomatic response to microwave heating. These data are 
consistent with a previous analysis from our group suggesting a significant association between 
decrease in outflow obstruction and improvement of urinary symptoms in the clinical response to 
low energy microwave thermotherapy with Prostatron.17
We were pleased to observe a link between the amount of energy released to the prostate during 
treatment and clinical outcome since these data makes sense to the problem of mechanisms of 
action of microwave thermotherapy. The amount of energy delivered during treatment is mainly 
dependent upon prostate volume, relative position of the antenna and the rectum, prostate tissue 
architecture and vascularisation, the possible influence of the treating physician/nurse is only 
limited and it is most often a down regulation. The correlation between the amount of energy 
delivered during treatment, the temperature induced within the prostate and the clinical response is 
investigated more thoroughly elsewhere in this issue.
A multi variate analysis recently performed from our group on baseline and treatment parameters in 
patient receiving high energy microwave treatment with the Prostatron device identified different 
parameters which independently predicted the clinical outcome.18 Age, prostate volume and the total 
amount of energy delivered were independently predicting parameters for a poor symptomatic 
response, a urodynamic parameter such as the linPURR and the total amount of energy delivered 
were independently predicting for the improvement of peak flow rate. Although older patients tend 
to have larger prostates, this analysis showed that higher age was independently predicting for a 
poor response as well as patients with smaller prostates and therefore intrinsic mechanisms in the 
prostate may contribute in the clinical response to microwave thermotherapy.
Data provided for Urowave and Prostalund devices were somehow limited and did not identify any 
other parameter which could possibly be related to clinical response. Analysis of the Dornier 
database confirmed the predictive value of baseline peak flow rate for clinical outcome at 6 months, 
the small numerosity of the sample may be responsible for an a  value greater than 5% at 12 months. 
No data were available as to the total amount of energy delivered during treatment but only the 
value of maximum released energy were provided; this latter parameter did not show to be 
significantly related to clinical outcome.
No predictive value could be observed for any of the baseline or treatment parameters provided for 
the Prostalund device possibly due to the limited number of patients available.
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The rationale for microwave thermotherapy of benign prostatic hyperplasia has been extensively 
discussed in the literature and it applies for all devices, nevertheless distinct differences exists as to 
microwave frequencies, sources, microwave antennas, applicators, cooling parameters and treatment 
software. Differences may also be encountered in the inclusion and exclusion criteria endorsed in 
the diverse clinical studies.
The results of this study reinforce the concept of patient selection for microwave treatment of 
benign prostatic hyperplasia. The value of the present analysis is twofold since it provides an insight 
into the clinical response to the different devices and offer an overview of the various parameters 
which may be used to select the best responders to the three microwave devices. We certainly plea 
for more multicenter, properly controlled and carefully conducted clinical trials of the different 
microwave devices and software to further investigate the inner mechanisms of clinical response to 
microwave thermotherapy which certainly remains the most successful minimally invasive 
treatment of BPH.
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ABSTRACT
To evaluate the relation between ASA-classification and response to transurethral microwave 
thermotherapy in patients with lower urinary tract symptoms and benign prostatic hyperplasia.
247 Patients with symptomatic benign prostatic hyperplasia treated with high energy transurethral 
thermotherapy were scored retrospectively for ASA status. Student’s "t-test" was used to determine 
differences in improvement at each point of follow-up between patients classified as ASA 1 or 2 and 
patients classified as ASA 3 or 4. Logistic regression analysis was performed to assess the predictive 
value of ASA status for response using the WHO-response evaluation criteria for IPSS, maximum flow 
rate and urodynamic obstruction (linPURR).
There was a significant improvement in objective and subjective parameters at 12, 26 and 52 weeks 
follow-up in both ASA 1 and 2 patients and ASA 3 and 4 patients. There was no difference in objective 
and subjective improvement between both groups at each point of follow-up. Objective and subjective 
improvement in ASA 3 and 4 patients with cardiovascular disease and ASA 3 and 4 patients with non- 
cardiovascular disease was the same, although patients with cardiovascular disease received less energy 
during thermotherapy treatment. Following logistic regression analysis ASA classification was not 
predictive for response after high energy transurethral microwave thermotherapy.
There is no relation between ASA classification and outcome after high energy transurethral microwave 
thermotherapy. Since these patients are considered high risk for peri-operative complications and post­
operative morbidity, microwave thermotherapy could contribute considerably to the treatment of BPH 
in this specific group of patients.
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INTRODUCTION
Transurethral resection of the prostate still is considered the standard intervention for lower urinary tract 
symptoms and is the second most common major operation in elderly men after cataract surgery. 1 
There is some morbidity associated with this surgical intervention and the necessity for spinal or 
general anaesthesia, possible blood transfusion and infection involve risks with a mortality rate of 
approximately 1%.2,3 Some degree of urinary incontinence and urethral strictures may occur. 4,5 Since 
BPH is principally a disease of men at old ages, there exists a high prevalence of inter current medical 
problems, particularly cardiac, respiratory and cerebrovascular problems,6 which increase peri-operative 
risk and post-operative morbidity.7,8
The avoidance of general or spinal anaesthesia during less invasive procedures is a clear advantage 
particularly for high risk patients who are unfit for anaesthesia.9
There is no consensus about the increased risk and treatment effect after TURP in elderly and high risk 
patients. A retrospective study of Matani et al.10 showed a satisfactory outcome following TURP and 
an acceptable morbidity and mortality rate in BPH patients over the age of 80 years (mostly ASA 3 and 
4). On the other hand, Mebust et al.2 found a higher early complication rate and peri-operative mortality 
rate in this age group when compared to younger patients.
Transurethral microwave thermotherapy is a minimally invasive, one hour effective intervention which 
is performed on an outpatient basis without the need for general or spinal anaesthesia and is therefore 
especially useful in high risk patients who cannot undergo invasive treatment, because of their cardiac 
or pulmonal condition. Until now there are no data published regarding the effectiveness and safety of 
higher energy transurethral thermotherapy in high risk patients. In patients with higher ASA 
classification and co-morbidity, one may assume (related or non related) tissue alterations which can 
influence the treatment procedure (by rectal or urethral triggering) and subsequently the clinical 
outcome.
In this study we performed a retrospective analysis of patients treated with high energy transurethral 
thermotherapy by correlating treatment outcome with their physical condition, according to the 
American Society of Anaesthesiologist operative risk classification (ASA). 11 The goal of this study is 
to determine the efficacy of high energy transurethral microwave thermotherapy in the treatment of 
BPH in patients with a severe functionally limiting or life threatening disease (ASA 3 or 4) compared 
to healthy patients or patients with a mild functionally limiting disease (ASA 1 or 2) and whether ASA 
classification in BPH patients has predictive value for clinical response after microwave thermotherapy.
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PATIENTS AND METHODS 
Study-population
Between July 1993 and July 1996, 246 men, with lower urinary tract symptoms and BPH were treated 
using the high energy thermotherapy protocol (Prostasoft 2.5). Patients were followed for 52 weeks. 
Inclusion criteria for this study were: males aged 45 years or older, with a prostatic length of 25 mm 
or more and a prostatic volume of 25 cm3 or more, voiding symptoms for longer than three months, a 
Madsen symptom score of 8 or more, a peak flow rate of 15 ml/s or less with a minimum voided 
volume of 100 ml and post-voiding residual volume of 350 ml or less. Patients with neurogenic 
disorders which may effect bladder function, prostatic carcinoma, surgical treatment of the prostate in 
the past, patients with possible microwave sensitive implants, diabetic neuropathy, urinary retention 
requiring indwelling catheter, evidence of renal implantment or an obstructed bladder neck by an 
isolated enlargement of a median lobe of the prostate or patients who were on medication prescribed 
for the treatment of the prostate or bladder were excluded from the study.
Treatm ent
The transurethral microwave thermotherapy treatments were performed on an ambulatory basis using 
the Prostatron ® device (EDAP Technomed, Lyon, France) and the software 2.5. The method of therapy 
has been described previously.12 Two hours prior to treatment 40 mg of morphine sulphate was 
administered orally. Since initial experience showed urinary retention in almost all of the patients, 
patients were given a transurethral catheter directly after treatment.
D ata collection
Pre-treatment assessment of subjective and objective voiding parameters included Madsen-Iversen 
symptom score, IPSS symptom score, uroflowmetry with measurement of post-void residual by 
abdominal ultrasound of the bladder and physical examination. Urodynamic investigation with 
pressure-flow (PQ) study analysis was performed at baseline and 26 weeks post-treatment. Prostate 
configuration and prostate volume was assessed at baseline and at 12 weeks and 52 weeks follow-up, 
by performing transrectal ultrasound. A urethrocystoscopy was carried out at baseline to judge the 
patency of the prostatic urethra for the presence of strictures or an isolated obstructing prostatic middle 
lobe and to exclude intra vesical pathology. Follow-up visits were scheduled at 12, 26 and 52 weeks 
after treatment.
ASA-classification
Patients were scored retrospectively by a medical record review performed by an experienced 
anaesthesiologist (H.K.) according to the ASA score system.11 The ASA-classification system is used 
by anaesthesiologists to assess peri-operative and post-operative risk in patients. ASA 1 patients are 
healthy, ASA 2 patients have a mild, controlled, functionally non-limiting disease, ASA 3 patients have
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a severe or poorly controlled systemic disease that is functionally limiting, ASA 4 patients have a 
severe systemic disease that is a constant threat to life and ASA 5 patients are moribund and not 
expected to survive 24 hours with or without surgery.
Statistical analysis
The Kruskall-Wallis test was used to test for statistical significant differences in baseline parameters 
between the ASA groups. Student’s "t-test" or Wilcoxon test were used to test for statistical differences 
in the baseline parameters between two stratified groups (ASA 1 and 2, and ASA 3 and 4). Wilcoxon 
matched paired signed rank test was used to assess treatment effect of microwave thermotherapy at 12, 
26 and 52 weeks after treatment. The same analysis were performed for patients in the ASA 3 and 4 
group with cardiovascular problems compared to patients in the ASA 3 and 4 group with non- 
cardiovascular problems.
Response Evaluation Criteria as stated at the 3rd International Consultation on Benign Prostatic 
Hyperplasia in Monaco13 were used to evaluate treatment outcome. In the Response Evaluation Criteria 
patients are stratified as poor, intermediate and good responders using either the IPSS symptom score 
or the maximum flow rate or the linPURR (according to the Schäfer classification for urodynamically 
recorded outlet obstruction14). Intermediate responders were merged with the good responders. Chi- 
square tests were used to test for differences in ASA classification between the response groups. 
Differences in the baseline parameters and ASA status between non-responders and responders at 26 
weeks after treatment were expressed as crude odds ratios with 95% CI, using univariate regression 
analysis. Multi variate regression models were composed and the additional value of ASA class into 
these models was assessed using the likelihood ratio test. ROC curves were composed to determine 
clinical relevance of the composed logistic regression models.
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RESULTS
Seventy patients (28%) were classified as ASA 1, 77 patients (31%) as ASA 2, 73 patients (30%) as 
ASA 3 and 9 patients (4%) as ASA 4. Seventeen patients could not be scored for ASA status, because 
of incomplete information in their medical record.
Not all patients completed the one year follow-up, but no difference was found in drop out between the 
different ASA groups (table 1).
Table 1. Number of patients, additional treatments and losses to follow up.
ASA 1 + 2 baseline 12 weeks 26 weeks 52 weeks total
Number of patients 147 143 140 129
TURP 2 - 3 5
Open prostatectomy - - 1 1
Bladder neck incision - - 2 2
Urethral stricture - 1 - 1
Medication - - 1 1
Prostatitis - - 1 1
Death /illness 1 - - 1
Other reasons for dropout 1 2 3 6
147 147 143 140 18
ASA 3 + 4 baseline 12 weeks 26 weeks 52 weeks total
Number of visits 82 81 74 68
TURP 1 - 2 3
Open prostatectomy - - 1 1
Bladder neck incision - - - -
Urethral stricture - - - -
Medication - - - -
Prostatitis - - - -
Death /illness - 3 1 4
Other reasons for dropout - 4 2 6
82 82 81 74 14
There was no statistical difference in baseline (pre-TUMT) parameters between the four ASA groups 
except for age and Qmax. Patients classified as ASA 1 were significantly younger than ASA 2, 3 and 
4 patients. ASA 2 patients had a significantly higher Qmax before treatment compared to ASA 1, 3 and 
4 patients. The baseline (pre-TUMT) parameters were compared between ASA 1 and 2 patients and 
ASA 3 and 4 patients as shown in table 2. No difference in baseline parameters was found between both 
groups except for age.
The relation between ASA status and age was assessed by logistic regression. The difference in age 
between ASA 1 and 2 and ASA 3 and 4 can be expressed as an odds ratio. The odds ratio is 1.04 (p = 
0.02). This indicates that the chance for a ASA classification of 3 or 4 increases with 4% every year a 
patient gets older.
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Table 2. Patients baseline characteristics.
Mean (SD) 
Range
Baseline characteristics ASA 1 and 2
(n=147)
ASA 3 and 4
(N=82)
p-value
Age (years) 65.8 (7.7) 68.4 (8.6) 0.02
45-88 51-87
Maximum flow rate (ml/s) 10.0 (3.2) 9.4 (2.8) 0.16
0.7-15.0 4.0-15.0
Residual (ml) 74.1 (87.5) 65.7 (73.2) 0.99
0-350 0-350
IPSS symptom score 19.0 (6.1) 18.6 (6.8) 0.62
5-35 6-35
Madsen symptom score 14.2 (3.6) 14.1 (4.0) 0.81
8-23 8-23
Pdet/qmax (cmHjO) 62.4 (21.9) 65.9 (27.9) 0.33
19.2-128.0 15.5-153.6
URA (cmHjO) 39.9 (14.9) 43.3 (19.9) 0.18
7.0-90.0 15.0-142.0
Prostate volume (cm3) 58.3 (25.8) 55.0 (25.5) 0.11
25.0-200.0 29.3-133.5
PSA ( g/l) 5.6 (4.0) 5.5 (5.7) 0.42
0.5-23.0 0.1-40.0
TUMT energy (KJ) 159.5 (39.2) 153.8 (44.7) 0.31
60.0-209.2 50.0-202.2
Table 3 shows the mean and 95% CI of subjective and objective parameters at each point of 
measurement in both ASA groups. Statistical significant improvement was observed in each parameter 
in both ASA groups (p < 0.05).
There was no statistically significant difference in improvement between the four ASA groups and there 
was no difference in the mean improvement in subjective and objective parameters between ASA 1 and 
2 and ASA 3 and 4 patients at each point of time (p > 0.05).
Mean catheterisation time after therapy in ASA 1 and 2 patients was 15.7 days and in ASA 3 and 4 
patients 19.8 days (p > 0.2).
Patient outcome (poor, intermediate and good response) at 12, 26 and 52 weeks for the IPSS symptom 
score, for the maximum flow rate and for the urodynamic response are presented in 
table 4. Poor responders in IPSS score at 26 weeks were significantly older, had a lower IPSS and 
Madsen score before treatment and received a smaller amount of energy during treatment compared to 
good responders. Poor responders in Qmax had a significant higher Qmax before treatment, less post 
void residual volume before treatment, a lower PdetatQmax before treatment and received less energy 
than good responders. Evaluating the response in linPURR at 26 weeks the good responders had 
significant larger prostates before treatment, higher URA and PdetatQmax at baseline, received 
significant more energy during treatment and had a higher PSA level at screening. There was no
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difference in distribution of ASA-status between the response groups in each criteria (p > 0.05). (results 
not shown)
Using univariate logistic regression analysis, ASA status did not have any predictive value for a poor 
response in either IPSS, Qmax or linPURR. Univariate, the total energy delivered, the prostate volume, 
the PSA-level, age, the Madsen symptom score and IPSS symptom score were predictive baseline 
variables for a poor response in IPSS at 26 weeks follow-up. Predictive baseline variables for a poor 
response in Qmax were linPURR, TUMT energy, PdetatQmax, maximum flow rate, free flow residual 
and IPSS symptom score. The PdetatQmax, the total energy delivered during treatment, the prostate 
volume, the voided volume, the URA, the PSA-level and linPURR were predictive baseline variables 
for a poor response in linPURR at 26 weeks.
Table 3. Mean and 95% CI of subjective and objective parameters at each point o f measurement 
(paired analysis).
Baseline 12 weeks 26 weeks 52 weeks
95% CI 95% CI 95% CI
ASA 1+2 ASA3+4 ASA 1+2 ASA3+4 ASA 1+2 ASA3+4 ASA 1+2 ASA3+4
Maximum flow 10.0 (147) 9.4 (82) 16.2 (130) 15.5 (69) 14.4 (118) 13.5 (63) 16.1 (93) 14.1 (51)
rate (ml/s) 15.1-17.3 13.9-17.0 13.4-15.5 12.0-15.0 14.9-17.3 12.5-15.6
Residual (ml) 74.1 (147) 65.7 (82) 38.8 (127) 23.5 (67) 31.6 (115) 35.9 (62) 32.9 (93) 27.7 (49)
25.8-51.8 16.2-30.8 14.8-48.4 17.3-54.4 21.6-44.1 16.8-38.6
IPSS 18.9 (147) 18.6 (82) 8.5 (129) 8.7 (73) 7.8 (124) 9.2 (63) 7.9 (94) 8.1 (52)
7.4-9.5 7.4-10.0 6.8-8.8 7.5-10.8 6.6-9.1 6.4-9.8
Madsen 14.2 (147) 14.1 (82) 5.7 (135) 6.2 (73) 5.0 (124) 6.1 (63) 5.4 (98) 6.0 (53)
4.9-6.5 5.2-7.2 4.2-5.7 4.9-7.3 4.5-6.3 4.6-7.4
PdetatQmax 62.4 (147) 65.9 (81) 38.3 (109) 43.7 (60)
(cmH2O) 35.3-41.3 38.5-48.9
URA (cmH2O) 39.9 (144) 43.3 (81) 22.3 (109)
20.2-24.4
26.3 (59)
22.6-29.9
Prostate volume 58.3 (147) 55.0 (73) 48.3 (132) 45.0 (73) 50.7 48.4 (45)
(cm3) 44.5-52.1 40.1-49.9 45.0-56.4 40.6-56.2
For all parameters: p<0.05
Multi variable regression analysis was performed to identify those baseline parameters that 
independently predict poor response, and ROC curves were composed to determine clinical relevance 
of these models (figure 1-3). Age, TUMT energy, prostate volume, IPSS symptom score and Madsen 
symptom score were independently predictive for a poor response in IPSS. Following these variables 
ASA status added as a continuous variable did not improve this model significantly (figure 1). When 
regarding the maximum flow rate at 26 weeks, the total energy received during TUMT, the linPURR 
and the maximum flow rate at baseline were predictive for a poor response. Adding ASA classification 
into this model did not improve the discriminating power of this model (figure 2). When considering 
the linPURR at 26 weeks as outcome criteria, TUMT energy, prostate volume and linPURR at baseline
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were predictive for a poor response after TUMT. ASA status did not improve this model significantly 
(figure 3).
Patients with a compromised cardiovascular system could well have a compromised (micro) 
vascularisation in the prostate which affects the heat response of the gland to heat. To determine 
whether TUMT is as effective in patients with cardiovascular disease compared to patients with non- 
cardiovascular disease, within ASA 3 and 4, patients were divided into 2 groups according to their 
cardiovascular problems. Patients with a history of aortic or cerebral aneurysm (2), cerebro-vascular 
accident (5), transient ischemic attack (6), angina pectoris (15), myocard infarction (16), cardiac valve 
disorders (3) and a (coronary) bypass or percutaneous trans-luminal coronary angioplasty (5) were 
considered to be patients with cardiovascular problems.
There was no difference in follow-up between patients with cardiovascular diseases and patients with 
non-cardiovascular diseases. Six patients (12%) with cardiovascular diseases and eight patients (27%) 
with non-cardiovascular diseases did not complete the one year follow-up. There was no difference in 
mean catheterisation time following treatment (22.7 days versus 14.3 days, p > 0.2).
Pearson correlation analysis was performed to determine the relation between the number of rectal and 
urethral triggers and the total amount of energy delivered by the device. Overall there was a significant 
reversed correlation between rectal triggers and TUMT-energy (R=-0.802, p=0.01). The urethral 
triggers, as to be expected, did not correlate with the TUMT energy (R=-0.037).
The prostate volume correlated significantly with the number of rectal triggers (R=-0.165, p=0.05), 
while age of the patients and their ASA score did not.
Evaluating the ASA 3 and 4 patients with cardiovascular problems, it appeared that these patients 
received less energy (147,1 KJ compared to 165,5 KJ, p=0.05), probably due to more rectal triggers. 
(R=-0.823, p=0.01).
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Table 4. Response after treatment when stratifying patients according to the Response Evaluation 
Criteria set at the 3rd International Consultation on Benign Prostatic Hyperplasia. 13
Criteria Response 12 weeks 
N (%)
26 weeks 
N (%)
52 weeks 
N (%)
IPSS Good screening >19 
posttreatment <=8
58 (22.9%) 51 (25.2%) 42 (26.1%)
Intermediate else 129 (59.2%) 112 (55.4%) 97 (60.2%)
Poor change <=3 39 (17.9%) 39 (19.3%) 22 (13.7%)
Qmax Good screening <=10 ml/s 
posttreatment >=15 ml/s
52 (24.2%) 30 (15.4%) 34 (21.5%)
Intermediate else 88 (40.9%) 71 (36.4%) 59 (37.3%)
Poor change <=3 ml/s 75 (34.9) 94 (48.2%) 65 (41.1%)
linPURR Good
Intermediate
Poor
screening >= III 
posttreatment <=I 
else
change <=I
62 (34.1%) 
32 (17.6%) 
88 (48.4%)
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Figure 1. Roc curve o f poor response in IPSS symptom score 26 weeks after TUMT based on TUMT 
energy, age, prostate volume, IPSS symptom score and Madsen symptom score at baseline.
1 - specificity (%)
Without ASA  
With ASA
Figure 2. Roc curve of poor response in maximum How rate 26 weeks after TUMT based on TUMT 
energy, linPURR, maximum flow rate and IPSS symptom score at baseline.
1 - specificity (%)
Without ASA  
With ASA
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Figure 3. Roc curve of poor response in linPURR 26 weeks after TUMT based on TUMT energy, 
linPURR and prostate volume at baseline.
1 - specificity (%)
Without ASA 
With ASA
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DISCUSSION
There is a general trend in medicine towards the implementation of minimally invasive techniques in 
the therapeutic arsenal (Laparoscopy and ESWL). In the Urological community a similar trend is 
observed in the management of male voiding problems caused by benign prostatic hyperplasia (BPH). 
Recently higher energy thermotherapy has been introduced resulting in considerable objective 
improvement over the lower energy protocol at the same excellent symptomatic improvement.15 
Although results following thermotherapy in general are favourable, it remains difficult to predict the 
response to microwave thermotherapy on an individual basis. Identifying criteria for the ideal patient 
profile for high energy thermotherapy could enhance treatment results and therefore avoid unnecessary 
treatments and morbidity.
Earlier studies, by d’Ancona et al.16,17, demonstrated several predicting clinical parameters for response 
to high energy TUMT (age, prostate volume, obstruction grade and total amount of energy) and 
suggested that comorbidity, which can reflect on the patient’s perception of well-being, might explain 
why older patients have a higher chance for poor symptomatic outcome following high energy 
microwave thermotherapy. In the present study, patients comorbidity (ASA score) is correlated with 
therapy outcome following high energy microwave thermotherapy. The results show no correlation 
between ASA score and response following microwave thermotherapy. By using a multiple logistic 
regression analysis on the same variables, ASA status was not found to have any additional predictive 
value. Between the different ASA groups, all patients tolerated the treatment well and no significant 
difference in catheterisation time could be found between the ASA 1 and 2 patients The retreatment rate 
in both groups was equal.
This study confirms that high energy thermotherapy is effective in the treatment of LUTS. Outcome 
following BPH is satisfactory in all ASA groups. We realize that the ASA system is designed for 
surgical patients who are in need for a surgical procedure with the use of anaesthesia. However in this 
study we present patients who are candidates for a surgical procedure like TURP as well as transurethral 
microwave thermotherapy. Therefore it seems fair to use this classification system in our patient cohort.
Patients with severe cardiovascular diseases experience the same improvement following 
thermotherapy, while receiving less energy during treatment. Several studies identified thermal energy 
during microwave thermotherapy to be strongly predictive for clinical response.16,17,18 Good responders 
receive significantly more energy during treatment. The high energy thermotherapy is an operator 
independent procedure. Less energy can only be explained by either interrupting the treatment manually 
or by rectal and urethral triggers. In this study the treatment sessions were not interrupted manually, 
but often feedback triggers occurred. Urethral triggers and rectal triggers have different implications 
for the total amount of energy. Rectal triggers influence the supply of energy most, resulting in less 
applicated energy. In this study, patients with severe cardiovascular diseases experienced more rectal
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triggers during microwave thermotherapy (mean of 10.30 rectal triggers versus a mean of 6.44 rectal 
triggers, p=0.04) and therefore received a lower amount of energy (147.1 KJ compared to 165.5 KJ, 
p=0.05). This poses the question why these patients experience more rectal triggers. It has been 
suggested that adaptation of vascularisation to application of heat and individual differences in tissue 
composition of the prostate play an important role.19 Arai et al. found that patients with a history of anti­
androgen therapy received less energy during microwave thermotherapy.20 Several other studies 
demonstrated a tremendous increase in prostatic blood flow during and following microwave 
thermotherapy, by using colour Doppler ultrasonography.21,22 The adaptation in vascularisation during 
transurethral microwave thermotherapy could serve as a heat sink. This suggests that patients with 
cardiovascular problems might have a less adequate blood flow response to heat, causing temperatures 
in the prostate to reach the trigger threshold sooner and eventually resulting in less energy.
Our correlation analysis did not show a relation between prostate volume and ASA score and the 
number of rectal triggers in the vascular compromised patients (in ASA 3 and 4). However age did 
correlate with the number of rectal triggers in this subgroup of patents, confirming a hypothesis as 
mentioned above.
Further research is needed to support the contribution of vascularisation and tissue composition of the 
prostate to response following high energy transurethral microwave thermotherapy. A better 
understanding of these mechanisms will refine case selection for the ideal patient profile for high 
energy transurethral thermotherapy.
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FOLLOWING HIGH ENERGY TRANSURETHRAL MICROWAVE 
THERMOTHERAPY OF THE PROSTATE?
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ABSTRACT
Despite good results of high energy TUMT in the treatment of benign prostatic hyperplasia it is still 
difficult to predict the response to treatment on an individual basis. Besides clinical baseline parameters, 
intrinsic histological parameters are suggested to play a role in the response variance after TUMT. In 
this study we analyzed histological parameters (vessel density and epithelium-stroma-(E/S) ratio) in 
patients who were selected for high energy TUMT and related these parameters to clinical outcome. 
We treated 42 patients with high energy TUMT, who prior to treatment agreed upon ultrasonographic 
investigation of the prostate in combination with biopsies of the peripheral and transitional zone of the 
prostate. For all separate biopsy locations the histological stained prostate slides were morphometrically 
quantified with computer assistance and analyzed for epithelium stroma ratio and vessel density. 
Response to treatment was measured by using standardized response evaluation criteria and correlated 
with histological outcome.
The E/S ratio in the inner gland biopsies tends to be higher in the good response group compared to the 
very poor responders. Furthermore a clear trend can be seen towards a lower vessel density in good 
responders. Large adenomatous prostates with a high E/S ratio respond well to the high energy 
thermotherapy. The total amount of energy still remains a very important independent predictor for 
response to thermotherapy.
Histopathological parameters of the prostate tend to be moderately predictive for clinical response in 
this research population. Poor responders appeared to have a somewhat higher vessel density in all 
prostate biopsy sides and also there was a trend towards a lower E/S ratio in these patients.
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INTRODUCTION
High energy transurethral microwave thermotherapy (TUMT) has become widely accepted as a minimal 
invasive, outpatient treatment, in patients with lower urinary tract symptoms and benign prostatic 
hyperplasia (BPH). Numerous clinical papers confirmed significant improvement of symptom scores 
and objective parameters such as maximum flow, post voided residual and pressure flow studies.1,2 In 
spite of these good results it is still difficult to predict the response to high energy, TUMT on an 
individual basis.
Several factors have been indicated to be responsible for treatment efficacy. With regard to prediction 
of outcome some clinical parameters at baseline have been postulated such as prostate volume, grade 
of outflow obstruction and age. An interesting finding also appeared to be the total amount of energy 
delivered.3 In all outcome categories4, the total amount of energy is the most predictive parameter for 
treatment outcome, despite the fact that this parameter can not be regarded as a patient characteristic 
and could be typed as ‘post’ priori.
Other factors related to treatment outcome have a more basic background. The operator independent 
Prostatron system using the 2.5 software is completely self regulating using a rectal and urethral 
feedback system, constantly monitored by temperature sensors. Automatic shutdowns (triggers) occur 
when exceeding threshold temperatures. Earlier analysis already showed the effect of a high number 
of urethral and rectal triggers during treatment on the total amount of energy delivered. It was 
demonstrated that the rectal triggers were mainly responsible for the final amount of energy. It was 
postulated that certain ‘intrinsic’ prostatic factors were responsible for these rectal triggers.5,6 Increases 
in blood flow could well be acting as a heat sink and therefore account for the refractoriness of the 
prostate gland in some patients.7 Another ‘intrinsic’ factor is the epithelium-stroma-ratio. Histological 
components of the prostate were suggested to play a major role in heat response.8 
In this study we analyzed histological parameters (vascularisation and epithelium-stroma-ratio) in 
patients who were selected for high energy TUMT. Subsequently we related these parameters to 
clinical outcome.
170
Chapter 4
M ATERIAL AND M ETHODS
Between October 1994 and December 1995 we treated 42 patients with high energy TUMT, who prior 
to treatment agreed upon ultrasonographic investigation of the prostate in combination with biopsies 
of the peripheral and transitional zone of the prostate. If digital examination, serum PSA level or 
ultrasonographic findings raised suspicion for prostate carcinoma, additional localized biopsies or 
random biopsies were taken. The ultrasound guided biopsies were performed in a standardized way 
retrieving tissue from the peripheral zone at the dorsal side, from the peripheral transition zone, and 
from the periurethral transition zone (Figure 1). Prostate configuration and ultrasound guided biopsies 
were assessed by performing transrectal ultrasound (TRUSP), volume being calculated using the 
ellipsoid formula with a 7.5 MHZ transrectal probe (Combison 330 Voluson, Kretz Technik, Zipf, 
Austria). Automatic cutting needles (Manan Medical Products,inc, USA) with a Biopty-gun (Bard, 
USA) were used for collecting the material. All patients received antibiotic prophylaxis during this 
investigation.
Figure 1.
A: Innergland biopsy localizations (Tcr: Transition zone periurethrally right, Tcl: Transition zone 
periurethrally left, Tpr: Transition zone peripheral right, Tpl: Transition zone peripheral left) and outergland 
biopsy localizations (Periph: peripheral zone, sv: seminal vesical) Schematic presentation of the biopsy- 
localizations in tranverse and longitudinal view.
T ranverse view Longitidinal view
B: Image of a two-plane (transversal and longitudinal) ultrasound guided prostate biopsy
X
Localization in transversal plane (X) Biopsy (<=> )in (peripheral) transition zone at right 
side in longitudinal plane.
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Baseline assessment and follow up included general history (including the AUA Symptom score and 
the Madsen symptom score), physical examination with digital rectal examination and urine microscopy 
and culture. Urine cytology and prostate specific antigen (PSA: Hybritech, Texas USA) levels were 
always measured in order to exclude coexisting malignancy.
The flow rates were recorded using a Dantec Urodyn 1000 flowmeter (Dantec, Skovlunde, Denmark), 
and the figures corrected for artifacts by measuring the peak flow sustained over a period of two 
seconds. Any recorded flow of greater than 15 ml/s excluded the patients from the study. Residual urine 
was measured by suprapubic ultrasound using the 3.5 MHz, abdominal probe (Combison 330 Voluson, 
Kretz Technik, Zipf, Austria). To quantify the grade of bladder outlet obstruction, urodynamic 
investigation with pressure-flow (PQ) analysis was performed. Intravesical and rectal pressures were 
recorded using 8 F catheters mounted with microtip-sensors (MTC, Dräger, Germany), and detrusor 
pressure was calculated as the difference between both. The digitally stored pressure and flow-data were 
analyzed by a program developed at our department (UIC/BME Research Center, Department of 
Urology, Nijmegen, The Netherlands). The following parameters derived from the pressure-flow 
analysis were used: detrusor pressure at maximum flow (Pdet at Qmax in cmH2O), maximum flow rate 
PQ-Qmax in ml/s), the linPURR (obstruction grading according to Schäfer9) and the URA (urethral 
resistence index). A patient is considered urodynamically obstructed when Pdet at Qmax falls into the 
obstructed area of the Abrams-Griffiths nomogram or when the linPURR is >3 or when the URA >29 
cm H2O. A urethrocystoscopy was carried out to judge the patency of the (prostatic) urethra for the 
presence of strictures or an isolated obstructing prostatic middle lobe and to exclude intravesical 
pathology.
Follow-up visits were scheduled at 1,3,6,12 months after treatment. Urodynamic investigation with PQ 
study analysis was performed at baseline and 6 months post treatment. Ultrasound of the prostate was 
repeated at 3 and 12 months. Response to treatment was measured by using the response evaluation 
criteria as defined during the 3th International Consultation on BPH in Monaco in 19954: A poor 
response is defined as an IPSS improvement < 1; a Qmax improvement < 3 ml/s or an improvement 
in grade of obstruction linPURR < 1. For this study, intermediate and good responders were combined 
in one group.
All TUMT treatments were performed on an ambulatory basis using the Prostatron (EDAP Technomed, 
Lyon, France) device and the software 2.5. The method of therapy has been described previously.10,11 
Treatment duration was 60 minutes with increasing thermal dose up to 70 Watts. To prevent thermal 
damage to urethral mucosa and rectal wall thermal sensors, urethrally and rectally positioned, gave 
continuously feedback signals about the reached temperature. When the maximum allowed temperature 
was detected by 1 of these thermosensors (urethral temperature 44.6 0C, rectal temperature 43.6 0C) the 
program automatically interrupted the treatment until the temperature decreased to a preset temperature. 
Prior to treatment 40 mg of oral morphine sulfate was administered. Initial experience showed urinary 
retention in nearly all patients, therefore all patients were given a urethral catheter with leg-bag directly 
after treatment.
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D ata collection
The biopsy material was collected and carefully numbered by location. To analyze the material by 
quantitative light microscopy techniques , two types of staining methods were used by a pathologist 
(F.S); hematoxyline and eosin (HE) staining for glandular and stromal components and immuno- 
staining, using monoclonal antibodies directed against factor VIII-related antigens for marking vascular 
components.
Morphometrical measurements were made by means of a microscope (Zeiss, Oberkochen, Germany) 
connected with a computer. To quantify our measurements we used an already existing method 
described by van der Poel et al.12 After digital, i.e. pixel-wise, recording with a black and white video 
camera and translation of grey values into a 8-16 bits computer memory, the images of the histological 
stained prostate slides can morphometrically be processed and analyzed. The size of the biopsy was 
measured by counting the number of pixels occupied by the histological slide and calibrated for 
magnification (10x). A PC-based image-analysis system (VS100-AT frame grabbing board, Imaging 
Technology, Woburn, USA) in a personal computer (Compaq 386s) was used for this purpose. A video 
camera (HCS-CCD, MXR, Vision Technology, Eindhoven, The Netherlands) was connected to an 
Axioskop light microscope (Zeiss, Oberkochen, Germany) to record images. Image handling and 
analysis software was written in TIM (TEA, Dordrecht, the Netherlands) and additional software was 
written in TURBO-Pascal. Images of 512x512 pixels were digitalized and stored on a computer hard­
disk prior to analysis. In the image analysis steps the images were corrected for background shading and 
filtered for segmentation applying local segmentation routines based on grey value histogram 
interpretation (figure 2).
Figure 2. Prostate biopsy image, digitalized and the contour automatically detected by the PC-based 
image analysis system. Glands are detected and contoured and vessels are pointed out.
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An experienced laboratory coworker (Y.A.), detected and contoured the glands in the histological 
section. Furthermore all vascular components in the same specimen were recorded, referring, if 
necessary, to the image at a higher magnification (25-40 x). The computer software stored the number 
of vessels, the imaged pixels and the gland pixels. A complementary software program was used to 
calculate the epithelium-stromal ratio (total surface glands (pixels)/ total surface image (pixels)) and 
vessel density (vsd) (total number of vessels/ total surface image (pixels)) in every prostate biopsy and 
was used to compare these data between the different biopsy localizations. The clinical data was used 
to identify two response groups (good and intermediate versus poor responders) and to correlate with 
histological outcome.
Statistical analysis was performed to compare the means of variables in different response evaluation 
groups using a non parametric test for two independent samples (Mann-Whitney U test). Pearson’s 
coefficients were used to analyze correlations between clinical and histological parameters.
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RESULTS
In forty-two patients (mean age 65.4, range: 52.8-80.2 years) with lower urinary tract symptoms due 
to BPH ultrasound guided prostate biopsies were performed prior to high energy TUMT treatment. The 
mean prostate size of the patients was 64.0 ± 26.3 cc (range: 32.0-162.0 cc), the mean total amount of 
energy delivered by the device was 169.9 ± 34.5 kJ (range: 54.3-207.6 kJ). After the treatment all 
patients received a transurethral catheter for a mean duration of 19.7 ± 19.5 days (range 6-92 days). 
Baseline clinical patient characteristics as well as the mean improvement during the follow-up period 
are presented in Table 1. The clinical response was evaluated after 26 weeks of follow-up. During 
follow-up, 12 patients were retreated; 6 patients underwent a transurethral resection of the prostate after 
a mean follow-up period of 319 days; 5 patients received medical retreatment (a-blocker-therapy) after 
a mean follow-up of 450 days. Due to a urethral stricture, in one patient an optical urethrotomy was 
performed 713 days after initial thermotherapy.
In Table 2, the histological parameters (vessel density (vsd) and epithelial-stromal ratio (E/S)) according 
to biopsy location are presented. Only the good responders in the IPSS group showed a significant (p< 
0.001) larger E/S ratio in the peripheral zone biopsies compared to the transitional zone biopsies. The 
Qmax and linPURR responder groups did not demonstrate such a difference. After stratification of 
patients according to the response evaluation criteria in poor and good responders, there appeared to 
be no statistically significant difference in E/S ratio and vessel density between poor and good 
responders. Within these two groups the significant difference in E/S ratio of the peripheral biopsy 
compared to the other (inner gland) biopsies, persisted.
Pearson analysis showed a clear correlation between vsd in the five biopsy locations. Also the E/S ratio 
demonstrated to correlate between these locations. Evaluating the objective parameters, only the 
response in linPURR correlated with the E/S ratio (-0.44, p< 0.01).
To evaluate any vascular or histological influence on heat response we stratified the patients into very 
poor responders (at 26 weeks: IPSS response < 3 and Qmax response < 3 and linPURR response < 1, 
or retreated within 1 year) and very good responders (presenting a good or intermediate response in all 
3 response evaluating criteria4). The E/S ratio in the innergland biopsies tends to be higher in the good 
response group compared to the very poor responders (Figure 3 a). Furthermore a clear trend can be seen 
towards a lower vsd in good responders. This counts for all biopsy localizations. (Figure 3b.)
Overall there was no significant difference in epithelium-stroma ratio in the prostate comparing very 
good and very poor responders. The eventual outcome will most certainly be defined multi factorial, 
and clinical baseline parameters should have additional predictive value. Adding the prostate volume 
as a major clinical predictors to the E/S ratio, very poor responders and very good responders are 
presented in a scatter diagram(Figure 4).
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Table 1. Baseline parameters and clinical results (mean ± std) during follow-up period of1 year.4
Baseline 26 weeks 52 weeks
n (patients) 42 39 36
Qmax (ml/s) 9.6 ± 3.2 14.6 ± 6.6 14.3 ± 6.0
Volume (ml) 196± 125 292.0 ± 152.1 218.2 ± 165.8
Residual (ml) 71.8 ± 85.6 48.1 ± 118.9 26.8 ± 60.4
IPSS 21.5 ± 6.7 8.3 ± 6.2 7.4 ± 6.1
Madsen 15.5 ± 4.2 5.3 ± 4.4 5.1 ± 4.6
Prostate volume (cc) 64.0 ± 26.3 50.5 ± 20.3 60.1 ± 31.2
URA (cmH2O) 42.8 ± 15.6 25.5 ± 17.4
linPURR (Schäfer) 3.0 ± 1.3 1.5 ± 1.4
Table 2. Mean values of epithelium stroma ratio (E/S ratio) and vesseldensity (vsd) in de separate 
biopsy locations, stratified according to the response evaluation criteria.4
A: IPSS response at 26 weeks
Biopsy Tcr Tpr Periph Tcl Tpl Total
E/S Ratio 10-2 (mean)
Poor response(n=5) 4.17 2.47 5.92 7.2 6.56 4.99
Good response(n=36) 4.82 5.34 7.71* 4.5 5.01 5.53
vsd 10-4 (mean)
Poor response(n=5) 1.58 1.41 1.15 2.01 1.84 1.63
Good response(n=36) 1.83 1.99 1.44 1.71 1.41 1.68
* Statistically different outcome (p< 0.01) compared to the other biopsy locations
B: Qmax response at 26 weeks
Biopsy Tcr Tpr Periph Tcl Tpl Total
E/S Ratio 10-2 (mean)
Poor response(n=20) 3.9 4.19 7.61* 5.23 5.06 5.3
Good response(n=20) 5.58 5.78 7.37* 4.57 5.31 5.62
vsd 10-4 (mean)
Poor response(n=20) 1.72 1.92 1.37 1.84 1.59 1.68
Good response(n=20) 1.87 1.92 1.44 1.68 1.35 1.67
* Statistically different outcome (p< 0.01) compared to the other biopsy locations
C: linPURR response at 26 weeks
Biopsy Tcr Tpr Periph Tcl Tpl Total
E/S Ratio 10-2 (mean)
Poor response(n= 19) 5.99 5.27 8.60* 5.63 5.74 6.04
Good response(n= 15) 3.19 4.5 7.48* 5.17 4.4 5.13
vsd 10-4 (mean)
Poor response(n= 19) 1.96 2.13 1.5 1.92 1.41 1.75
Good response(n=15) 1.56 1.76 1.23 1.72 1.33 1.57
* Statistically different outcome (p< 0.01) compared to the other biopsy locations
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Figure 3. Error bar plot demonstrating the mean values (+ 2 SE) ofthe epithelium-stromal ratio (A) 
and ofthe vessel density (B) in the different biopsy locations, stratified according to very poor and very 
good responders.
A:
B:
LU
CO
Figure 4. Scatter diagram plotting total E/S ratio and prostate volume at screening (cc) in patients 
stratified for very good and very poor response. The arrow marks a questionable very poor responder 
who had a very good response in linPURR (5 to 2), but underwent a TURP after 240 days because of 
subjective complaints.
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DISCUSSION
With the introduction of low and high energy thermotherapy, an attractive new and minimally invasive 
alternative treatment modality became available to patients with lower urinary tract symptoms due to 
BPH. The overall treatment results are clearly encouraging and with the introduction of the high energy 
modalities also thermoablative results could be achieved in a considerable patient cohort.13 Durability 
studies then showed satisfactory results up to 3 years, but a tendency for medical or surgical intervention 
after 1 year could be demonstrated.14,15 Earlier studies were already conducted to identify a subgroup of 
patients with a more or less ideal patient profile for good treatment response using clinical baseline 
parameters and indeed certain clinical parameters (prostate volume, grade of obstruction and age) 
appeared to help predicting outcome in one of the response evaluation criteria (IPSS, Qmax, linPURR) 
used.6 An important finding appeared to be the importance of the total amount of energy delivered to 
the prostate, which had great impact in all three response evaluation criteria, while this is a parameter 
we can not (yet) predict due to the operator independent character of the treatment. Another study 
confirmed the contribution of the numbers of rectal triggers which occur during many treatments and 
are mainly responsible for the total amount of energy.5 It was therefore postulated that histological 
composition and prostate vascularisation are important contributors to these rectal triggering, and 
therefore to the total amount of energy delivered by the device.
In our study we used a standardized semi-automatic method in evaluating the prostatic morphology in 
order to exclude intra and inter-observer variations as much as possible. These variations were tested 
in a subgroup (not presented) and appeared to be acceptably low.
Earlier it was reported that the stromal-epithelial ratio of the prostate markedly varies from patient to 
patient.16,17 Using manual analysis techniques Marks et al.18 demonstrated major differences in tissue 
composition which may identify different hyperplastic prostates. In accordance with our study they 
found BPH tissues rather symmetrically distributed within several prostates. Subsequently they 
hypothesized that histological differences between prostates could be important in clinical decision­
making. Although Mc Neal19 found biopsy studies not reliable to predict BPH tissue composition, other 
studies18,20,21 supported the concept that biopsies can be representative for the individual distribution of 
various tissue components in the prostate. Our data support the latter since we confirmed a very high 
correlation between the inner-gland biopsies. Only the peripheral biopsy showed a significant higher E/S 
ratio compared to the inner-gland biopsies. This is in concordance with the study of Marks et al.18 and 
Feneley et al.22 who found significant more epithelium in the outergland compared to the inner prostate.
The idea of relating and predicting histological parameters to clinical response of certain BPH-therapies 
is not new. Shapiro et al.23 suggested a relation between symptomatic BPH and the relative proportion 
of stromal and epithelial tissue; Deering et al.24 found the stromal component between patients as a 
possible (partial) indicator for therapy selection; Arai et al.8 reported results suggesting a poor 
interaction of microwave thermotherapy and prostate tissue with an artificially lack (due to finasteride
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therapy) of glandular tissue, suggesting that the histological composition plays an important role in 
terms of microwave thermal interactions and treatment outcome. Furthermore Hefty et al.25 showed 
differences in the stroma-epithelial ratio of the transition zone of prostates treated with laser 
prostatectomy correlating with treatment outcome. In our study we only evaluated symptomatic patients 
with BPH, but within this group no correlation could be detected between the symptoms at baseline and 
the epithelium stroma ratio. We could however confirm the observation of Arai et al.8 of a higher E/S 
ratio in inner-gland biopsies in (very) good responders (figure 3a). The delicate differences in E/S ratio 
may well be of more significance when intraprostatic temperatures are in the moderate range (low 
energy protocols). The higher energy protocols however reach intraprostatic temperatures over 600C. 
It may well be that only a considerable variation in E/S ratio of the inner gland prostatic tissue can be 
useful as a (co)factor in predicting response.
From earlier studies we know that several parameters do contribute in the prediction of response to high 
energy transurethral thermotherapy. Adding the E/S ratio with an already known other important 
predictor (prostate volume), a high prostate volume seems to correlate with a low E/S ratio. Large 
adenomatous prostates with a high E/S ratio will potentially respond well to the high energy 
thermotherapy (figure 4). The total amount of energy still remains a very important independent 
predictor for response to thermotherapy.
Vascularisation is suggested to be another important contributor to heat response. Tubaro et al.26 
measured the prostate vascularisation during thermotherapy and although they noticed a 12.5 fold 
increase in blood flow after thermotherapy treatment mainly in the adenomatous part of the prostate, 
Doppler imaging remains a problem in terms of reproducibility and quantification. Bolmsjo et al.27 
assumed the blood flow to be the key factor in outcome of TUMT. By measuring temperatures with an 
intraprostatic needle during low energy TUMT, they adjust treatment parameters for large variations 
in prostatic blood flow, to eventually minimize rectal triggers and treatment shutdowns.
Deering et al.28 investigated microvascularity in benign prostate tissue obtained by open prostatectomy 
and found a higher micro vessel density in nodular hyperplasia than in stromal or epithelial tissue alone. 
These nodules were often present near the urethra, exhibiting significantly higher vessel densities than 
in the surrounding stroma. In our biopsy study we demonstrated no significant differences between 
vessel density in different individual biopsy locations. The response of microwave thermotherapy 
however seemed to correlate with the mean vessel density, suggesting an increased heat transport and 
intrinsic cooling mechanism (heat sink phenomenon) of prostates with higher vesseldensity eventually 
causing a poor response to treatment. Overall the use of the two parameters (E/S ratio and vessel 
density) demonstrated not to be independent predicting parameters for clinical response in one or even 
all response evaluating criteria.
Should we now perform prostate biopsies studies in all patients prior to high energy TUMT to predict 
outcome? The data from this study do not support such a protocol, however it may well be that response 
prediction could be improved considerably by adding histological parameters. In our study we did not 
discriminate between small and large vessels while this may be of critical importance during heat
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transport. Biopsy studies only reveal static information, while heat-tissue interaction is basically a 
dynamic process. Therefore the use of dynamic parameters derived from color flow Doppler studies 
could be helpful. This minimal invasive technique and quantification is currently under investigation. 
When histological and vascular parameters can be quantified and administered in a minimal or non­
invasive manner one could add this “baseline”information to the current predicting models for response 
evaluation criteria3,29 in order to increase their predictive value.
CONCLUSION
Histolopathological parameters of the prostate are not independently predictive for clinical response 
in this research population. However they may increase the predictive value of already existing 
predictive nomograms for clinical response. Poor responders appeared to have a higher vessel density 
in all prostate biopsy sides and also there was a trend towards a lower E/S ratio in these patients, 
supporting both theories of the ‘heat sink’ by increased vascularity as well as the better heat response 
in glandular tissue.
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Summary
SUMMARY
Due to the aging population, the costs incurred by the treatment of BPH represent a substantial portion 
of health expenditure in most countries. Because of these economic factors, as well as the desire of 
many men to avoid surgery wherever possible, the management of symptomatic BPH is in a transitional 
phase. It now also includes medical management that is reversible at the end of the treatment, and 
several minimally invasive procedures which aim to remove pathologic tissue. Transurethral microwave 
thermotherapy (TUMT) was designed to apply microwave energy deep within lateral prostatic lobes, 
in an outpatient based anesthesia-free procedure. The efficacy of thermotherapy has been enhanced by 
applying higher energy levels which increase the intra prostatic temperature. The results of high energy 
thermotherapy studies over former lower energy protocols showed a significant obj ective improvement 
with a similar subjective outcome.
In chapter 1 an update is presented of clinical results of low and high energy transurethral microwave 
thermotherapy protocols. Lower energy protocols using the Prostatron device provide a significant 
symptomatic improvement and an improvement in maximum flow of about 35% over baseline. When 
using other TUMT devices, similar changes are reported. Higher energy protocols, using the Prostatron 
device, result in a similar symptomatic improvement as lower energy protocols, while the improvement 
in uroflow is much more pronounced. However the latter is achieved at the price of increased morbidity. 
In conclusion numerous studies unequivocally support the efficacy and safety of transurethral 
microwave thermotherapy for treatment of symptomatic benign prostatic hyperplasia. Significant 
improvement in both obj ective and subjective parameters has been realized with TUMT across multiple 
centers in the United States and Europe.
In chapter 2 clinical results of a prospective randomized study of 52 patients comparing transurethral 
microwave thermotherapy with transurethral resection of the prostate are presented. After both TURP 
and TUMT there was a significant improvement in all clinical parameters. At 1 year follow-up a 
symptomatic improvement of 78 % in the TURP group was found and of 68 % in the TUMT group. The 
improvements in free flow rate were 100 % and 69 % in the TURP and TUMT group respectively. No 
serious complications occurred in either group while 1 patient from each group required retreatment. 
Overall we found objective and subjective improvement results which were comparable to the ‘gold­
standard’ i.e. transurethral resection of the prostate. However the urodynamic results still show a 
significant better relief of obstruction after TURP than High energy TUMT treatment. A long term 
study of the TUMT population after an average of 2.5 years showed a durable outcome, which was the 
range of TURP. Most retreatments were performed after a follow-up of one year, and decision for 
additional surgical therapy was based on subjective observations. Finally we presented a retrospective 
study of 301 patients treated with high energy transurethral microwave thermotherapy, to analyze 
outcome and durability of this treatment modality. At two years the response in patients with bigger 
prostates was better than the response in patients with smaller prostates. Twenty two patients were 
retreated during the 2 year follow-up period. At two years follow-up high energy thermotherapy results
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in a durable outcome in 93% of patients with an objective improvement of 42% and a subjective 
improvement of 65%. The best predictor of durability of this therapeutic approach appeared to be the 
response evaluation criteria in desobstruction . Fourteen patients of 96 poor responders in this group 
(linPURR) underwent retreatment, compared to 6 patients out 100 good responders.
In chapter 3, several studies are presented in which clinical baseline parameters are laid down, capable 
of predicting a good therapeutic response at 26 weeks. Multi variable analysis on baseline parameters 
was performed to evaluate their predictive value for response using the WHO-response evaluation 
criteria for IPSS, maximum flow and urodynamic obstruction (linPURR). Independently predictive 
baseline parameters for poor response in at least one of the evaluation criteria were patient age, prostate 
size and grade of bladder outlet obstruction (BOO). The total amount of energy delivered during 
treatment appeared to be strongly predictive of response which in our view suggests an important role 
of other mechanisms such as vascularisation and tissue composition in determining the outcome of high 
energy TUMT treatment. Subsequently baseline parameters were stratified and for each category the 
predictive value for good response at 26 weeks after high energy TUMT was calculated and presented 
in nomograms. Cut-off points were then calculated in an effort to present graphs capable of guiding 
urologists in their decisions to treat patients with lower urinary tract symptoms and BPH, using the high 
energy transurethral microwave thermotherapy with the Prostatron (software version 2.5) device. In this 
way the urologist will be able to verify whether the treatment is justified using objective evaluation 
response criteria.
To evaluate whether case selection with simple outcome criteria is possible with other microwave 
devices, we performed analysis on clinical data from Urowave® (Dornier Medical System, Germering, 
Germany - Dr.Trachtenberg) and Prostalund® (Lund Instrument, Lund, Sweden - Dr. Nordling) as well. 
Baseline parameters with significant predictive value for clinical response could be identified for the 
Prostatron device only.
Transurethral microwave thermotherapy is performed on an outpatient basis and is therefore especially 
useful in high risk patients who cannot undergo invasive treatment, because of their cardiac or 
pulmonary condition. In chapter 4 a retrospective analysis is presented to correlate treatment outcome 
and patients' physical condition, according to the American Society of Anaesthesiologists operative risk 
classification (ASA). There appeared no relation between ASA classification and outcome after high 
energy transurethral microwave thermotherapy which implies that patients considered at high risk for 
peri-operative complications and post-operative morbidity, could benefit considerably by microwave 
thermotherapy treatment of BPH. Patients with cardiovascular disease may have a less adequate blood 
flow response to heat, causing temperatures in the prostate to reach the trigger threshold sooner so that 
less energy may be applied. This suggestion and the apparent important contribution of total energy to 
treatment outcome finally lead to a semi-automatic quantative morphological analysis of prostate 
biopsies taken from 42 patients prior to high energy TUMT, in order to relate vessel density and 
histologic parameters to clinical response of high energy TUMT. Our study demonstrated that the 
histolopathologic parameters studied in the prostate are only moderately associated with clinical
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response. However they may increase the predictive value of existing predictive nomograms of clinical 
response. Microscopic evaluation of prostate biopsies showed that poor responders appeared to have 
a higher vessel density and also there was a trend towards a lower E/S ratio in these patients than 
patients showing an adequate response, supporting both the theories of the ‘heat sink’ due to increased 
prostate vascularity as well as the better heat response in glandular tissue.
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More and more transurethral microwave thermotherapy is becoming an accepted therapeutic option 
for patients with lower urinary tract symptoms due to BPH. It is generally considered to be between 
medical therapies and surgical interventional techniques. However several important issues need to be 
clarified such as its mode of action, how treatment should be monitored, how patient morbidity is to 
be dealt with and proper patient selection These questions need to be answered before the permanent 
establishment of this treatment modality and furthermore to understand more about the general concept 
of heat treatment and heat response of the prostate.
TUMT was introduced almost 9 years ago but despite many investigations, its mechanism remains 
controversial. It is considered to be a treatment for lower urinary tract symptoms caused by bladder 
outlet obstruction. However the pathophysiology underlying the symptoms and their relationship to 
outlet obstruction are not completely understood. Furthermore the tissue changes that occur in the 
prostate as a result of high energy transurethral thermotherapy have not yet been completely elucidated. 
There is histologic evidence that thermotherapy induces coagulative necrosis in the prostate. Both in 
stromal and glandular tissue, inflammatory edema, hemorrhagic vascular lesions with coagulative 
necrosis occur.1 Coagulation necrosis can result in a reduction of prostate volume and obstructing tissue 
but it also changes the pliability of the periurethral tissues or reduces efferent neuromuscular elements 
(a-blockade), eventually reducing obstruction. Some propose that there could be a reduction of sensory 
neural elements in the regenerated area, reducing some of the symptoms without affecting obstruction.2 
Groups working with reported a correlation between the presence of a post treatment prostate cavity 
and the final peak urinary flow rate obtained, however, the appearance of a cavity does not seem to be 
necessary for an improvement in flow.3
All investigations report distinct variations in clinical response following TUMT. This may be 
explained on the basis of inter-individual clinical differences (for example prostate volume at baseline), 
but also on the basis of the heterogeneous tissue composition of the prostate. For this reason more 
knowledge concerning intrinsic prostatic factors such as histology and vascularisation is required. 
From our histology study we learned that evaluation of epithelium-stromal ratio and vascularisation in 
a prostate biopsy taken prior to treatment only gives limited information regarding clinical response. 
The histological tissue however contains much more information which could be essential to our 
understanding of heat response. Vessel diameter and the spatial relation between vessels and glands 
could be important in this respect. Other histological stromal components could also be responsible for 
the heterogeneous response to thermotherapy. Histologic information may be considered static data, 
while the response to heat is considered to be a dynamic process.
Transrectal ultrasound techniques are now under evaluation in imaging prostate vascularisation. Color 
Doppler imaging can be used to determine and quantify vascular blood flow patterns.4-6 (Figure 1) 
Recently new imaging techniques were introduced, using ultrasound micro bubble contrast agents
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combined with ultrasound apparatus such as Power Doppler angiography. In this way both static and 
dynamic information can be obtained.7 Three dimensional imaging techniques are now becoming 
commercially available which are capable of demonstrating localized changes in blood flow. 
Correlating typical histological features with these new innovative and minimally invasive techniques 
such as color-flow-Doppler could be a powerful tool in future research capable of obtaining an 
individual blueprint of a prostate.
Color flow Doppler of the prostate Enhanced Color flow Doppler after (microbubble 
contrast) Levovist® intravenous administration
Overall there is a trend towards rational patient selection for almost every medical procedure (diagnostic 
or therapeutic). With the introduction of minimally invasive techniques, selection of patients will help 
to individualize treatment for patients with lower urinary tract symptoms and benign prostate 
hyperplasia.
Individualization of BPH-therapies is only possible on the basis of a sound understanding of the 
pathophysiology of prostate disease. Additional research into the pathofysiology of bladder outlet 
obstruction and the clinical outcome of therapies will enhance our understanding further. To 
individualize TUMT modalities, treatment monitoring devices are also under investigation.
To date transurethral microwave thermotherapy is guided in it’s effective power by the rectal and 
urethral temperatures while intraprostatic feedback temperatures would be preferable. Innovational 
techniques are required to better monitor the intra prostatic temperature changes in order to increase the 
efficacy and selectivity of transurethral microwave thermotherapy. Temperature measurements can be 
performed with a stereo tactic interstitial thermal mapping method, with the drawback that this still 
remains an invasive method.8 Radio frequency and magnetic resonance are at present under 
investigation as non invasive techniques capable of measuring intraprostatic temperature changes during 
thermotherapy treatment.9,10 Also ultrasound techniques have been investigated in this respect. Seip and 
Ebbini11 reported that tissue temperature may be estimated with an error smaller than 0.4 degrees and
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they located heating fields with millimeter resolution. Other investigators presented an in vitro model 
representing a simple method to monitor temperature changes. 12,13Consequently efforts should be made 
to relate the treatment profile to intra prostatic temperature by implementing this data in the treatment 
software; so treatment time and energy levels vary according to threshold intra prostatic temperatures 
in each individual patient. This would be beneficial both to morbidity and efficacy.
Reduction of invasive techniques will almost certainly not always be accompanied by increased 
efficacy and lower morbidity; but the question is whether this is important. For example we accepted 
without argument that the efficacy quotient of large renal calculi is not as great when treated by 
Extracorporal Shock Wave Lithotripsy (ESWL) as opposed to open surgery or percutaneous 
nephrolithotomy. Retreatment with ESWL is much more acceptable to a patient than is a single open 
procedure. Consequently, it may be the legitimate aim of a particular therapeutic approach in the 
management of prostatic problems to include a planned second or even third intervention. Recently new 
developments in the treatment profiles by changed software; higher energy levels and shorter duration 
of the treatment were combined with extensive cooling of the urethra, were presented. Preliminary 
results show a good clinical response in patients which are as effective as the 'older' high energy 
protocol, but with less morbidity during treatment according to visual analogue scales and with the 
added advantage of a short treatment duration of half an hour. Also, new developments were recently 
presented with the object of influencing the post treatment period. Until recently all patients received 
a transurethral catheter with leg bag for an average of 2 weeks, which sometimes caused problems such 
as: urgency, pain, infections, blocking, transfers etc. With the introductions of non-resorbable temporary 
stents and also biodegradable stents the post treatment period can be positively influenced.14,15 Patients 
are able to void immediately after treatment and are, if  the stent is positioned correctly, completely 
continent. Removal of the stent (if it is not resorbable) can be performed easily in a short non 
anaesthesia outpatient procedure.
Future studies should be performed in which predictive intrinsic prostate parameters for heat response 
are identified, in order to better individualize transurethral microwave thermotherapy. To preserve the 
minimal invasive character of TUMT, we should focus on developing non invasive feedback systems. 
The same holds true for per and post treatment morbidity such as post treatment retention. In this 
respect the transurethral stent is a major contribution. Treatment software and duration should be guided 
by intraprostatic temperature monitoring devices in order to individualize and optimize the high energy 
TUMT treatment.
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Samenvatting
SAMENVATTING
De kosten die verschillende behandelingen van BPH met zich meebrengen stijgen, mede gezien de 
toenemende vergrijzing, en nemen een belangrijke plaats in van het totale gezondheidszorg budget van 
de meeste landen.
Dit probleem, maar ook de toenemende vraag van veel mannen om een minimaal ingrijpende 
behandeling te krijgen en daarmee een chirurgische behandeling te vermijden, speelt een rol bij de 
veranderde benadering van patiënten met mictieproblematiek ten gevolge van BPH, waarbij 
medicamenteuze en minimaal invasieve behandeltechnieken een steeds belangrijker plaats toegemeten 
krijgen. Transurethrale microwave thermotherapie is een procedure waarbij microgolven diep in het 
prostaatweefsel worden afgegeven met als gevolg een thermische laesie. Hierdoor ontstaat necrose en 
weefselverlies hetgeen uiteindelijk tot desobstructie moet leiden en zo het klinische effect moet 
verklaren. De effectiviteit is de laatste jaren verbeterd door de toegediende energie te verhogen, waarbij 
de intra-prostatische temperatuur toeneemt. Deze hoge energie thermotherapie liet significant betere 
klinische resultaten zien ten opzichte van de lagere energie versie. De mate van klachtenvermindering 
na therapie bleek voor deze twee versies niet te verschillen.
Dit proefschrift behandelt de mogelijkheid om patiënten zodanig te selecteren dat een individuele 
afstemming van therapie mogelijk wordt gemaakt. Met de komst van alle behandelmethoden voor 
patiënten met mictie klachten is het tenslotte niet aanvaardbaar om een soort cascade aan therapieën 
voor te stellen in oplopende graad van intensiteit, waarbij in geval van onvoldoende effect een meer 
ingrijpende therapie wordt voorgesteld. Gezien het feit dat eerdere onderzoeken van lage en hoge 
energie microgolf therapie een behoorlijke diversiteit in uitkomst hadden laten zien, rees de 
vraagstelling of selectie van een groep patiënten voorafgaande aan therapie mogelijk zou zijn. Hiermee 
zou de effectiviteit van de therapie vergroot moeten kunnen worden, terwijl de totale kosten van de 
behandeling minder worden.
In het eerste hoofdstuk wordt een overzicht weergegeven van de verschillende studies met de lage en 
hoge energie trans urethrale microgolf therapie. De lage energie versie laat een goede symptomatische 
verbetering zien en een verbetering in maximale plasstraal (flowmetrie) van 35% ten opzichte van voor 
de behandeling. Verschillende andere machines blijken soortgelijke resultaten te geven. Resultaten van 
de hogere energie versie zijn met name bekend van de Prostatron® (EDAP Technomed, Lyon, 
Frankrijk), het apparaat dat ook is gebruikt voor dit proefschrift. Deze hoge energie versie laat in 
verschillende studies een hoge effectiviteit zien ten aanzien van de maximale plasstraal, terwijl de 
symptomatische verbetering ongeveer gelijk is met de lage energie versies. Echter de morbiditeit van 
deze versie is ook hoger, waardoor tijdens en na behandeling patiënten meer irritatieve plasklachten 
ervaren. Tevens is het noodzakelijk alle patiënten na de therapie een trans urethrale catheter te geven 
vanwege de hoge kans op urine retentie.
In het tweede hoofdstuk wordt een drietal studies gepresenteerd met de klinische resultaten van hoge 
energie trans urethrale microgolf therapie. Een prospectief onderzoek waarbij de resultaten van hoge
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energie trans urethrale microgolf therapie werden vergeleken met de ‘gouden standaard’ therapie; de 
trans urethrale resectie van de prostaat (TURP), liet een significante verbetering van klinische 
uitkomsten zien in beide groepen. Na 1 jaar was de symptomatische verbetering van de TURP groep 
78% en van de TUMT groep 68%. De plasstraal verbetering bedroeg voor de TURP groep 100% en 
voor de TUMT groep 69%. Er werden geen serieuze complicaties gezien tijdens en na beide 
behandelingsvormen. Hoewel de klinische resultaten over het algemeen vergelijkbaar zijn tussen de 
twee groepen, blijken er toch wel significante verschillen in de mate van desobstructie te zijn; TURP 
resulteert uiteindelijk in een sterkere mate van desobstructie.
Ook na 3 jaar blijken de resultaten stabiel te zijn. De keuze van herbehandeling wordt uiteindelijk in 
deze populatie ingegeven door de klachten van de patiënt en wordt niet ondersteund door objectieve 
argumenten of door de uiteindelijke uitkomst.
In een grote retrospectieve studie met 301 patiënten bleek 93% van de patiënten na 3 jaar zonder 
herbehandeling te zijn, waarbij hun verbetering in plasstraal gemiddeld 42% bedroeg na 3 jaar en de 
symptomatische verbetering 65%. De beste voorspellende parameter voor de duurzaamheid van de 
behandeling bleek de mate van desobstructie te zijn gemeten na een half jaar.
In hoofdstuk 3 wordt verder ingegaan op voorspellende factoren voor een goede dan wel slechte 
uitkomst van hoge energie trans urethrale microgolf therapie. Middels een multivariante analyse van 
de klinische data van 246 patiënten blijken de leeftijd van de patiënt, zijn prostaatgrootte en de mate 
van obstructie belangrijke voorspellers te zijn. De mate van totale energie afgifte door het apparaat 
blijkt echter de sterkste voorspellende waarde te hebben hetgeen een belangrijke bijdrage suggereert 
van intrinsieke prostaat factoren zoals vascularisatie en histologische componenten. In dit hoofdstuk 
demonstreren we nomogrammen en grafieken met afkappunten wanneer iemand wel of niet behandeld 
zou moeten worden. Op deze manier moet het de behandelend uroloog gemakkelijker worden gemaakt 
te bepalen welke patiënten hij wel of niet voor de hoge energie TUMT met de Prostatron® in 
aanmerking moet laten komen.
Ook werden verschillende onderzoekers van andere apparaten gevraagd klinische data aan te leveren 
om te kijken of voorspellende klinische parameters konden worden gedetecteerd. Alleen de hoge 
energie TUMT met de Prostatron ® toonde de evident voorspellende waarde van de hoeveelheid 
geleverde energie.
De TUMT behandeling wordt in poliklinische setting uitgevoerd zonder gebruik van anesthesie en is 
daarom bij uitstek geschikt voor patiënten die pulmonaal of cardiologisch gecompromitteerd zijn. In 
hoofdstuk 4 wordt in een retrospectieve analyse de uitkomst van behandeling gecorreleerd aan de pre- 
operatieve conditie van de patiënt. Voor wat betreft uitkomst maakt het niet uit of patiënten in een 
goede of slechte conditie zijn. Toch blijkt dat patiënten met hart en vaatziekten minder energie nodig 
hebben om dezelfde mate van resultaat te behalen, hetgeen suggereert dat mogelijk intraprostatische 
factoren zoals vascularisatie bij de behandeling van grote invloed zijn op de uitkomst. In een 
histologische studie, waarin van 42 patiënten prostaatbiopten zijn afgenomen alvorens zij werden 
behandeld met hoge energie TUMT, werden vaatdichtheid en stroma-epitheelverhouding
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gekwantificeerd teneinde een correlatie te vinden met de behandelingsuitkomst. Met de door ons 
gebruikte analyse methode kon niet een heel duidelijke voorspellende intraprostatische parameter 
worden geïdentificeerd, echter wel is er een tendens die laat zien dat de slechte responders 
verhoudingsgewij s minder klierweefsel hebben en een hogere vaatdichtheid. Dit ondersteund de theorie 
dat hierdoor de gegenereerde warmte te gemakkelijk kan worden afgevoerd waardoor er vervolgens 
minder therapie effect optreed.
TOEKOM STVERW ACHTINGEN
Onderzoek naar de reactie van prostaatweefsel op warmte kan ook voor andere prostaat therapieën die 
het concept van warmte toediening gebruiken (lasertherapie, TUNA; behandeling via hoogfrequente 
radiogolven) van belang zijn. Tevens kunnen verbeteringen in de applicatie (temperatuur afhankelijke 
energieafgifte)-en controle-mechanismen (niet invasieve intraprostatische temperatuurmeting) van de 
hoge energie TUMT voor een hogere effectiviteit zorgen en kan de behandeling beter individueel 
afgestemd worden. Recente onderzoeken met aangepaste microgolf-software laten een even effectieve 
behandeling zien met een kortere behandelingstijd dan de gebruikelijke 60 minuten, waardoor de 
behandeling zelf door patiënten makkelijker verdragen wordt. Tevens zijn er ontwikkelingen om de 
mate van ongemak na de therapie te verminderen. Tot op heden verkreeg elke patiënt een trans urethrale 
catheter na de therapie gedurende ongeveer 2 weken. De introductie van prostaatstents (wel of niet 
oplosbaar) geeft de mogelijkheid van een verbeterd plaspatroon direct na de behandeling, waardoor een 
catheter na de behandeling overbodig wordt.
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